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RIASSUNTO
Premesse scientifiche
I fenomeni di interazione e migrazione cellulare sono rilevanti in diversi processi 
fisiopatologici dallo sviluppo embrionale all’infiammazione. Le tecnologie finora 
disponibili per lo studio di tali fenomeni in vitro sono in larga parte non adatte per 
applicazioni biotecnologiche industriali. Infatti, l’analisi delle interazioni cellulari viene 
spesso effettuata con saggi di biologia cellulare quali osservazioni in 
immunofluorescenza di campioni fissati, che sono limitate a condizioni statiche e si 
prestano con difficoltà a fornire misure quantitative di eventi dinamici, come la 
motilità cellulare, su larga scala. Scopo del progetto di tesi è lo sviluppo di un sistema 
innovativo per l’analisi della motilità e delle interazioni cellulari in 2D e 3D che, 
superando i limiti già accennati dei saggi finora disponibili, si presti a utilizzo 
biotecnologico industriale per future applicazioni in screening di sostanze a 
potenziale valenza terapeutica. In particolare, è stato sviluppato un sistema che 
consente l’analisi quantitativa del fenomeno di chemiotassi, in cui un gradiente di 
chemochine, attraverso recettori di superficie, innesca cascate di segnali intracellulari 
che culminano nel movimento di cellule infiammatorie in direzione del 
chemoattrattante (Hynes R.,Cell 2002). Si tratta di un fenomeno in cui una costante e 
dinamica interazione fra il microambiente e la superficie cellulare induce 
modificazioni dello stesso fenotipo della cellula che risponde a questi stimoli con 
movimenti finalistici (Ridley A, et al. Science 2003). Cio' avviene, ad esempio, per il 
movimento dei neutrofili in risposta all’interlechina 8 (IL-8).  
Il lavoro di tesi è stato organizzato nel modo seguente. In un prima fase l’attività di 
ricerca è stata indirizzata all’individuazione di meccanismi molecolari che regolano la 
risposta infiammatoria alla base della produzione di fattori chemoattraenti, come IL-8, 
utilizzando in particolare come modello la fibrosi cistica. Questa prima parte del 
lavoro di tesi è stata condotta con tecniche classiche di biologia cellulare e 
molecolare ed è stata finalizzata alla comprensione del meccanismo molecolare alla 
base della produzione di IL-8. E’ stato studiato l’effetto di un ambiente infiammatorio 
su fattori come la transglutaminasi (TG2) che a sua volta regola la modulazione di IL-
8. I risultati ottenuti in questa prima parte del lavoro sono stati utilizzati per la messa 
a punto di una cella di chemiotassi in cui neutrofili migrano in un gel di collagene 
tridimensionale sotto l’effetto di un gradiente di IL-8. E’ stato inoltre messo a punto un 
sistema di valenza trasversale per l’analisi quantitativa della migrazione collettiva di 
una linea cellulare (T84, utilizzata come modello nella patologia celiaca) durante il 
processo di confluenza in una piastra di coltura 2D. Si tratta di un ulteriore esempio 
dell'interazione dinamica fra cellule attraverso il quale cellule poste in piastre di 
coltura in apposito terreno raggiungono la confluenza muovendosi in uno spazio 2D. 
Questo fenomeno e' particolarmente studiato per le cellule epiteliali ed e' coordinato 
non solo da non ancora ben definiti stimoli esterni, ma soprattutto da modificazioni 
dinamiche della cellula, come la proliferazione e il riarrangiamento del citoschelestro 
che consentono alle cellule di entrare in contatto con le cellule vicine. La complessità 
di questi eventi e' ulteriormente provata dal fatto che le cellule stesse, interagendo 
con le cellule vicine vanno incontro a differenziamento come nel caso delle linee 
cellulari epiteliali intestinali T84 in cui la confluenza induce produzione di enzimi di 
superficie, quali la lattasi, propri delle cellule mature. Questo processo di migrazione 
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collettiva viene inoltre influenzato dagli stessi fattori, studiati nella prima parte del 
lavoro di tesi, che regolano la produzione di IL-8. 
Le motivazioni per lo sviluppo del sistema biotecnologico di analisi dei fenomeni di 
interazione e motilità cellulare oggetto di questa tesi sono da ricercarsi in ambito 
patologico. Infatti, nel panorama cosi' complesso della motilità e interazione fra 
cellule in un determinato microambiente la ricerca dei fattori che determinano le 
modifiche cellulari che conducono all'interazione rappresenta un elemento di grande 
interesse in patologia umana in quanto il decorso di malattie croniche e' spesso 
influenzato da alterazioni dei meccanismi di interazione fra cellule. Un esempio e' 
fornito dal comportamento cellulare in patologie neoplastiche in cui il controllo della 
invasività delle cellule cancerose rappresenta il goal di terapie anti-tumorali. 
Infine lo studio del "movimento" e della sua direzionalità in patologia umana  puo' non 
riguardare cellule in toto o sistemi di cellule in un ambiente specifico. La "motilità" e' 
infatti anche una caratteristica del compartimento intracellulare in cui organelli, 
aggregati di proteine e le stesse proteine si muovono all'interno della cellula secondo 
regole ben definite. Un esempio e' rappresentato dal trafficking di proteine in 
membrana e dal loro continuo reciclying fra la membrana e gli endosomi nonche' la 
progressione verso i compartimenti degradativi intracellulari. Meccanismi di 
"movimenti" intracellulari sono alla base di complessi meccanismi di degradazione 
quali l'autofagia e compoprtano anche un riarrangiamento del citoscheletro che 
regola la motilità "esterna" dell'intera cellula.
In un panorama cosi' complesso l'identificazione dei fattori che possono disregolare il 
complesso sistema della motilità in senso lato e' pertanto di grande interesse e la 
identificazione di molecole potenzialmente capaci di modulare questi processi puo' 
avere enormi implicazioni terapeutiche per applicazioni biotecnologiche industriali. 
La scelta di modelli di malattia idonei allo studio dei fattori putativamente coinvolti nei 
meccanismi di motilità/interazione cellulare  dovrebbe basarsi essenzialmente sulla 
evidenza che questi meccanismi costituiscono  un elemento patogenetico della 
malattia e non un semplice evento bystander. La comprensione di una pathway 
specifica puo' aprire la strada alla identificazione di sostanze capaci di modulare 
questi processi biologici e rappresentare molecole eventualmente implementabili 
nella terapia di molte patologie umane.
Come già accennato, nel corso del dottorato di ricerca sono stati utilizzati diversi 
modelli cellulari di due differenti patologie umane, la Fibrosi Cistica e la Celiachia  
che hanno come fattore comune valori elevati della Transglutaminasi tissutale (TG2), 
un enzima multifunzionale con un ruolo patogenetico noto in diverse patologie 
umane, che induce cross-linking di proteine substato o espleta altre funzioni  quali 
una attività isomerasica o di G protein (Malorni, W., et al. 2008, Curr. Pharm. Des).
La Fibrosi Cistica, la piu' comune malattia monogenica ad esito letale nella 
popolazione caucasica, dovuta a mutazioni del gene CFTR, e' caratterizzata, fra
l'altro, da infiammazione polmonare a prevalente componente neutrofilica in risposta 
ad elevata secrezione di IL8 con ricorrenti infezioni batteriche (Smith, J. J., et al. Cell.
1996; Ratjen, F., and G. Doring. 2003. Lancet). Nella prima parte del lavoro di tesi, 
sono state utilizzate linee cellulari epiteliali per identificare la pathway mediata da 
TG2 che porta ad incrementati livelli di IL8 e di infiammazione. Sono stati quindi 
validati inibitori specifici di questa pathway ed individuato il meccanismo di controllo 
dell'infiammazione e della secrezione di IL8 in vitro e in vivo in 2 diversi modelli 
animali di malattia. 
La celiachia, una intolleranza permanente a determinate sequenze peptidiche della 
gliadina del frumento e delle prolamine di orzo  e segale, e' una comune intolleranza 
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alimentare con una prevalenza di 1:100 nella popolazione generale, e caratterizata 
da una disregolazione della risposta immune mucosale innata ed adattativa con 
componente autoimmune (Sollid LM. Nat Rev Immunol 2002).  E' ampiamente 
dimostrato come la gliadina induca aumentata espressione e attivazione  della 
proteina TG2 che esercita un ruolo patogenetico nella malattia. Nella prima parte del 
lavoro di tesi, sono state utilizzate linee cellulari epiteliali intestinali per studiare i 
meccanismi di internalizzazione e degradazione di peptidi della gliadina e il loro 
impatto sulla upregolazione della TG2. Infine sono state utilizzate queste acquisizioni 
per studiare gli effetti dei peptidi tossici della gliadina sulla motilità delle cellule 
epiteliali in coltura e sulle loro interazioni e per comprendere se l'inibizione della TG2 
possa esercitare un ruolo chiave nel controllare gli effetti dei peptidi della gliadina 
sulla motilità delle cellule epiteliali in un sistema 2D. 
Risultati ottenuti e metodologie  
La Fibrosi Cistica (FC) è un nota malattia genetica caratterizzata da uno stato 
infiammatorio basale, la cui natura è ancora oggetto di controversie. 
A) Al fine di comprendere il link tra difetto della Cystic Fibrosis Transmembrane 
Conductance Regulator (CFTR) e infiammazione con elevati livelli del fattore 
chemoattrattante IL-8, sono stati condotti esperimenti su linee epiteliali portatrici della 
piu' comune mutazioni del gene CFTR, la F508del-CFTR,  le IB3  e su le 
corrispondenti linee epiteliali in cui il difetto è stato geneticamente corretto,  le linee 
isogeniche C38 (Smith, J. J., et al. Cell. 1996).
Esperimenti di Western Blot, Immunoprecipitazione, siRNA, Microscopia confocale 
ed analisi dell'attività enzimatica  hanno permesso di evidenziare che nelle cellule 
epiteliali FC gli elevati livelli di TG2 e la sua conseguente attività enzimatica sono 
delle funzione della CFTR in quanto sia inibitori della funzione di CFTR, quali il 
CFTR-inhibitor-172 che il silenziamento del gene CFTR mediante siRNA, aumentano 
i livelli di TG2 nelle cellule C38. Abbiamo poi dimostrato che l'inibizione della TG2, 
sia mediante silenziamento genico che con inibitori della sua attività enzimatica 
(cystamina o R283), riduce drammaticamente alcuni marcatori di attivazione 
epiteliale, quali la fosforilazione delle MAP-chinasi ERK1/2 (p42/44), e la produzione 
di citochine infiammatorie, quali TNF-a, sia della chemochina IL-8. Questi dati 
suggeriscono che il difetto di CFTR induce infiammazione e produzione di IL-8
mediati da TG2.
B) Abbiamo poi voluto comprendere come il difetto di CFTR induca persistenza di 
elevati livelli di TG2 nelle cellule epiteliali FC. E' noto che la difettiva funzione di 
CFTR induce un aumento delle Specie Reattive all'Ossigeno (ROS) (Yi, S. J., et al.. 
2006. Mol. Cells). Abbiamo dimostrato che molecole scavenger di ROS, quali la N-
acetyl-cysteine (NAC) e la catalasi Superossido-Dismutasi(SOD)-mimetica EUK-134
riducono infatti i livelli di TG2 con drammatica riduzione della sua attività enzimatica. 
La dipendenza di elevati livelli di TG2 dall' ambiante pro-ossidativo ci ha indotto a 
pensare che l'incremento di ROS potesse indurre modifiche posttraslazionali della 
proteina TG2. Fra le piu' comuni modifiche post-traduzionali sono la Sumoylazione 
(Meulmeester, E., and F. Melchior. 2008. Nature), e l’ ubiquitinazione nota per 
intervenire in processi di degradazione via proteasoma. Entrambe competono per gli 
stessi residui di Lys e quindi sono mutualmente esclusive e richiedono enzimi E3-
ligasi specifici.
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I risultati ottenuti in seguito a IP di TG2 in cellule IB3 e C38 hanno evidenziato elevati 
livelli di Sumo in IB3 rispetto alle C38, e silenziamenti genici di PIASy (specifica E3 
ligasi di SUMO) o di SUMO hanno dimostrato uno sbilanciamento a favore della 
Ubiquitinazione. Tali informazioni hanno suggerito l’ idea che la persistenza di TG 
fosse Sumo-dipendente. L’inibizione della produzione di ROS in cellule IB3 ha 
evidenziato che i livelli di SUMO e PIASy erano notevolmente abbassati e con essi la 
SUMOylazione di TG2. I dati sottolineano che l ambiente pro ossidativo della CF 
giuda la persistenza di TG2 via SUMOylazione PIASy-dipendente.
C) Gli effetti della persistenza di elevati livelli di TG2 mediati da CFTR via ROS 
hanno dimostrato avere importanti effetti pro-infiammatori che portano ad elevati 
livelli di IL8. Per individuare le strade più idonee per antagonizzare questa pathway 
che dal difetto di CFTR conduce all'infiammazione, abbiamo studiato gli effetti della 
persistenza della TG2 negli epiteli FC.
La TG2 induce modifiche posttraslazionali di proteine substrato ed abbiamo 
identificato un link diretto tra TG2 e il modulatore anti–infiammatorio PPAR
(Daynes, R. A., and D. C. Jones. 2002. Nat. Rev. Immunol.). Infatti I livelli di PPAR
sono stati ritrovati bassi in IB3 rispetto alle C38. Questa relazione fra TG2 e PPAR
è stata dimostrata dipendere dalla attività cross linkante operata da TG su PPAR
con formazione di legami isopeptidici. Studi con agonisti o inibitori del PPAR hanno 
dimostrato che il crosslinking di PPAR e' uno dei meccanismi attraverso cui TG2 
induce infiammazione in epiteli FC. 
D) Studi di microscopia  confocale hanno poi evidenziato che il PPAR e' 
sequestrato in struttre note come aggresomi (Kopito, R. R. 2000. Trends Cell Biol.), 
che rappresentano stazioni di accumulo di proteine misfolded o modificate post-
traslazionalmente e che sono eliminate attravesro un meccanismo alternativo di 
degradazione, noto come autofagia. Nelle cellule epiteliali FC osserviamo un 
accumulo di aggresomi, caratterizzati dalla presenza del marcatore HDAC6 
(Kawaguchi, Y.,et al. 2003.Cell) e di ubiquitina, con sequestro di PPARg oltre ad 
aggresomi contenenti la stessa CFTR misfolded. L'accumulo di aggresomi in cellule 
FC suggerisce una alterazione complessa del degradasoma e suggerisce che le 
cellule con difettiva CFTR potrebbero presentare un difetto del meccanismo di 
autofagia.L'autofagia e' un meccanismo che le cellule adottano in condizioni di stress 
o di carenza nutrizionale come meccanismo di sopravvivenza (Mizushima, N., et al. 
2008 Nature; Moreau, K., Luo, S. & Rubinsztein, D. C. 2010 Curr. Opin. Cell Biol.).  
Con tecniche di trasfezione, rel time PCR, western blot, immunoprecipitazione, 
microscopia confocale e microscopia elettronica, Noi abbiamo dimostrato che le 
cellule epiteliali FC presentano un difetto di autofagia con riduzione di autofagosomi, 
aumento del pool di proteine ubiquitinate e aumento del marcatore p62 che aumenta 
in maniera significativa in condizioni di difettiva autofagia. 
Abbiamo poi dimostrato che questo difetto di autofagia e' dovuto al crosslinking di 
beclin 1 da parte di TG2. Beclin 1 e' una proteina cruciale per la formazione di 
membrane di autofagosomi (Axe, E. L. et al. 2008, J. Cell Biol.) e la sua associazione 
nel reticolo endoplasmico (ER) con altre proteine del complesso III del  
phosphatidylinositol-3-kinase complex (PI3K), e' cruciale per iniziare il processo 
autofagico (Matsunaga, K. et al.2009,Nature Cell Biol.; Zhong, Y. et al. 2009,Nature 
Cell Biol.). Noi abbiamo dimostrato che le modifiche posttraslazionali (crosslinking) di 
beclin 1 operato dalla TG2 induce uno spiazzamento del complesso III PI3K dall'ER 
e suo sequestro in aggresomi con inibizione dell'autofagia. La overespressione di 
Beclin 1 cosi' come l'inibizione della TG2 ripristina la normale funzionalità del 
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processo autofagico con eliminazione degli aggresomi e riduzione deli marcatori di 
infiammazione fra cui IL8.
E) Pertanto il difetto di CFTR induce una attivaione dll'asse ROS-TG2 che attraverso 
una inibizione dell'autofagia conduce ad infimmazione. Per dimostrare la valenza di 
questo meccanismo nella patogenesi dell'infiammazione in FC, abbiamo utilizzato 
altri 2 modelli biologici. Il primo e' rappresentato dalla coltura ex vivo di mucose di 
polipo nasale di pazienti con FC, e il secondo è il modello murino di malattia. (Mall, 
M.et al. 2004, Nature Med.).I topi sono stati trattati con cystamine o NAC. Queso 
trattamento ha indotto riduzione dell'infiammazione polmonare, riduzione di livelli di 
MIP-2, l'analogo murino della IL8 e riduzione dei neutrofili intratissutali.Nel loro 
complesso questi dati dimostrano che inibire la TG2 o ridurre i livelli di ROS e' un 
approccio estremamente utile in vitro e in vivo per controllare l'infiammazione e i 
livelli di IL-8.
Per ipotizzare un trasferimento dei nostri risultati alla biotecnologia industriale si e' 
pensato di ipotizzare un device che consentisse lo studio della dinamica del 
processo di migrazione dei neutrofili in risposta al fattore chemoattrattante IL8 che 
abbiamo visto giocare un ruolo patogenetico nella infiammazione respiratoria in FC.
E’ stata realizzata una matrice tridimensionale di gel di collagene (principale 
componente delle matrice extracellulare) per mimare le reali condizioni fisiologiche. 
Sono stati eseguiti esperimenti di motilità su neutrofili in presenza o in assenza di IL8
in una matrice 3D di gel, utilizzando un’appropriata cella di flusso. 
La matrice di gel è costituita da una soluzione liquida di collagene al quale è aggiunto 
e una sospensione cellulare contenente 2·105 cell\ml e fatta gelificare per 30minuti 
in un incubatore per cellule. Per lo studio del fenomeno è stata progettata e 
realizzata una cella di chemiotassi, costituita da un blocco di alluminio, adeso ad un 
vetrino portaoggetti, che alloggia un pozzetto al cui centro presenta un blocchetto 
(inserito tra due guide) sul quale viene fatta aderire una membrana semipermeabile 
per la realizzazione di un flusso diffusivo.
La cella di chemiotassi contenente le cellule in gel di collagene, in assenza o 
presenza di chemoattraente, viene alloggiata sul tavolo portaoggetto di un sistema 
time-lapse, il quale consta di un microscopio rovesciato equipaggiato di 
motorizzazione per il tavolino portaoggetti e di un micro incubatore per cellule. In
maniera completamente automatizzata le immagini vengono acquisite a diverse 
profondità, effettuando delle scansioni 3D del campione in esame ad intervalli 
regolari nel tempo.Le immagini sono poi analizzate tramite tecniche di image 
analysis al fine di: determinare la posizione 3D per ogni istante di tempo, ricostruire 
la traiettoria seguita, e definire la direzionalità perseguita da ogni singola cellula.
Per validare il sistema è caratterizzare il flusso diffusivo utilizzando destrano 
fluorescente (FITC-destrano), avente peso molecolare paragonabile a quello del 
chemoattraente. In seguito, i primi esperimenti di controllo sono stati condotti su 
neutrofili (da donatori sani) in presenza e assenza di uno stimolo chemiotattico. I
risultati ottenuti indicano, come atteso, un movimento cellulare del tutto casuale in 
assenza di IL8 e fortemente direzionato in condizioni di presenza dello stimolo.
Questo strumento di analisi direzionale e quantitativo potrà consentire innanzitutto di 
utilizzare questo modello per screening di sostanze con potenziale effetto 
chemoattrattante per leucociti in diverse patologie umane. La definizione dei 
meccanismi che regolano la produzione di IL8, come dimostrato nel percorso di 
dottorato, potrà inoltre  aprire la strada ad un nuovo approccio per testare la 
produzione di chemochine da parte di cellule epiteliali di CF o di altre patologie 
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infiammatorie croniche poste nel device insieme ai leucociti per screenare "in situ" 
l'effetto di inibitori di pathways che regolano la produzione di IL8.  
I risultati ottenuti nel corso di questo percorso di dottorato di ricerca aprono la strada 
ad un ulteriore modello di potenziale applicazione alle Biotecnologie Industriali, 
l'analisi dinamica e direzionale 2D di cellule epiteliali poste in piastre di coltura.
Infatti l'attivazione dell'asse ROS-TG2, oltre ad avere un impatto sui meccanismi 
patogenetici della FC precedentemente descritti, e' anche in grado di influenzare la 
fisiologia del citoscheletro cellulare, fattore notoriamente cruciale nel mediare 
l'interaione fra popolazioni cellulari. 
A tale scopo abbiamo utilizzato un modello di un'altra patologia infiammatoria 
cronica, la celiachia, in cui precedenti evidenze, fra le quali quelle ottenute dal nostro 
gruppo di ricerca, hanno dimostrato il ruolo determinante della TG2 nella patogenesi 
della malattia.
La celiachia e' una intolleranza alimentare caratterizzata da una attivazione del 
sistema immune mucosale a particolari sequenze peptidiche della gliadina, una 
proteina del frumento. In particolare alcuni peptidi, fra cui quello corrispondente alla 
sequenza  aminoacidica 31-43 della A-gliadina, sono in grado di attivare le cellule 
epiteliali intestinali predisponendo la mucosa intestinale alla azione di altre frazioni 
peptidiche, fra cui la 56-68 (a-9) che in un contesto di attivazione della risposta 
innata sono presentati alle cellule T gliadina-specifiche, evocando in tal modo una 
attivazione del sistema immune adattativo(Sollid LM.. 2002, Nat Rev Immunol; Sollid 
LM. 2000 Annu Rev Immunol; Shan L, et al. 2002 Science; Maiuri L, et al. Lancet,  
2003).Nel corso del dottorato abbiamo dimostrato come il peptide 31-43 sia 
internalizzato nelle cellule epiteliali e accumuli nei lisosomi con un ritardo della 
degradazione che induce un aumento di produzione di ROS e conseguente 
upregolazione della TG2. Cio' induce un profondo riarrangiamento del citoscheletro 
con riarrangimento dei filamenti di actina.
Per le ragioni precedentemente dette, abbiamo voluto verificare se la tossicità del 
peptide 31-43 potesse impattare sul movimento e interazione delle cellule epiteliali 
intestinali poste in piastra di coltura, in considerazione dei suoi effetti sul 
citoscheletro.
A tale scopo sono stati condotti esperimenti in 2D in piastre da coltura su linee 
cellulari epiteliali di T84  in presenza o meno di stimoli infiammatori, quali il p31-43, 
seguiti da una regolazione della TG2 mediante inibizione con un anticorpo 
monoclonale (TG 4G3) o mediante inibizione dei ROS utilizzando l’ EUK134
(mimetico chimico della catalasi- Superossido Dismutasi).
I movimenti delle cellule sono stati seguiti mediante la tecnologia Time-Lapse; è stato 
eseguito un esperimento in 2D in cui le immagini dei campi di vista sono acquisite 
ogni 15 min, per un totale di 48h.
La caratteristica morfologia cellulare delle T84 si esplicita nella formazione di 
strutture isolari che si accrescono durate le fasi si duplicazione e mostrano 
movimenti di associazioni di più isole (simile ad un  processo di inglobazione).
Le immagini ottenute mostrano una chiara alterazione della motilità delle isole in 
presenza  del solo p31-43 rispetto al controllo non trattato (medium alone). L’ 
aggiunta dei modulatori di TG2 e dei ROS riporta il sistema ad una condizione 
paragonabile al campione non trattato, mostrando una riduzione di motilità rispetto al 
p31-43.
Le cellule sono state in seguito fissate e utilizzate per l’ osservazione in fluorescenza 
di un marcatore tipico del citoscheletro, la falloidina; le immagini acquisite tramite 
microscopia confocale mostrano un chiaro riarrangiamento citoscheletrico  nel 
 CHAPTER  I      
 
7 
 
campione trattato con p31-43 rispetto al non trattato; analogamente al movimento, in 
seguito alle inibizioni della TG2, il citoscheletro riprende una struttura paragonabile al 
non trattato.
I risultati dimostrano quindi che l’ alterato profilo infiammatorio impatta sul movimento 
cellulare e consente di identificare sostanze capaci di modulare le cause che 
determinano alterazioni della  motilità.
Questo modello offre importanti applicazioni potenziali in diverse patologie umane in 
quanto l'alterazione del citoscheletro e la TG2 sono entrambi coinvolti in processi di 
migrazione e interazioni cellulari alla base della invasività di cellule neoplastiche.
Conclusioni e prospettive future
I risultati della ricerca svolta nei tre anni di Dottorato offrono innanzitutto un 
importante contributo alla definizione dei meccanismi patogenetici dell'infiammazione 
polmonare in FC e identificano nuove opzioni terapeutiche per i pazienti.
In particolare i principali risultati dello studio che hanno riscontro in 4 lavori pubblicati 
su riviste internazionali definiscono:
a) il ruolo della TG2 come fattore patogenetico nuovo nella FC
b) il ruolo di modifiche posttraslazionali della TG2 come link fra difetto genetico di 
CFTR ed infiammazione
c) i meccanismi attraverso i quali l'asse ROS-TG2 inibisce l'autofagia nelle cellule 
epiteliali respiratorie FC. Questo studio definisce per la prima volta la FC come 
malattia correlata ad autofagia.
Questo percorso di studio fornisce poi il razionale per l'implementazione di modelli di 
motilità/migrazione cellulare come strumenti idonei per testare l'efficacia di molecole 
a potenziale impatto farmacologico.
La possibilità di disporre di un modello di analsi quantitativa e qualitativa potrà 
consentire di saggiare l'efficacia di diversi farmaci che mirano a controllare l'invasività 
di cellule neoplastiche e per modulare la farmaco-resistenza che costituisce un 
problema cruciale di terapia. Gli effetti da noi osservati di modulazione di TG2 e di 
ROS su questi processi dinamici potrà consentire la messa a punto di device idonei 
sia per finalità di ricerca che per screening dell'efficacia di farmaci.
Infine la difficoltà di utilizzare modelli di malattia e' spesso un limite per effettuare 
screening di sostanze a potenziale impatto terapeutico. Questo modello dimostra di 
possedere sia i vantaggi di un "modello in vitro", cioe' la manipolabilità e versatilità, 
sia le caratteristiche peculiari del modello ex-vivo. E' infatti possibile screenare 
farmaci sul loro target naturale, cioe' le cellule del paziente poste in coltura con il 
grande vantaggio di poiter tener conto della variabilità interindividuale di risposta al 
trattamento che costituisce un problema cruciale nella farmacologia clinica. Queste 
caratteristiche rendono il sistema per l’analisi quantitativa della motilità e delle 
interazioni cellulari sviluppato nell’ambito di questo lavoro di tesi adatto per 
applicazioni biotecnologiche industriali.
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ABSTRACT
Cell migration is a very complex mechanism linked to the inflammatory response as 
well as to several processes of cell biology and development.  
The movement of cells in response to a chemokine gradient is the most popular form 
of interaction between cell environment and surface and specific surface receptor 
triggers an intracellular signaling pathway. This phenomenon is known as chemotaxis 
and is characteristic of neutrophil movements in response to the chemokine 
Interleuchin-8 (IL8) in a 3D space. Another paradigm of dynamic interaction between 
cells is the mechanism underlying the confluency of cells cultured in a Petri dish. This 
process is particularly studied  in growing epithelial cell lines, and is influenced by still 
undefined external stimuli as well as by cell proliferation and cytoskeleton 
reorganization, that allow the contact and interaction between  cells in 2D space.
Chronic inflammation is an ideal condition for the study of cell migration and its de-
regulation; understanding the mechanisms  involved in cell motility and their putative 
modulation, is the first step in setting new appropriate models of study.
During PhD project, different cellular models have been used: IB3 cell lines belonging 
to patients with  Cystic Fibrosis (caused by mutations of cystic fibrosis 
transmembrane regulator (CFTR)), and T84 cell lines, a popular model of study of 
Coeliac Disease, a common intolerance to proteins of wheat. Both disease are 
characterized by a pro-inflammatory milieu with high level of tissue Transglutaminase 
(TG2), a multi-functions enzyme with a defined role in several human pathologies.
Cystic Fibrosis is the prototype of diseases in which an uncontrolled production of IL8 
leads to a dysregulated neutrophil recruitment. The IB3 cell lines have been used to 
understand a molecular mechanisms of  enhanced IL8 production and their 
modulation. The results evidence i) the role of TG2 as a new pathogenic factor in 
Cystic Fibrosis; ii) the role of post-translational modifications of TG2 as a link 
between genetic defect of CFTR ad inflammation iii) the mechanisms of autophagy 
inhibition via ROS-TG2 axis, in epithelial airway cell line and mice model of CF. The 
consequence is a fine modulation of IL8 production. The system allows the design of
a 3D model to study cell migration under IL8 diffusive flux in qualitative and 
quantitative ways.
Another important pathological system with chronic inflammation is celiac disease 
and the analysis of interactions of alimentary peptides with the frontline gut 
epithelium is a useful model of study. The epithelial cells are pivot in the innate 
immune activation in CD and cytoskeleton rearrangement is the earliest event in 
such a response to gliadin peptides. The data in T84 cell model show a gliadin 
peptide-driven pro-inflammatory environment as a consequence of its impaired 
lysosomal degradation. Moreover, alterations of motility and cytoskeletal 
reorganization emphasize the “toxic” effect of peptide. Therefore, CD offers an ideal 
opportunity to set up a 2D model of study of cell motility.
Understanding the mechanisms of migration and the identification of appropriate 
target of modulation of cell recruitment could allow wide industrial applications in 
biotechnology and  will be successful to provide a useful tool to test potential 
therapeuthic molecules.
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INTRODUCTION
Motility and Inflammation
Cellular interaction and migration are common physiological events triggered and 
finely tuned by different mechanisms either intrinsic to the cell or present in cellular 
environment. Multiple interactions between environment and cell surface induce 
dynamic modifications of cellular phenotype (1). 
Cell migration, both single and collective, is a highly integrated multistep process that 
is essential in embryonic morphogenesis, tissue homeostasis and immune surveil-
lance to inflammation. In  collective migration a  movement of cohesive groups of 
cells is required (2) and the single migrating cell shows a highly polarization with 
complex regulatory pathways that are spatiotemporally controlled (1). Migration 
contributes to several important pathological processes, including cancer progression 
and metastasis formation. Metastasis, dissemination of malignant tumors to a distant 
organ, is the major cause of cancer mortality. Tumor cell motility is the hallmark of 
invasion and is an essential step in metastasis(3). 
Cell migration is a very complex phenomenon also linked to the inflammatory 
response as well as to several processes of cell biology and development.  
Cell movements into solid surfaces require a controlled sequence of cell protrusions 
and retractions that mainly depends on sophisticated regulation of the actin 
cytoskeleton and  the contribution of microtubules (4,5).
The movement of cells in response to a chemokine gradient is the most popular form 
of interaction between cell environment and surface in which specific surface 
receptor triggers an intracellular signaling pathway. The final event is the movement 
of cells in direction of chemoattractant (6). This process is characteristic of 
neutrophils movements in response to the chemokine Interleuchin-8 (IL8) in a 3D 
space.
Another paradigm of dynamic interaction between cells is the mechanism underlying 
the confluency of cells cultured in a Petri dish. This may be considered the prototype 
of movements in 2D space. This process is particularly studied  in growing epithelial 
cell line, and is influenced by still undefined external stimuli as well as by cell 
proliferation and cytoskeleton reorganization, that allow the contact and interaction 
between  cells. Cell contact and interaction may in turn impact on cell differentiation, 
as in confluent intestinal epithelial Caco-2 cell lines, which undergo differentiation 
with surface expression of brush border enzymes, markers of terminal differentiation.
Both attraction forces that compromise the adhesion of cell to fiber of matrix and 
cellular adaptative mechanisms are required to respond  to matrix resistance. In 3-D
ECM, in contrast to 2-D substrate, the cell shape is mostly bipolar and the 
cytoskeletal organization is less stringent, frequently lacking discrete focal contacts 
and stress fibers.(7)
Cell migration can be seen as a cyclic process usually driven by several factors, 
among the others actin polymerisation, stabilized upon adhesion to the extracellular 
matrix (ECM). Although matrix adhesion dynamic is very important for understanding 
cell migration behavior, the molecular mechanisms that regulate adhesion dynamics 
and signalling in disease conditions are still unclear (8,9).
All together these findings indicate that cell motility and migration occur as a 
consequence of a finely tuned interaction between intracellular and cell surface 
signaling pathways which can be influenced by a wide range of environmental 
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factors. Moreover such a signaling cascade may be disrupted in several disease 
states and migration itself can be considered a key step in disease evolution (10,11).
In the complex overview of motility and interaction between the cells within a specific 
environment, the research of factors influencing the interaction in human pathology is 
mandatory. As a matter of fact, the progress of many chronic disease is influenced by 
alterations of motility or interaction. An important instance is represented by neo-
plastic movements of cancer cell and its deregulation during disease progress; 
understanding the mechanism of modulation of factor involved in this deregulation 
will be relevant for therapeutic applications.
The study of “moviments” and their directionality in human pathology is not only 
relevant for cell-to-cell interactions within a specific environment. Such a process is 
also  a feature of intra-cellular processes where cytoplasmatic organelles, proteins 
aggregates and proteins (nuclear translocation) move within the cell with defined 
rules. A typical example is the trafficking and reciclying of membrane proteins within 
endosome-structure or  degradation route (proteasome). These movements are the 
basis of several processes, among the others autophagy and cytoskeleton 
rearrangement that in turn can influence the “external” motility.
Cell migration may also take place within a proper tissue environment. This is the 
case of mucosal tissues approaching a luminal cavity, as airways or gut mucosa. In 
this case the spatial organization of tissues allow a compartmentalization of different 
cell types whose location reflects a specific function. Epithelial cells are the front line 
of airways and intestine and represent a set of specialized cells. These cells are also 
able to orchestrate cell migration within the tissues to maintain a proper tissue 
homeostasis in response to environmental triggers. In this context they are able to 
fight "toxic" environmental challenges, either bacterial or alimentary triggers, by 
secreting specific chemoattractant factors that recruit immunocompetent cells to the 
"damaged" luminal surface. This process is a well orchestrating event that involves 
different types of cells moving within the tissue and interacting each other in 
response to a given triggering factor. 
The release of chemoattractants is the results of the activation of complex 
intracellular signaling cascades also involving a cytoskeleton rearrangement and 
generating a "stressed" environment (5). 
The physiological mechanisms underlying such a complex production of 
chemoattractant factors is often impaired in disease conditions in which an improper 
activation of specific pathways or the lack of physiological mechanisms of control, 
lead to impaired production of chemoattractants with derangement of cell motylity 
and physiology.
The most popular examples of intra-tissue migration of cells are chronic inflammatory 
diseases occurring at the mucosal surface.  Airway and gut chronic inflammatory 
diseases are the ideal condition for the study of cell migration and its de-regulation 
within a controlled environment. In these conditions several cell populations are 
recruited in response to the enhanced local release of chemo-attractant molecules 
(chemokines) that favor the infiltration of circulating leukocytes within a disease-
target tissue. This phenomena is noted as chemotaxis and the chemical mediators 
(chemokine, citokine) recall the white cells from blood; the cells must go through 
different layers(blood vessel, extracellular matrix, epithelia) (12). The formation of 
chemical gradient (cytokine-chemokine)  become an important motor for cell 
migration.
One of main factors regulating the chemokine-chemical gradient is the presence of 
an inflammatory status. Inflammation is a physiological process of response to tissue 
 CHAPTER  I      
 
12 
 
injury. However, the dysregulation of the proper control of inflammation, induces a 
massive infiltration of leukocytes (neutrophils, monocytes, lymphocytes)  within the 
target tissue as it occurs in gut, airways, skin, joints leading to chronic inflammatory 
response and tissue damage. Inflammation is also strictly linked to many events that 
favor cell motility, such as cytoskeleton rearrangement
In chronic inflammatory diseases at the mucosal sites the rules of cell migration are 
strictly dependent on disease pathogenesis as well as on the nature of the unwanted 
triggering event dictating the time-course and the type of the release of 
chemoattractants by the injured epithelia (13). In arways, bacterial challenge is a 
common  "toxic" event  which requires neutrophil recruitment. As a consequence, the 
release of IL8, a potent neutrophil chemoattractant, is required. The prototype of 
diseases in which an uncontrolled production of IL8 leads to a dysregulated 
neutrophil recruitment, is Cystic Fibrosis, a most common lethal genetic disorder in 
caucasians characterized by chronic inflammation and recurrent pulmonary bacterial 
infections.
These evidences highlight that the identification of factors that dysregulate the 
complex mechanism of motility is the key model to develop molecules able to 
regulate this factor in order to find putative biotechnological applications.
The choice of a suitable disease model for the study of potential factors involved in 
motility\interaction processes, must take in account that these mechanisms are a 
pathogenic element of disease and not only a bystander event. Understanding the 
specific pathways involved may lead to the identification of molecules able to 
modulate this biological process in human pathology. 
During PhD project, different cellular models of these two main diseases have been 
used as model of study to understand the molecular mechanisms that influence 
inflammation-triggered cell movements : IB3 and C38 cell lines belonging to patients 
with  Cystic Fibrosis and T84 cell line, a popular model of study of Coeliac Disease, a 
common intolerance to proteins of wheat. Both disease are characterized by a pro-
inflammatory milieu with high level of tissue Transglutaminase (TG2), a multi-
functions enzyme with multiple functions, as cross-linking of substrate protein, 
isomerase or G protein activity, with a defined role in several human pathologies
(33).
Cystic fibrosis is caused by mutations of cystic fibrosis transmembrane regulator 
(CFTR), which functions as a chloride channel in epithelial membranes. More than 
1000 mutations in CFTR gene have been identified and they can be grouped into six 
classes: (1) CFTR is not synthesized; (2) defective processing; (3) regulation; (4) 
conductance; (5) partial defective production or processing; or (6) defective 
regulation. The most common CFTR mutation belongs to class 2, and is caused by 
the deletion of phenylalanine at position 508 (F508del) of CFTR. The impaired 
chloride transport leads to water/volume depleted periciliary liquid with a increase of 
mucus viscosity . Bacteria invading the cystic fibrosis lung are trapped within this 
viscous mucus layer at the surface epithelial layer.  As a consequence, recurrent 
pulmonary infections, principally by Pseudomonas Aeruginosa, colonization together 
with chronic inflammation are main features of CF lung pathology(14).
CF chronic inflammation is neutrophil-mediated, as circulating neutrophils are 
recruited within the airways and contribute to the extensive lung damage and to the 
development of impaired lung function. Accordingly, CF lung pathology is associated 
with a marked increase of proinflammatory cytokines, such as TNF--6, IL-	-
17 (15, 16), and the potent neutrophil chemoattractant and activator IL-8, which 
recruits large numbers of neutrophils into the airways.
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However, conflicting results have been reported on whether CF airways undergo 
proinflammatory response in the absence of bacterial infections (17-19). Several 
studies have shown that both cytokine profile secretion and NF-B activation are 
similar in CF and normal cells (20, 21). However, mounting evidences suggest that 
inflammation may occur before infection, and CFTR-defective cells have an 
intrinsically proinflammatory phenotype (22-24). Recently, it has been shown that 
CFTR is a negative regulator of NF-B-mediated innate immune response, and its 
localization to lipid rafts is involved in control of inflammation (25).
The neutrophil involvement in CF chronic airway inflammation could suggest a 
development of a 3D motility model to study neutrophils migration under diffusive flux 
of IL8 and their containment upon identification of the main rules governing IL-8
production.
As chronic inflammation may represent a driving force of cell motility/migration, we 
could envisage several disease-related models of study, either 3D or 2D models. The 
study of cell migration in a given disease-related model could help in defining  novel 
devices useful in validating several attracting mechanisms and related molecules 
with potential implicatrions in human therapy.
Among the others, another important pathological system with chronic inflammation 
is celiac disease and the analysis of interactions of alimentary peptides with the 
frontline gut epithelium is a useful model of study (a popular model of study is 
represented by the T84 cell lines). 
Coeliac disease (CD) is a very common pathology that affects 1% of the general 
population, caused by the ingestion of gluten proteins,in susceptible individuals (26-
28). Its strong associations with HLA class II (HLA DQ2 or DQ8) and a well-defined 
triggering antigen suggest that coeliac disease is a prototype of T-cell-mediated 
disease.(26). Evidence suggests that CD4(+) T cells are central in controlling the 
immune response to gluten that causes the immunopathology (29-31). The primary 
HLA association in the majority of CD patients is with DQ2 and in the minority of 
patients with DQ8. DQ2 or DQ8 are the predominant restriction elements for gluten-
specific T cells. Lesion-derived T cells predominantly recognize deamidated gluten 
peptides. A number of distinct T cell epitopes within gluten exist. DQ2 and DQ8 bind 
the epitopes so that the glutamic acid residues created by deamidation are 
accommodated in pockets that have a preference for negatively charged side chains. 
Evidence indicates that deamidation in vivo is mediated by the enzyme tissue 
transglutaminase (TG2). This may result in the formation of complexes of gluten-
TG2. These complexes may permit gluten-reactive T cells to provide help to TG2-
specific B cells by a mechanism of intramolecular help, thereby explaining the 
occurrence of gluten-dependent TG2 autoantibodies that is a characteristic feature of 
active CD(27). Moreover it is well known that a co-operation between the innate and 
adaptive branches of the immune response are crucial in CD pathogenesis. Some 
gliadin peptides, which are not recognized by gliadin-specific T cells, are effective in 
activating the innate response either at epithelial or dendritic cell level. This innate 
activation is essential in setting the tone of the adaptive response, as the 
immunodominant peptides turn on toxic only if the gut mucosa has been primed by 
the so-called "innate" gliadin fractions (77). These peptides are able to induce 
profound epithelial changes in celiac mucosa as well as in models of CD, as T84 or 
Caco2 cell lines. Innate epithelial activation include phosphirylation of proteins, 
cytoskeleton riorganization and even IL-15-mediated apoptosis (77). The peptide
p31-43 is the prototype of these peptides and it has been reported as also effective in 
inducing early TG2 activation. 
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A link between these two models of human diseases, CF and CD, the first 
monogenic, the second one multifactorial with a strong involvement of the immune 
response, is the presence of high tissue levels of the enzyme Tissue 
Transglutaminase (TG2) a protein with pleiotropic functions, as a consequence of the 
genetic defect in CF, or triggered by gliadin peptides in CD. In addition, both 
diseases show a chronic inflammatory phenotype, although neutrophil-mediated in 
CF and devoid of neutrophil component in CD. Finally in these two pathological 
conditions surface epithelial cells  are key players in disease pathogenesis.
The epithelial cells are pivot in the innate immune activation in CD and cytoskeleton 
rearrangement is the earliest event in such a response to gliadin peptides; moreover 
cytoskeletal reorganization is a known factor of cell differentiation (32) . Therefore, 
CD offers an ideal opportunity to set up a 2D model of study of cell motility. In this 
study we have also developed  a 2D motility model to test i) the effects of gliadin 
peptides in deranging cell motility and interaction in a 2D monolayer epithelial culture 
model and ii) to test the role  of  several modulatory molecules with potential 
therapeutic application.  
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AIMS
 
Cell migration is a very complex phenomenon that regulates the inflammatory 
response as well as several processes of cell biology and development.  The 
identification of a specific regulatory pathway, offers  a potential strategy to modulate  
many human pathology.
Understanding the mechanisms involved in cell motility and their putative 
modulation, is the first step in setting the new appropriate model of study. 
Therefore, the PhD activity consisted of two main activities:
A) the study of the molecular mechanisms leading i) to release and modulation of 
major chemoattractant factors’ (such as IL8) and their containment; ii) the effects of 
chronic inflammation in deranging cell-to-cell interaction and the putative
mechanisms of control. To this aim two human disease models of chronic 
inflammation, Cystis Fibrosis with IL8-driven neutrophil-dominated chronic airway 
inflammation and iii) Celiac disease, the prototype of food induced activation of the 
mucosal immune response have been used. 
B) the development of motility models: i) a 3D model of neutrophil migration in an IL-
8-rich environment; ii) a 2D model of interaction of epithelial cells upon challenge with 
celiac disease-triggering peptide in presence or absence of putative modulator 
factors.  
Both disease models are characterized by increased tissue levels of TG2 and chronic 
inflammation, as constitutive chronic airway inflammation characterizes Cystic 
Fibrosis, and gluten-triggered gut inflammation is a feature of Celiac Disease. 
The first condition is  characterized by a defective CFTR-driven pro-
inflammatory environment mediated by increased levels of Reactive Oxygen Species 
(ROS) and high level of TG2, a pleiotropic enzyme involved in many pro-
inflammatory conditions. In such a disease model the modulation of ROS-TG2 axis 
leads to restoration of cellular homeostasis with inhibition of IL-8 production. To 
understand the mechanisms of  TG2 regulation, we use (i) classical and innovative 
technique of cellular and molecular biology in CF and control epithelial cell lines; ii) 
an “ex vivo” model of human nasal biopsies; iii) “in vivo” mice models of disease. 
These in vitro and in vivo approaches allow the identification of the link between 
defective CFTR and inflammation through the disregulation of TG2-ROS axis.
The second condition, Celiac Disease, allow the identification of the rules of 
TG2 upregulation upon challenge with specific gliadin-derived triggers. In such a 
condition the study revealed how the modulation of ROS-TG2 controls gliadin-
induced mucosal inflammation. 
To translate these results into an appropriate study model of motility for putative 
biotechnological applications, a 3D model for neutrophils migration assay has been 
set up. The 3D model is an ideal model to study the movements of cells in a 3D 
matrix of gel, where a diffusive flux of molecule induces  migration.
Moreover a 2D model has been used to test whether controlling ROS-TG2 pathway 
might restore the derangement of cell-to-cell interaction and cytoskeleton 
reorganization taking place upon challenge of T84 intestinal epithelial cells with 
gliadin-derived peptides. The results highlight  the feasibility of this model as a 
prototype to screen, in a very fast way, different molecules with potential therapeutic 
application. 
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RESULTS
The first part of PhD research program focused on the analysis of the molecular 
mechanisms responsible for the induction of the pro-inflammatory phenotype that 
characterizes Cystic Fibrosis airways, and the processes that regulate high TG2 
levels. 
Transglutaminase 2 (TG2) is an inducible transamidating acyltransferase that 
catalyzes Ca(2+)-dependent protein modifications. It acts as a G protein in 
transmembrane signalling and as a cell surface adhesion mediator, this distinguishes 
it from other members of the transglutaminase family (30 ). In mammals, nine distinct 
TGase isoenzymes have been identified at the genomic level; however, only six have 
so far been isolated and characterized at the protein level. All members of this 
superfamily possess a catalytic triad of Cys-His-Asp or Cys-His-Asn. Recent 
structural studies have described the regulatory mechanism of the transamidating 
activity for the TG2, but can be assumed to act in all the family members. The 
arrangement of the amino acids of the catalytic centre (Cys277, His 335 and Asp358) 
in a charge-relay catalytic triad, analogous to that of thiol proteinases such as papain, 
confers high reactivity on Cys277 to form thioesters with peptidylglutamine moieties
in the protein substrate. This high reactivity, in the presence of Ca2þ, of Cys277 has 
been employed to develop a wide range of active-sitedirected irreversible inhibitors of 
the enzyme(34)
The sequence motifs and domains revealed in the recent TG2 structure, can each be 
assigned distinct cellular functions, including the regulation of cytoskeleton, cell 
adhesion and cell death. Ablation of TG2 in mice results in impaired wound healing, 
autoimmunity and diabetes, reflecting the number and variety of TG2 functions. An 
important role for the enzyme in the pathogenesis of coeliac disease, fibrosis and 
neurodegenerative disorders has also been demonstrated, making TG2 an important 
therapeutic target.  
Understanding the mechanisms of migration and the identification of appropriate 
target of modulation of cell recruitment could allow wide industrial application in 
biotechnology.
1.The Inflammatory environment of Cystic Fibrosis 
1.1.The up-regulation of TG2 in  human CFTR-defective cells
To underpin the molecular link between a defected CFTR and the excessive 
inflammatory responses typical of CF airways, here we have studied CFTR-defective 
bronchial epithelial cell lines, IB3-1 human CF bronchial epithelial, (carrying 
F508del/W1282X CFTR mutation) and isogenic stably rescued C38 . 
We demonstrated in CF airway epithelial cell lines and in human CF nasal biopsies 
increased levels of  TG2. 
We observed levels of TG2 protein in IB3 and C38 cells, that were analysed by  
Western Blot. The figure 1A shows high levels of TG2 (72 kDa)  in IB3 compared to 
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FIGURE 1. TG2 in CF cell line
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C38. Therefore, we explored whether ,besides TG2 high levels, also its enzymatic 
activity were up-regulated in CFTR-defective cell lines. The confocal microscopy 
images reveled a signi
         
C38, upon incubation with biotinylated monodansylcadaverine (bio-MDC; Molecular 
Probes), a known molecule  substrate of TG2 (Fig. 1A).
To assess that the pathway described to date was a direct consequence of CFTR 
dysfunction, we blocked the functional CFTR in the normal bronchial 16HBE cell line 
with the selective inhibitor CFTRinh-172 (22). The enzymatic activity of TG2 and protein 
were high increased in presence of CFTRinh-172 compared to control without inhibitor, 
as shown in confocal microscopy images in Fig. 1B.
These results clearly indicate that CFTR-defective epithelial cells are characterized 
by an intrinsic TG2 functional increase.
Exposure of the IB3-1 cells to the irreversible TG2-speci
 !"#$%
M. Grif
&'% '()(*$+-37) as well as reversible inhibitor 
cystamine or gene silencing by TG specific siRNA, reveled that TG2 activity also 
in,   -  ,(  !tion of TG2 induced a signi

reduction of the phosphorylated p42/p44 MAPKs, of the nuclear translocation of NF-
./01--1 cells(Fig.1C). 
TG2 is therefore a master regulator of inflammation in CF airways and mediates the 
production of inflammatory cytokines and chemokines via targeting key regulatory 
pathways of inflammation.
1.2. SUMOylation of Tissue Transglutaminase
Because TG2 activity is also regulated by ROS (38) we tested whether ROS 
in,/ -induced in,n CF. In agreement with previous reports, 
high levels of ROS were  only detected in CF tissues and CFTR-defective cells (data 
not  shown) (39). The IB3 cells were treated with ROS scavenger NAC (N-Acetil-
Cysteine) or EUK 134 and analysis by confocal microscopy and ELISA assay shown 
a  signi
 /  2 /  234332 2  $/
not shown), and TNF-a release (Fig. 2A) in both CF tissues and IB3-1 cells. The 
inhibitor CFTRinh-172 in 16_HBE normal bronchial cell lines reveled an increase of 
intracellular ROS (Fig. 2B) and increase of p42/44 phosphorylation. 
Altogether, these results clearly demonstrated how pro-oxidative environment 
influences TG persistence and  CFTR disruption directly leads to the development of 
airway in,51(
TG2 is regulated by retinoids, steroid hormones, peptide growth factors and 
cytokines that also lead to  a time-dependent decrease in TG2 ubiquitination (40). 
This indicates that posttranslational control mechanisms may regulate TG2 tissue 
levels in CF airways. We focused on small ubiquitin like-modifier (SUMO) post-
translational modification since this has been defined as a central way of regulating 
key cellular functions and stability of proteins (41,42). SUMOylation  has been 
defined as a key player of the post-translational network to regulate key cellular 
functions including transcription, nuclear translocation, stress response and 
chromatin structure as well as of diversifying localization and even stability of the 
modified proteins (41,42). Sumoylation is accomplished via an enzymatic cascade 
involving, among the others, E3 ligases, that catalyze the transfer of SUMO from the 
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FIGURE 2. CFTR inhibition induces airways inflammation
conjugating enzyme UBC9 to a substrate (41). E3 ligases have gained a central role 
in the SUMO machinery, since they regulate sumoylation  in response to different  
stresses (41).
To investigate whether posttranslational modifications could result in the persistence 
of high levels of TG2 protein, the protein extract of IB3-1 and C38 cells were 
analyzed by Western blots and  revealed that SUMO-1 protein level was increased in 
IB3-1 cells as compared with C38 cell lines (Fig. 3A). Sequence analysis and SUMO 
motif screening revealed three SUMO accepto$67-89*$3*:(
The experiments of figure 3A shows, also, that when TG2 immunoprecipitates from 
IB3-1 cells were probed with the anti-TG2 Antibody, two TG2 bands were detected, 
with the upper band corresponding to the SUMOylated TG2. 
Since Protein Inhibitor of Activated STAT (PIAS)y, a member of the PIAS family (43), 
has recently been defined as the first SUMO ligase for NF-kB essential modulator 
(NEMO) (43) and PIASy-NEMO interaction is mediated by Reactive Oxygen Species 
(ROS) (43), we also investigated whether PIASy-TG2 interaction could mediate 
ROS-driven post-translational modifications of TG2.
To investigate whether PIASy could mediate TG2 SUMOylation, we performed 
experiment of Immunoprecipitation of  PIASy and TG2  in IB3-1 cells .  
IB3 cells were treated or not with virus infection of human manganese superoxide 
dismutase (MnSOD) to regulate the pro-oxidative environment of cell. The IP 
analysis underline a direct interaction between PIASy and TG2 shown with band 
corresponding to reciprocal antibodies of IP, with a strong decrease of interaction in 
presence of MnSOD; as well as PIASy-TG2 interaction also TG2 Sumoylation is 
decreased upon MnSOD infection (Fig 3B). The western blot analysis of SUMO, 
TG2, PIASy evidenced  the reduction of level with MnSOD(Fig.3C). 
The data of experiments indicate that in CF airway epithelia the  pro-oxidative 
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FIGURE 3. PIASy mediates TG2 SUMOylation in CF airway epithelial cells
intracellular milieu leads to PIASy-mediated TG2 sumoylation. 
SUMOylation influence ubiquitination since these two main posttranslational changes 
may compete each other for the same lysine residues on the aminoacid sequence. 
SUMOylation may induce protein stabilization by blocking ubiquitination of the same 
lysine residues (44).  
We performed experiments of SUMO or PIASy gene silencing. IP studies revealed 
an increase of TG2 ubiquitination upon proteasome inhibition by MG132 (Fig.4A,B), 
thus allowing TG2 to be targeted to proteasome for degradation. This induced 
decreases of TG2 protein (Fig. 4C) and activity.
Therefore, oxidative stress increases PIASy protein levels and favors TG2 
SUMOylation that leads to the persistence of high TG2 tissue levels by 
downregulating TG2 ubiquitination and proteasome degradation. 
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FIGURE 4. Decrease of TG2 protein levels and TG2 activity by either SUMO or 
PIASy gene silencing
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TG2 SUMOylation might provide the missing link between cellular stress and 
inflammation. We investigated whether the control of TG2 SUMOylation might
modulate TG2-driven inflammation (24). The figure 5 demonstrated that gene 
silencing of either PIASy or SUMO by specific siRNAs induced a significant decrease 
of p42\44 phosphorylation(Fig.5A) and TNF-$1%(+B) in IB3-1 cells. 
FIGURE 5. SUMO-1 or PIASy gene silencing control inflammation in CF airway 
epithelial cells
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1.3.Imapct of TG2 persistence in CF epithelia
The data underline  that CF environment ROS-mediated leads to a persistence of 
TG2 with strong pro-inflammatory effects and increase of citochine release sucs as 
01/#(
To identify  a more effective way to antagonize this  pro-inflammatory pathway 
CFTR-driven, we studied the effect of TG2 persistence in CF epithelia.
TG2 is an enzyme with a vast array of biological functions that mainly catalyzes 
cross-links or deamidation of target proteins in the presence of high Ca2+ levels.
Previously, we shown high  TG2 protein level in IB3 cell lines compared to low livel in 
C38. In these data we demonstrated low levels of 55 kDa Peroxisome Proliferator-
Activated Receptor gamma (PPAR), (Fig 6A) a nuclear hormone receptor 
expressed in monocytes, macrophages and epithelial cells that negatively regulates 
inflammatory gene expression by “transrepressing” inflammatory responses (45.). 
To unravel the putative link between TG2 and PPAR, we then  performed 
experiment of Immunoprecipitation (IP) of protein lysates of IB3 vs C38 cell line The 
IP analysis underline a direct interaction between PPAR and TG2 shown with band 
corresponding to reciprocal antibodies of IP, with a strong decrease of interaction in 
presence of TG2 inhibitor (data not shown).
We, then  tested the hypothesis that TG2 might induce posttranslational 
modi
$-linking) of PPAR in CFTR-defective cells, because the QP and 
QXXP motifs in the PPAR sequence could be recognized as speci

activity (40)
We demonstrated that  in IB3 cell TG2 catalizes crosslinking and ubiquitination of 
PPAR. After  IP of PPAR !;!/0<$=-L-glutamyl)-L-lysine 
isopeptide antibody that reveled the specific bound between TG2 and target protein. 
The figure 6A shows high molecular weight corresponding to modification induced by 
TG2 (130-250 kDa). Exposure of the IB3-1 cells to the irreversible TG2-speci

inhibitor R283 or silencing of TG2,  induced a signi
/ % 
mass PPAR ,TG2-induced  (Fig. 6B) and a signi
   ++ -
kDa PPAR in the IB3-1 cells (Fig. 6B). This indicated that the crosslinked PPARy 
was due to increased TG2 activity. 
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FIGURE 6. Effects of TG2 on PPAR protein expression and localization
In IB3-1 cells, PPAR nuclear translocation was promoted only by R283, whereas 
rosiglitazone, a PPAR agonist with potent antiin,  /  
(46), induced only a marginal nuclear PPAR increase (Fig. 6C). In contrast, 
rosiglitazone alone was able to induce an impressive PPAR nuclear translocation in 
C38 cells (Fig. 6C). 
These results indicate that crosslinking of PPAR by TG2  in CFTR-defective cells 
flavored  a pro-inflammatory environment.
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As previously described, TG2 SUMOylation may have great relevance in driving CF 
inflammatory phenotype and release of pro-inflammatory cytokines and 
chemoattractants. PPAR which may be targeted by TG2 to crosslinking, may also 
be  targeted by SUMO-1 and undergo sumoylation in response to a PPAR
agonists, such as Rosiglitazone (47).  Sumoylated PPAR interacts with the nuclear-
receptor co-repressor (N-CoR)-histone deacetylase 3 (HDAC3) complex and thereby 
blocks its ubiquitination, thus maintaining a repressor condition (47).  
This study shows that sustained TG2 activation inhibits PPAR SUMOylation and its 
interaction with the N-CoR (47) thus favoring inflammation. Moreover  TG2 induces 
crosslinking and degradation of Ik- -;! $3#*/%
regulator of NF-kB activation, inhibits Ik- >'?@  /  01-kB 
activation (Figure 7). 
Immuprecipitation experiments shown an increased  PPAR sumoylation (Fig.7A) , 
blocking TG2 through specific gene silencing or with specific inhibitor cystamine , in 
response to rosiglitazone (agonist of PPAR)  in IB3 cell line,  ; confocal microscopy 
images shown an enhanced N-CoR protein and its nuclear localization (Fig. 7B), and 
favored N-CoR- PPAR interaction (data not shown). Moreover siRNA of TG2 or 
cystamine induced increase of Ik-/2($%(A5*(
TG2 SUMOylation may therefore switch off the intracellular regulatory machinery, 
preventing PPARy SUMOylation, IkBa stabilization, and leading to an uncontrolled 
in,ammatory response. 
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FIGURE  7. TG2 inhibition modulates PPAR 	
 pathways in CF airway 
epithelia.
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1.4. Aggresome: a  feature of CF epithelia
To test whether persistence of PPAR due to TG2-crosslinkin influenced its 
proteasome degradation, we performed immuprecipitation of PPAR upon 
treatments with MG132 (chemical inhibitor of proteasome), and reveled for Ubiquitin.
The figure 8A shows that IB3 cell after treatments with MG132  increased PPAR
protein level and its ubiquitination  and microscopy images  evidenced that it was  
mainly limited to perinuclear localization in CFTR-defective IB3-1 cell line . 
This perinuclear localization was suggestive of aggresomes, a speci
c cellular 
response against accumulation of ubiquitinated misfolded and/or aggregated 
proteins, which might also result from impaired proteasome function (49). Although 
aggresomes containing PPAR have not been described before, aggresomes 
containing ubiquitinated misfolded MF508 CFTR molecules have been previously 
observed as result of overexpression of the defective CFTR (49). The aggresomes of 
CFTR also contain HDAC6, a microtubule-associated deacetylase that interacts with 
ubiquitin and stabilizes polyubiquitin chains (50). We have shown by confocal 
microscopy images that in the CFTR-defective IB3-1 cell line, the perinuclear 
aggregates of PPAR also colocalize with both HDAC6 and ubiquitin (Fig. 8B); 
inhibition of proteasome by MG132 increased this  colocalization and the level of 
HDAC6 and Ubiquitin (Fig.8B). The data thus demonstrated  the aggresome nature 
of these aggregates.
FIGURE 8. Aggresome: a  feature of CF epithelia
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1.5. Aggresome and autophagy
In previous data we described the presence of peroxisome proliferator activated 
receptor (PPAR)- in aggresomes in CF airways (24), and the mutant CFTRF508del 
has been described as the prototype of a misfolded aggresome-prone protein (51-53) 
Sequestration of the anti-inflammatory PPAR- into aggresomes, mediated by the 
increased TG2 levels, contributes to the lung inflammation in CF (54). This is the 
result of ROS-mediated TG2 SUMOylation inducing the crosslinking, ubiquitylation 
and aggresome sequestration of several target proteins (54). Because oxidative 
stress and accumulation of protein aggregates are features of CF airway epithelia
(24,54,55), we speculated that the accumulation of aggresomes in CF is due to 
defective autophagy.
Autophagy is a cytoprotective mechanism for the degradation of misfolded/ 
polyubiquitylated proteins and damaged organelles through lysosome mediated self-
digestion (56,57). 
Autophagy is important in clearing protein aggregates after overload of 
polyubiquitylated proteins (58,59). Here we demonstrate how defective CFTR drives 
autophagy inhibition in mouse and human CF airway epithelia by means of the ROS–
TG2 pathway, with sequestration of beclin 1 interactome, a key player of 
autophagosome formation (60-62), in the aggresomes. Rescuing beclin 1 and 
autophagy restores CFTR trafficking and damps down inflammation.
We cultured human CF airway epithelial IB3-1 or CFBE41o- cells(F508del/F508del), 
C38, or bronchial epithelial 16HBE14o-cells under nutrient starvation to stimulate 
autophagy (63,64).
In first analysis we observed, through transmission electron microscopy, the 
presence of autophagosomes containing mitochondria and cellular organelles in C38 
but rarely in IB3-1 cells (Fig. 9A). The western blot analysis shown the accumulation 
of LC3, a marker of autophagosomes (64) in IB3 and C38 cells line. Increase of LC3 
II, the lipidated product of LC3 (63,64), was observed in C38 but not in IB3-1 cells 
under starvation (Fig. 9B). E64d and pepstatin A, inhibitors of the lysosomal 
proteases (Fig. 9C), as well as chloroquine, a weak base disrupting lysosomal 
functions failed to increase LC3-II, thus indicating that reduced LC3 II levels were not 
due to LC3 lysosomal degradation. Defective autophagy in IB3-1 cells was also 
revealed by the increased pool of polyubiquitinated proteins, and accumulation of 
p62 (Fig. 9C,D), a LC3- and ubiquitin-binding protein, that accumulates in 
intracellular aggregates under defective autophagy (63,64). IB3-1 cells were also 
resistant to rapamycin, a known autophagy inducer (63,64). 
Real-time PCR analysis of several autophagy-related genes(64,65), ULK1, ULK2, 
ATG5,  ATG6 (beclin 1), ATG7, ATG14, Bcl-2, vacuolar protein sorting (hVps)34,
regulatory myrisoylated kinase hVps15 and Ambra1 did not reveal reduced mRNA 
expression levels in IB3-1 and CFBE41o- as compared to C38 and 16HBE14o- 
cells(Fig.10A).
Growing evidences indicate that beclin 1, a tumor suppressor gene (60,61), interacts 
with the class III PI3K, hVps34 (65,66) and ER associated class III PI3K activity is 
crucial in the initiation of autophagosome formation (67,68). Moreover the 
dissociation of beclin 1 from  Bcl-2 promotes autophagy during stress conditions, 
such as starvation (67-70).
PI3K core complex binds either to Atg14L or UV-irradiation-resistance-associated 
gene (UVRAG) (65,71), involved in distinct functional complexes driving either 
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FIGURE 9. Autophagy is defective in human and mice CF airway epithelia
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autophagy or endosome-to-Golgi retrograde trafficking (71), and Atg14L appears to 
divert hVps/Class III PI3K into an autophagic role (71)
We preformed  immunoprecipitation of beclin 1 in IB3-1 and C38 cells with or without  
starvation and reduced Bcl-2 immunoreactivity was observed in IB3-1 with  starvation 
compared to nutrient condition; hVps34, hVps15, Ambra1 and Atg14L 
immunoreactivities were detected in beclin 1 immunoprecipitates from C38 but also 
IB3-1 cells and increased upon starvation, thus suggesting an intracellular 
environment favourable to autophagy induction (Fig.10B). Reduced protein levels of 
beclin 1, hVps34, hVps15, Ambra1 and Atg14L (Fig.10B), as well as of UVRAG (data 
not shown), were observed in IB3-1 cells. Western blots of the insoluble protein 
fraction revealed increased beclin 1 in IB3-1 as compared to C38 cells, this 
suggesting retention of beclin 1 as an insoluble protein within aggregates in CF 
epithelia (Fig.10C). Interestingly, hVps34 (Fig. 10D), beclin 1 and the other beclin 1 
interacting proteins (data not shown) colocalized with the ER marker calnexin in C38 
but not in IB3-1 cells. In CF cells beclin 1 and beclin 1 interacting proteins, are 
sequestered in perinuclear aggregates, where they co-localized with the aggresome 
marker HDAC6 (50) (Fig. 10D). The results indicated an essential role of Beclin 1 in 
autophagy machinery due to aggresome formation.  
To test the role of Beclin 1, we overexpressed beclin 1 in IB3-1 cells. HA-tagged 
beclin induced increased LC3 II and reduced p62 accumulation (Fig. 11A) and 
increase of autophagosome formation (Fig. 11A); moreover, HA-beclin was detected 
at the ER level (Fig. 11B, top panel) and restored co-localization of hVps34 (Fig. 11B, 
bottom panel), hVps15, Ambra1, and Atg14L (data not shown) with calnexin
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FIGURE 10. Sequestration of beclin 1 interactome in aggresomes drives defective
autophagy in CF airway epithelia
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FIGURE 11. Effect of Beclin 1 overexpression
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These findings suggest post-transcriptional regulation of beclin 1 expression in CF 
airways. Since beclin 1 protein sequence contains QP and QXXP motifs, specific 
target sites for TG2 activity (40), we tested the hypothesis that beclin 1 might undergo 
TG2-mediated cross-linking and in Beclin 1 immunoprecipitates from IB3-1 cells we 
observed positive isopeptide immnureactivity that were reduced upon TG2 knock 
down as well as by the TG2 inhibitor cystamine (40) (Fig.12A)  or the calcium 
chelator BAPTA-AM (24,54). TG2 siRNA or cystamine restored the soluble forms of 
beclin 1 and beclin 1 interactor proteins (Fig. 12B) and reduced also, beclin 1/HDAC6 
co-localization and aggresome sequestration (Fig. 12B). These results indicate that 
TG2-mediated cross-linking drives defective autophagy in CF epithelial cells.
Because increased ROS sustain high TG2 levels via PIASy-mediated TG2 
SUMOylation (54), we incubated IB3-1 cells with EUK-134 (54) and we observed 
reduced beclin 1 cross-linking and aggresome sequestration (data not shown),  
autophagosome formation (Fig. 12C), and beclin 1 upregulation 4 or knocked down 
PIASy (Fig. 12C). CFTR knock down in autophagy-competent C38 cells reduced 
beclin 1 and LC3 II protein, and p62 (Fig. 12D). These effects were prevented by 
cystamine as well as by EUK-134 (Fig. 12D) or NAC (data not shown)These results 
indicate that ROS-mediated TG2 SUMOylation is responsible for defective autophagy 
in CF epithelia. 
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FIGURE 12. TG2-mediated crosslinking of beclin 1 induces aggresome sequestration 
of beclin 1 interactome and drives defective autophagy in CF airway epithelial cells
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These results indicate that defective CFTR plays a pivotal role in driving beclin 1
downregulation and defective autophagy in CF airways via ROS-TG2 pathway. 
Next, we investigated whether defective autophagy might play a role in CF 
inflammation. HA-tagged-beclin 1 rescued pro-inflammatory phenotype of IB3-1 cells 
as it reduced p42-44 phosphorylation (Fig. 13A), increased 55 kDa PPAR protein 
(Fig. 13A), and reduced TNF-  / $2BC(C* $1%( &*(D 
investigated whether defective autophagy might in turn sustain TG2 activation. HA-
beclin 1 decreased ROS (p<0.01) and TG2 SUMOylation (data not shown),  PIASy 
and TG2 proteins (Fig. 13A). Since targeting TG2 restores inflammation in human 
and mice CF airways, we investigated whether these effects were mediated by 
rescue of autophagy. The effects of cystamine or antioxidants (data not shown) in 
controlling p42-44 phosphorylation, and TNF- secretion (Fig. 13B) were neutralized 
upon beclin 1 knock down. This indicates that rescue of beclin 1 and autophagy 
mediates the effects of cystamine and antioxidant molecules in CF epithelia. 
These results indicate that targeting ROS-TG2 axis ameliorates human and mouse 
CF airway phenotype by restoring beclin 1 and autophagy.
FIGURE 13. Restoring beclin 1 and autophagy rescues CF phenotype in IB3-1 cells.
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1.6.In vivo model
The data described above in CFTR-mutated cell line or normal given a strong 
concept that in CF induced an activation of ROS-TG2 axis that leads to a pro-
inflammatory environment. To demonstrate  the importance of this pathway in CF, we 
used others two biological model: ex vivo human nasal polyp mucose and mice 
model of CF disease.
The first one was the more representative model of human pathology since give a 
correlation between pathological phenotype and genotype of patient considering the 
thousand known mutation (divided  in six classes). The mice model were the 
fundamental approaches for therapeutic valence of study.
The data of TG2 high protein level and activity on nasal polyp was shown by confocal 
microscopy in fig.14A, and the effects of inhibition of TG2 on inflammatory target, 
p42\44 and Tyr phosphorilation, was shown in fig. 14B. The fig.14C shown the 
PPAR level in control and CF nasal polyp and the effect of R283 (fig 14C).
To investigate whether TG2-PIASy interaction and TG2 SUMOylation may take place 
in human airways of CF patients and whether it was induced by the oxidative stress, 
we used a well established tissue culture model of biopsies of human CF nasal 
polyps (72).
FIGURE 14. TG2 and PPAR in “ex vivo” human model
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These data allow to validate this experimental model (24,72) and reported that 
increased TG2 levels are a feature of CF nasal polyp mucosa and that the inhibition 
of TG2 is effective in controlling mucosal in,!%  els of 
PPARy protein (24). We found that TG2-PIASy colocalized in human CF airways 
(Fig. 15A) and that this interaction was inhibited upon treatment with the EUK-134
(Fig. 15B). After EUK-134 treatment the distribution of TG2 in CF nasal polyp 
biopsies was similar to that observed in non-CF controls (24). 
  
FIGURE 15. ROS-mediated PIASy-TG2 interaction in human nasal polyp mucosa.
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This suggests that the inhibition of TG2-PIASy interaction restores the physiological 
levels and distribution of TG2 in CF airways (22). Furthermore, in CF nasal polyp 
mucosa TG2 colocalizes with SUMO-1, and the incubation with EUK-134 inhibited 
TG2-SUMO-1 colocalization (data not shown). Non-CF control nasal polyp mucosa 
showed very faint TG2, PIASy, or SUMO-1 expression at the epithelial level (Fig. 
15C and D).
To test the effects of TG2 inhibition in vivo, we treated CF mutant mice homozygous 
for F508del-CFTR mutation (73) and their control littermates (36) with cystamine, 
previously reported to inhibit TG2 and ameliorate disease manifestations in a mouse 
model of  Huntington’s disease (38). We treated CF and wild-type mice with a daily 
injection of cystamine or PBS, for 7 days. After treatment with PBS the expression 
and distribution of the tested markers remained unaltered as compared with the pat-
tern observed in untreated CF mice. Before treatment, as well as after treatment with 
PBS, all seven tested CF mice showed increase of ROS (FIG.16A), as well as TG2 
activity (Fig. 16B), as compared with control littermates. PPARy was also reduced 
and sequestered in aggresomes (Fig. 15B), whereas phosphorylation of p42–44 (Fig. 
16B) and increase of TNF-a protein were observed (Fig. 16C). Cystamine did not 
induce any changes in wild-type mice (data not shown). 
This cascade of events leads to reduced secretion of inflammatory cytokines as TNF-
/ 2  oattractant IL-8. 
As above described,  targeting ROS-TG2 axis ameliorates human and mouse CF 
airway phenotype by restoring beclin 1 and autophagy, therefore we used ex-vivo 
and mouse model to validate the data of CFTR defective cell line, and control.
Defective basal autophagy was also observed in human nasal polyp biopsies from 
severe CF patients (n=10) and mouse lung tissues from F508del-CFTR homozygous 
mice (CftrF508del) (73). Reduced beclin 1 protein levels were also observed in CF nasal 
polyp biopsies (24,54,72) (n=10) and in airway tissues from CftrF508del mice (n=10) 
(Fig. 17A). To investigate whether rescuing  beclin 1 was  effective in restoring 
autophagy in vivo in CF airways, CftrF508del mice (n=3 per group) were 
administered intranasally with  a lentiviral vector encoding beclin 1 (74,75) or a 
lentiviral vector expressing the GFP. Overexpression of beclin 1 from the lentivirus 
induced significant increase of LC3 dots (p<0.001), reduced p62 accumulation, TG2 
protein level and activity as compared to CftrF508del mice treated with LV-GFP (Fig. 
17B).
To study the effects of  Cystamine or NAC in vivo, we treated CftrF508del mice with 
daily intraperitoneal injections of NAC (n = 10) or PBS (n = 10). Treated mice showed 
a pattern similar to cell line.
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FIGURE 16. TG2 inhibition in mice model
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FIGURE 17. Restoring autophagy by cystamine or beclin 1 overexpression rescues 
CF phenotype in mice CF airways
The data obtained reveled a direct link between the regulation of IL8 and 
inflammation TG2-ROS driven.
The IL8 was a drive key in neutrophils movements, and the data obtained about its 
regulation and modulation in inflammatory environment offer a mechanism for the 
study of migration IL8-induced and can to develop a model for biotechnological 
application.
For this reason, in second part of activity, we developed a 3D motility model for study 
of migration driven by chemoattractant molecule, and we employed an important 
system for screening of potential molecules in therapeuthic application
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2.Chemotaxis: Motility model
Cell motility is involved in a number of biological processes, from morphogenesis to 
inflammation. In spite of its relevance in human physiology the currently available 
techniques for the characterization of cell motility do not allow clear advantage in 
quantitative interpretation and application in biotechnology for industrial purposes. 
Furthermore the automation of measurement and a contemporary analysis  of 
multiple samples are controversial . The application of new technologies,  as the 
time-lapse microscopy (available in our lab)  has revealed to be useful in overcoming  
these limits and allowed quantification of the random or directional (chemotaxis) cell 
movement as well as haptotaxis or contact guidance phenomena (1) and represents 
the nearest approach to in vivo assays.
Cell migration is a very complex phenomena that are strictly related to the 
inflammatory response as well as several processes of cell biology and development. 
Chronic inflammation is an ideal condition for the study of cell migration and its de-
regulation. In this condition several cell populations are recruited in response to the 
enhanced local release of chemo-attractant molecules (chemokines) that favour the 
infiltration of circulating leukocytes within a disease-target tissue. This phenomena is 
known as chemotaxis and the chemical mediators (chemokine, citokine) recall the 
white cells from blood; the cells must go through different layers (blood vessel, 
extracellular matrix, epithelia). The formation of chemical gradient (cytokine-
chemokine)  is an important driving force for cell migration.
The first problem in studying the motility is the creation of physiological habitat for   
cell. The 2D model or microscopy approaches are not a real condition of organisms 
where the cells interact with other cells (tissue), matrix or liquid (blood cells). For this 
reason the generation of a 3D model system is mandatory.
During inflammation, the neutrophils are recruited in the site of injury by 
chemoattractant  molecules that create a gradient flux in tissue; this gradient induce 
a extravasion of neutrophils from blood vessel and a movement to site of 
inflammation. These molecules are the chemokines (interleukin 8, IL-8) which react 
with specific receptor present on cell membranes to activate their movements. After 
extravasation, the neutrophils need to cross over a 3D structure, rich in fibronectin, 
collagen, elastin, the extracellular matrix. This structure is very complex and alters 
the movement of cell and was subjected to continuous modeling. Many membrane 
proteins interact with it (i.e. integrin) inducing a rearrangement of cytoskeleton.
2.1.The 3D matrix collagen gel
The first experiments were focused on the study of a ideal 3D model to observe  
neutrophil motility  in basal condition, as well as in pathological condition.
The literature offers different models to study motility in 3D such as Boyden assay 
(76) (a typical indirect assay), that was ideal to perform an initial screening, but the 
results can be affected by variations in adhesion, motility or spatial orientation. For 
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FIGURE 18. Schematic representation of 3D model: matrix collagen gel and 
chambers
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example, an increased motility (chemokinesis) would result in an increased migration 
of randomly directed cells and might score as chemotaxis in many studies.
To perform 3D motility experiments, we created a matrix gel to mimic the extracellular 
matrix and to allow a movement of cell without impediments. To prepare the gel we 
used collagen rat-tail high concentration, to dilute in different percentage. We added
in the mix a precise quantity of medium 1X and 10X free, to allow the cell viability, 
and we used NaOH 0,1 M to stabilize the pH around  physiological value (pH 7.2). All
components were kept in ice to prevent gelification of mix during preparation. The 
gelification required 30 minutes in the incubator  at 37°C and 5% CO2.
In first analysis we used a multiwells culture dish to test the polymerization of gel. 
The confocal microscopy images reveled an auto florescence and a fine structure of 
collagene fibres (Fig.18A). A fibroblast cell line (HT1080) was used to verify cell 
vitality and the absence of constriction in movement. 
In second analysis, to study the chemotaxis phenomena, we projected and realized  
a prototype of chamber to surpass the limits of Boyden assay. It is a rectangular and 
horizontal chamber splits in  two compartments by a divisor barrier. It is composed by 
two aluminum blocks: A) charatterized by one well for the matrix gel with cells, B) 
have two wells, one for control gel without the cells and other one for gel with 
chemoattractant; the two blocks are separated by a semipermeable membrane to 
allow the flux of chemoattractant. The chamber is equipped with a coverslide on the 
bottom (for microscopy analysis) and a lid to close the chamber (to keep sterile 
conditions). The two block are united by some screws and a little quantity of silicon 
grease, to close all slits (Fig.18B). More experiments underline a objective limit in
assembling  of chamber. 
On the basis of these observations, we realized  a second prototype of chamber 
composed by single aluminum block with one single well, in the center; this well is 
“subsplited” in two wells by a little aluminum block covered with a semi-permeable 
membrane of 0.22 μm pores (Fig.18C). The assembling processes is more easy. To 
demonstrate the efficiency of chamber, we performed more experiments of  
gelification test and cell viability test. We kept the cells in the chambers at 37°C and 
5% CO2 for 24h or more, and observed the viability of the cell with TIME LAPSE 
microscopy images. The Fig.19 showed the HT1080 cell line in different layers of the 
gel at time 0h and after 24 hours; these images reveled any alterations of  cells 
morphology and composition of matrix gel.
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FIGURE 19. HT1080 in collagen gel
2.2. TIME-LAPSE system
To study the 2D cell motility phenomena ,fluorescence microscopy techniques  was 
available on fixed samples, where the examined cells are observed in instants of time 
that precede and follow the addition of particularly factor, missing the progression of 
motility event. The advent of technology as time-lapse microscopy has allowed to 
overcome these limits, being able to follow cell motility from time to time and obtain 
quantification of the random or directional (chemotaxis) cell movement. Microscopy 
images give a static moment of processes lacking  a intermediate time of 
phenomena. Therefore to study complex phenomena such the chemotaxis or cell
with high motility a system able to follow all time of neutrophils\ cells movements was 
required, as the  time lapse video system.
The TIME LAPSE  system was based on an inverted optical microscope, equipped 
with mercury lamp and epifluorescence reflectors. The microscope was placed on an 
anti-vibrating table and was equipped with motorized stage and focus, that allowed to 
automatically position the field of view within the sample under observation. Images 
are acquired using a monochrome CCD camera and sent to the PC through Firewire 
interface.
In order to mimic environmental conditions required to run time-lapse experiments, a 
microscope incubator was used, consisting in a plexiglass box, coated with a 
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FIGURE 20. TIME-LAPSE work station  
polystirol thermal isolator, in the box a radiator and a fan allow heat transfer and 
temperature uniformity. The temperature in the incubator was monitored by a
thermocouple, connected to a PC via serial port. Temperature control was ensured 
by a software PID control that continuously update the temperature of the radiator. A 
5% CO2 air flow is humidified through a bubbling column inside the incubator, and 
sent in a micro chamber that keeps the sample in a controlled air, constant 
temperature environment
The system was connected to a video-camera with high solution and velocity to 
follow the motility of  high speed cells, and this was manage by a software on PC. 
The software allowed to move the table (the sample) on three axis (x,y,z) to follow 
the sample in all 3 dimension. The x and y axis was controlled by a joystick connect 
to motor of table, and the z axis was controlled by a system of focus. Using the 
software we selected a specific object with a defined x, y position and chose a 
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position in the gel that corresponded to a layer with cell on focus; with specific 
functions of software we selected the total delta of layer (in μm), the number of layers 
that const the total delta and the time of acquisition: a Z-stack acquisition. In this way 
we followed the single cell (of selected object) in 3D for every single instant of 
time(Fig.20). 
Time lapse experiments ran according to the following protocol. Once introduced the 
samples in the incubators, image acquisition  started. A software allowed periodic 
scanning of marked positions in the sample. Input parameters was the sample 
positions to image and the acquisition time frequency. Each time cycle the software 
was then control the microscope stage and focus in order to cyclically place any 
marked position under the field of view and automatically acquire images, that was 
stored on hard drive, the software was than wait a pause up to the next acquisition 
cycle. At the end of the experiment we obtained a number of images for every single 
layer in single instant of time, and we could create a sequences of images as like a 
film.
The single cells present in the images were analyzed by a specific software of cell 
analysis (Image Pro-Plus) provided of a macro to follow the single cell; through a 
mathematical model we obtained many parameter such as speed, dimension, 
trajectory, diffusion profile (in presence of chemoattractant molecules). 
2.3.Calibration of system
The diffusion profile of chemoattractant was basic to analyze the cell motility in 3D 
model.
The concentration gradient was studied  by measurement of concentration of  a 
fluorescence type  of chemoattractant, IL8, or by a component with analogous 
molecular weight that take bound the fluorescent tag (dextran bound to FITCH). The 
measurement of fluorescence was perform by means of optic microscopy and 
images analysis by using the Imege ProPlus software. A preliminary calibration was 
performed on sample with different concentration of FITCH-dextran without the 
barrier, in order to have a uniform distribution. The sample exposition at excitant 
radiation was minimize to avoid the photobleaching of tag. In second time we 
performed the experiments by using different concentrations of FITCH-dextran. We 
kept in the well a mix collagen  with FITC-dextran and observed the diffusion trough 
the membrane in  control well with gel alone. The emitted fluorescence was 
proportionally direct to concentration of FITCH-dextran used (Fig.21A). The intensity 
of fluorescence was expressed as mean of grey level. We calculated the 
concentration profile of FITCH-dextran during time and in the space, by measuring 
the emitted  intensity of sample light into control well at different distance from 
membrane, in chancing  of time since the adding  of FITCH-dextran. The fitting data 
revealed a diffusion coefficient of 2·10-6 cm2/sec, according to literature data 
(Fig.21B).
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FIGURE 21 Diffusion of FITC-dextran: calibration system
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2.4. Neutrophils in collagen gel: 3D model
To test whether the chamber was an ideal condition to study neutrophils as well as 
other cell line (epithelial, fibroblast, gut, etc.) we performed a experiment with 
neutrophils isolated from peripheral blood.
The neutrophils were isolated from blood followed a specific protocol with Ficoll-
Paque  buffer. Ficoll-Paque was normally placed at the bottom of a conical tube, and 
blood was then slowly layered above Ficoll-Paque. After being centrifuged, the 
following layers will be visible in the conical tube, from top to bottom: plasma and 
other constituents, a layer of mono-nuclear cells called buffy coat (PBMC/MNC), 
Ficoll-Paque, and erythrocytes & granulocytes which should be present in pellet form. 
This separation allows easy harvest of PBMC's. After washing and Dextran-NaCl 
lysis, the nutrophils were isolated; an appropriate number of white blood cells(5*105
cell\ml) was counted in Burcker chambers. The mix of collagen was prepared in a 
conical tube without any cheattractant, and was divided in two mix: one of them was 
put into control well and other one was mixed with appropriate number of cell. In this 
way the cells were included in collagen fibres reticulum that block the sedimentation 
and represent a tridimensional substratum and  can partially reproduce the 
microstructure of extracellular matrix. After gelification at 37°C and 5% CO2, the 
chambers was fixed on specific supporter of TIME LAPSE STATION. The cell motility 
was observed for 24h with Z-stack acquisition images every five minutes (Fig.22A). 
The quantitative analysis of  single cell performed by Image Pro-Plus software, 
reveled a random motility in absence of chemokin (Fig.22B). Moreover  we 
performed the experiments in same conditions (number cells, acquisition time)  in 
presence of  IL8 (50μg\ml); its diffusion time was very early and neutrophils  showed 
a directional motility. The results were obtained from mathematical analysis of motility 
parameters.
The qualitative and quantitative data analysis  evidenced a directional motility of 
neutrophils  under IL8 diffusion compared to absence of IL8. The results indicated 
that the prototype chamber was an ideal model to study migration of different cell 
lines. The qualitative and quantitative analysis of images allow to obtain many 
information about the “parameters” motility-dependent. Moreover, was more hopeful 
for application in industrial biotechnological sector. 
Furthermore, the system offered a new approaches to study the motility IL8-induced 
and IL8 modulation (see above data) represented a key strategy for new therapeutic 
application.  
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FIGURE 22. Neutrophils in collagen gel
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2.5.T84 motility: 2D model
The 3D model was one of many way to study  cell movements in  a physiological 
system with  a collagen gel to mimic extracellular matrix. the neutrophils migration 
under chemokine flux offered a valid model to set the system condition, and 
modulation of chemoattractant factors was the key to study chemotaxis phenomena 
and develop biotechnological application. CF disease represented the optimal 
system to study the mechanisms of modulation since it was characterized by a strong 
recruitment of neutrophil under IL8 diffusive flux CFTR-defective driven. The 
inflammatory environment was crucial effector of this condition such as for many 
other patholy as well as Coeliac  Disease (CD).
The common characteristic of either CF and CD, besides the inflammation condition, 
was the presence of high TG2 level. In CD the inflammatory milieu was a response to 
a persistence attach from its inductor, the gluten, which led to an evident modification 
of tissue (or cell line model) architecture with consequent re-arrangement of 
cytoskeleton. 
This data offered a valid condition to develop a  2D-motility model to study epithelial 
cell line in adhesion and view the cytoskeleton modification.
Coeliac disease is a relatively common pathology that affects 1% of the population, 
and is precipitated by the ingestion of gluten proteins. In predisposed individuals, 
gliadin acts as leading to a powerful activation of gliadin speci
  ( >
fragments of gliadin have been found to be ‘toxic’ for predisposed individuals and it 
has also been suggested that different portion(s) of gliadin, ostensibly not those 
recognised by Tcells, modulates this innate activation of coeliac small intestine.
Further studies have indicated that TG2 is the essential “pivot” in the pathogenesis of 
celiac disease (27) because TG2 operates a crucial posttranslational modification, 
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FIGURE 23. Internalization and pro-inflammatory effects of p31-43 and control 
peptide
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the deamidation of strategic glutamine to glutamic acid, within the sequence of 
immunodominant gliadin epitopes(Subunits of the antigenic determinant that are 
most easily recognised by the adaptive immune system and thus most effective in 
the induction of antibody and T-cell responses).  
Among toxic peptides , p31-43 induces the expression of early markers of epithelial 
activation and leads to enterocyte apoptosis (77) both in coeliac intestine and in 
sensitive intestinal epithelial cell lines. Moreover, p31-43 induces early tissue 
transglutaminase (TG2) upregulation compared to immunodominant gliadin peptides 
(35). This indicates that TG2 is not only central to the adaptive response to gliadin as 
the main deamidating enzyme of the immunodominant epitopes, but is also a key 
player in the initiation of inflammation in coeliac disease. However, it is still unknown 
how p31e43 induces early TG2 activation in both coeliac intestine and ‘gliadin-
sensitive’ intestinal epithelial cells (35,79).
We have demonstrated that in cystic fibrosis (CF) airway epithelia (24) sustained 
TG2 activation is driven by the increased levels of reactive oxygen species (ROS) 
caused by the CFTR genetic defect. We therefore investigated whether p31-43 was 
able to drive an intracellular prooxidative environment and demonstrate that p31-43
leads to an increase of ROS levels in celiac duodenum as well as T84 intestinal 
epithelial cells. To understand how p31-43 challenge induces oxidative stress, we 
analysed the delivery of this peptide to the intracellular degradation systems. 
Recent data demonstrated increased transepithelial translocation of the 33-mer
(p56–89) in active coeliac disease compared to healthy controls. Moreover, 
incomplete degradation of the 33-mer and protected transport of the peptide 31-49
occurs in patients with untreated coeliac disease, thus favouring their respective 
immunostimulatory and toxic effects (79). Here we show that p31-43 is retained 
within the lysosomes as compared to the more rapid disappearance of the 
immunodominant peptides pa-2 or pa-9 from the intracellular compartments. T84 
cells were incubated with biotinylated p31-43, p-a2, p-a9 for 15, 30, 60, 90 min, 3 h 
and 24 h at 378C. Soon after 15 min of challenge, peptides co-localised with EEA-1
(Fig. 23A), a marker of early endosomes; After 90 min the internalized peptides co 
localised with Lysosomal Associated Membrane Protein-1 (LAMP-1) (Fig. 23A), a 
marker of lysosomes. No internalisation of peptides or colocalisation with LAMP-1
were observed when T84 cells were pre-incubated with M-	-CD, which inhibits 
clathrin-mediated endocytosis (80), or filipin, a specific inhibitor of lipid raft- or 
caveolae-dependent endocytosis (80) (data not shown). This suggests that 
endocytosis is essential for the delivery of gliadin peptides to the lysosomes for 
degradation. Increasing appearance of the internalised p31-43 in LAMP-1- positive 
vesicles, mainly limited to perinucelar localisation, was observed after 3e24 h of 
challenge (Fig. 23A). At these late time points p-a9 (Fig. 23A) or pa-2 (data not 
shown) were only faintly detected in LAMP-1-positive structures, thus indicating that 
p31e43, but not p-a9 or p-a2 is retained within the lysosomes. Moreover, after 90 min 
of challenge neither p31e43 nor pa-9, induced significant increase of ROS (Fig. 23B). 
At the later time points (3 e 24 h of challenge), p31-43, but not pa-9 (Fig. 23B), 
induced a time-dependent significant increase of ROS levels, suggesting that the 
prolonged persistence of p31-43 in LAMP-1 positive vesicles generates a pro-
oxidative environment. Blocking p31-43 endocytosis with M-	-CD, prevents the 
increase of ROS (data not shown).
The generation of a pro-oxidative environment induces activation of different stress 
sensitive signalling pathways (78,24); therefore, we investigated whether p31e-43-
induced ROS-mediated p42/44 MAPK phosphorylation in T84 cells. We 
 CHAPTER  II     
 
53 
 
demonstrated that p42\44 MAPK phosphorylation induced by the challenge with 
p31e43 was prevented by the incubation with the catalase-superoxide dismutase 
(SOD) mimetic EUK-134 (Fig.23C). To investigate whether the increased levels of 
ROS may account for the p31-43-induced increase of TG2 levels,(24)we incubated 
p31-43-challenged T84 cells with EUK-134. We demonstrated that EUK-134 was 
effective in controlling the increase of TG2 protein levels (Fig.23C) and TG2 activity 
(data not shown) induced by p31e43. No increase of TG2 was observed after 
challenge with p31-43 upon M-b-CD or filipin treatment (data not shown). This 
indicates that p31-43 internalisation is critical for the induction of ROS-mediated TG2 
activation.  
The pro-inflammatory environment p31-43-driven induces a strong re-organization of 
cytoskeleton; as matter of fact the lumen intestinal of CD patients shown atrophy of 
villi and cryptic hyperplasy due to persistence T-cells infiltration gluten-toxicity 
induced. 
To test whether the p31-43 toxicity could impact on cell motility and interaction of gut 
epithelial cell line (T84), we used a 2D model.
The T84 cell line was characterized by a typical collective migration where the cell 
line was organized in a compact structure such as “island”, and their movement was 
due to movement of total and contemporary motility of single cell that composed the 
island. During the movements,  the cells\islands have interaction either between 
single cell, either between the island, and we showed a phenomena like 
“englobetion”  of island after their touching.
To demonstrate the role of p31-43 on cell motiliy, we cultured the T84 cell line on 
multiwells cultur dish; we incubated p31-43-challenged T84 cells with EUK-134 or 
with TG2 monoclonal antibody, 4G3, to block the toxic effect with specific inhibition of 
ROS or TG2 
We performed a 2D motility experiments using time-lapse workstation and setting the 
acquisition time every 15 minutes for a total of 48 hours. 
The images reveled a visible motility alteration ,evidenced by a strong collective 
migration of cell and faster “englobetion” of island in presence of p31-43versus the 
control not treated; moreover, in presence of inhibition the motility rescued its pattern 
like not treated.(Fig.24A)
To demonstrate whether the alteration of motility p31-43 induced, was due to re-
organization of actin, we fixed the samples and used a specific fluorescent molecule, 
FITCH-phalloidin, to marker the cytoskeleton. The confocal imges reveled a tipical 
actin structure of T84 in control not treated and a rearrangement of cytoskeleton after 
p31-43; the actin rescued the structure after inhibition of ROS or TG2.(Fig.24B)
The results indicated that TG2-ROS axis was critical point to regulation in Coelic 
Disease, and its modulation will be the goal to treatments of pathology; moreover, the 
2D model analysis open the way to possible system of screening of molecule with 
high impact on motility and become a future fast test screening in biotechnological 
application.
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FIGURE 24. T84 motility and cytoskeleton organization: 2D model
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CONCLUSIONS
The results of PhD thesis project give an important contribution in defining the
pathological mechanisms of airway inflammation in CF and identifying new 
therapeutic options for patients .
The principal results of the study have been published in four papers on international 
journals  (J. Immuol 2008, J. Immunol 2009; Gut 2010; Nature Cell. Biol. 2010) and 
underline:
A) the role of TG2 as a new pathogenic factor in Cystic Fibrosis (24).
The novel 
/%  of the study is the demonstration that CFTR mutations lead to an 
increase of TG2 levels and activity that, in turn, down-regulate the anti-in,ammatory 
effects of PPARy. We have shown that PPARy is not only reduced in CF epithelium 
and CFTR-defective cell lines, but also sequestered in perinuclear aggresomes, 
prominent pathological features common to many neurodegenerative conditions such 
as Huntington and Parkinson’s diseases (81). Aggresomes are generated in re-
sponse to alterations of the ubiquitin proteasome system, the principal cellular 
mechanism of degradation of misfolded proteins and represent a cytoprotective 
mechanism that cells adopt to clear mutant/modified aggregate-prone proteins (82). 
This suggests that the formation of the aggresomes in CF is caused by the 
accumulation of misfolded proteins fated to 
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TG2 is a pleiotropic enzyme with a calcium-dependent transamidating activity that 
results in cross--%2<(y-glutamyl) lysine bonds (36,40). Our results 
demonstrated a signi
    2 /   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epithelium and CFTR-defective cell lines. TG2 up-regulation was also responsible for 
the aggresome formation in CF. Importantly, TG2 induced cross-linking of PPAR
and its sequestration into aggresomes, because the TG2-inhibitor R283 produced a 
signi
 /EE&" protein aggregates and restored a wider intracellular 
protein distribution.
Collectively, our study provides a molecular explanation of the reported association 
between CFTR defective function and sterile inflammation. Highlighting the role of 
TG2 in CF, we have also indicated novel ways to modulate inflammation, a key 
component in CF pathogenesis.
B) the role of post-translational modifications of TG2 as a link between genetic        
defect of CFTR ad inflammation (54)
These data have underpinned the relationship between CFTR defective function, 
oxidative stress, and chronic airway inflammation in CF. We have identified TG2 
SUMOylation as a pivot in driving the pro-inflammatory CF phenotype.
SUMOylation has been defined as a key player of the posttranslational             
network to regulate key cellular functions. Herein we demonstrate that in CF airway 
epithelia the increased levels of ROS lead to TG2 SUMOylation via interaction of 
TG2 with PIASy, an E3 ligase. Oxidative stress increases PIASy protein levels and 
favors TG2 SUMOylation that leads to the persistence of high TG2 tissue levels by 
down-regulating TG2 ubiquitination and proteasome degradation. Our results also 
indicate that TG2 SUMOylation is a general response to oxidative stress. The 
rheostat role of TG2 makes this enzyme an attractive target to restore cellular 
homeostasis and dampen chronic inflammation in CF airways. The regulation of the 
high levels of TG2 protein or the inhibition of sustained TG2 enzyme activation may 
represent a new attractive approach to control disease evolution in CF patients. To 
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evaluate whether we can translate our in vitro 
/%  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
model and con
 !%vance in vivo we have studied CF mutant mice 
homozygous for F508del-CFTR. Our results highlight TG2 as an unforeseen unifying 
link between genetic defect, deregulation of cellular homeostasis, and in,ammation. 
They also indicate TG2 as a candidate target for the design of a pathogenic-based 
therapy in CF and add to the rationale for attempting inhibition of TG2 in CF patients..
C) the mechanisms of autophagy inhibition via ROS-TG2 axis , in epithelial 
airway cell line and mice model of CF. For the first time this study defined the 
CF as an autophagy-related disease (87).
Defective autophagy is a critical mechanism in several chronic human diseases (83) 
such as neurodegeneration (84) and cancer. Here we show that defective autophagy 
due to decreased levels of beclin 1 protein, a key molecule involved in 
autophagosome formation (60,63,66,70), drives lung inflammation in CF.
A common feature between this neurodegeneative disease and CF is the aberrant 
intracellular accumulation of misfolded proteins within the affected tissues (85,86). In 
CF airways, misfolded or damaged proteins, such as misfolded CFTR and PPAR,
accumulate into aggresomes. Here we demonstrate that in CF epithelia TG2-
mediated crosslinking and sequestration of beclin 1 dislodges PI3K platform from the 
ER, thus inhibiting initiation of autophagy. TG2-driven defective autophagy in turn 
increases ROS and TG2 levels, thus generating a vicious cycle leading to a 
deleterious pro-oxidative and pro-infammatory environment. Autophagy inhibition 
with p62 accumulation (58) increases the levels of proteasome substrates and 
compromises the Ubiquitin Proteasome System (UPS) (58), thus favouring 
aggresome formation. TG2 contributes to proteasome overload and aggresome 
formation in CF airways by inducing cross-linking and aggregation of several 
substrate proteins. Therefore, TG2 functions as a rheostat of the post-translational 
network and UPS under disease conditions and switch off the post-translational 
regulatory mechanisms. As a consequence of this function, TG2 is involved in the 
pathogenesis of neurodegenerative diseases due to protein aggregates. 
We have previously reported that CFTR inhibition results in the upregulation of ROS
and their downstream events leading to inflammation. Here we show that CFTR 
knock down drives defective autophagy as it occurs in  human and mouse epithelia 
carrying either homozygotes for F508del or compound heterozygotes for  two severe 
CFTR mutations. Our results provide a new mechanism linking CFTR defect and 
inflammation via ROS-TG2-mediated inhibition of autophagy. Therefore, we have 
provided a novel rationale and the mechanism of action for both NAC  and cystamine 
in treatment of CF patients. 
In conclusion, our study suggests that restoration of beclin 1 and autophagy may be 
a novel approach to treat CF and may pave the way for the development of a new 
class of drugs that by enhancing beclin 1 levels could be effective treatments for CF.  
D) the development of model for 3D migration assay and 2D motility
The study of mechanisms that regulate the IL8 is mandatory to develop a 3D model 
for IL8-induced neutrophils migration assay for potential biotechnological application.
The 3D model is a ideal model to study the movements of cell in a 3D matrix of gel 
where a diffusive flux of molecule induced migration; instead, a useful model to test 
the cell motility in adhesion condition was the 2D model. The 2D model is ideal 
condition to study effect of molecule that influenced cell motility due to a organization 
of cytoskeleton; for this propose, the intestinal epithelial cell (T84), model of Coeliac 
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Disease, represent  an ideal application of 2D the model.
The Coeliac Disease is characterized by sensitive response to A-gliadin peptide 
fragments, that induce an immune activation with an inflammatory response. Among 
the gliadin peptide, the p31-43 induces an alteration of inflammation via ROS-TG2
pathway (82), which have many implications in the organization of actins filaments.
This pathology is strong linked to TG2 that has a crucial role in the pathogenesis of 
disease. The 2D model  offers a ideal screening test to verify whether the p31-43 
toxicity can impact on cell motility and interaction of epithelial cell line (T84).
The results highlight  the possibility to use this model as a prototype of fast screening
procedures to test the effects of several putative toxic fragments as well as 
molecules that prevent gluten-induced toxicity.
These data provide the rationale for the development of cell motility and migration
assays as  ideal instruments to test the efficiency of molecules with potential 
pharmacological impact.
The use of quantitative and qualitative analysis could also be implemented in the 
screening of various drugs potentially effective in controlling cancer cell invasiveness 
and in modulating drugs-resistance. The effects of  TG2 and ROS modulation on 
these dynamic processes could allow the set up of appropriate devices for either 
research purposes or industrial biotechnological application.
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MATERIALS AND METHODS
Cell lines and cultures. Human CF bronchial epithelial cell line IB3-1, carrying
F508del/W1282X CFTR mutation and isogenic stably rescued C38 (LGC 
Promochem, Milan, Italy), were cultured with LHC-8 medium (Invitrogen) 
supplemented with 5% FBS and the appropriate amount of penicillin/streptomycin.
Normal bronchial epithelial 16HBE (LGC Promochem, Milan, Italy) were cultured with 
MEM Earl's salt medium supplemented with 10% FBS and 1% 
penicillin/streptomycin, as recommended by American Type Culture Collection. 
CFBE41o- human CF bronchial epithelial cells  (gift from Dr. D. C. Gruenert) were 
cultured MEM Earl's salt L-Glutamine (200 mM L-Glutamine) medium supplemented 
with 10% FBS and the appropriate amount of penicillin/streptomycin. Cell lines were 
incubated for 24 hours with R283 (+CF?), μ$+CF?>%&/ *0-
acetyl Cysteine (NAC, 10 mM, Vinci Biochem), EUK-3$+CF%/ml, Vinci Biochem), 
rapamycin (100 nM, Sigma Aldrich), chloroquine (25μM, Sigma Aldrich), E64d (50 
F%/ml for 4 ho*/22&$+CF%4 3 *"%$CF?3
hours, Vinci-Biochem); BAPTA-&?$+F%/ml, Calbiochem, for 4 hours), proteasome 
inhibitor MG132 (+C F? 5!   G  *. C38 and 16HBE cells were 
incubated for 48 hours with CFTRinh172 (20 μM, Calbiochem) followed by cystamine 
or EUK-134.
Human colon adenocarcinoma T84 were cultured in DMEM:F12 mixture 1:1 medium 
supplemented with 5% FBS and the appropriate amount of penicillin/streptomycin, as 
recommended by American Type Culture Collection (ATCC).
The cells were challenged with p31-43 for 24 h in the presence or absence of the 
ROS scavenger EUK-134 (50 mg/ml; Alexis Biochemicals), or the TG inhibitor 
cystamine (400 mmol/l; Sigma). To study internalisation of peptides, cells were chal-
lenged for 15, 30, 60 or 90 min, 3 or 24 h at 378C with the biotinylated peptides (20 
mg/ml). To inhibit endocytosis, the cells were pre-treated with the cholesterol-binding 
agent methyl-bcyclo-dextrin (M-b-CD, 10 mmol/l; Sigma) or 
lipin (5 mg/ml; Sigma) 
and then challenged with biotinylated peptides
Human subjects and ex vivo cultures of nasal polyp mucosal biopsies. Ten CF 
patients carrying severe CFTR mutations (Table 1) and ten consecutive non-CF 
patients (mean age 21 years, range 16–32) underwent surgical treatment for non-
allergic nasal polyposis were enrolled. Nasal polyp biopsies from seven patients for 
each group (patients #4-10 of Table 1) were cultured for 4 hours with or without EUK-
3 $+C F%4*  0&5 $C?*   $3CC?*  "# $+CH?*( 0
polyp biopsies from five CF patients (patients #6-10 of Table 1) were also incubated 
with NAC or Cystamine or PPARyantagonist GW9662 (1 μM; Alexis Biochemical), or 
R283 for 24 h, followed by GW9662 (1 μM) for 4 h. Informed consent was obtained 
from all subjects, and the ethical committee of Regione Campania Health Authority 
approved the study. 
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Mice and treatments. Young adult female CF mice homozygous for the F508del 
mutation (abbreviated CftrF508del) in the 129/FVB outbred background (obtained 
from Bob Scholte, Erasmus Medical Center Rotterdam, The Netherlands), and their 
wild-type littermates were housed in static isolator cages at the animal care specific 
pathogen free facility of Charles River (Varese, Italy). To prevent intestinal 
obstruction CF mice were weaned to a liquid diet (Peptamen; Nestle´ Nutrition). 
Peptamen was replaced daily. The genotype of each animal was checked at 21 days 
of age. These studies and procedures were approved by the local Ethics Committee 
for Animal Welfare and conformed to the European Community regulations for animal 
use in research (CEE no. 86/609).We treated CftrF508del homozygous mice by 
intraperitoneI$(2(*; //CCFC(C?E>
solution for 7 days16 (n=7 for each group of treatment) or NAC with a daily dose of 
100 mg per Kg (body weight) in PBS solution for 5 days or with PBS solution (n=10 
for each group of treatment). Mice were then killed by i.p. injection of 20 mg of 
sodium pentobarbital (Abbott Laboratories).
Airway administrations of lentiviral vectors expressing the mouse beclin 1 or GFP 
were performed in anesthetized CftrF508del homozygous mice aged 4-8 weeks as 
previously described (74). Mice were sacrificed 5 days post-vector administration and 
lung tissues were collected for analyses. 
Plasmids and transfection. The pcDNA3-HA-beclin 1 expression vector (gift from 
Dr. N. Mizushima) and the corresponding empty expression vectors were used for 
transfection experiments. IB3 cells were transfected with pcDNA3-HA-beclin 1 and 
empty vector , as control, using Lipofectamine 2000 (Invitrogen) according to the 
manufacturer’s protocol. Briefly, one day before transfection, we plated cells in 
growth medium without antibiotics such that they will be 60-70% confluent at the time 
of transfection; the day of transfection we prepared the complex of DNA and 
Lipofectamine 2000 (in a ratio of 1μg:3μl, DNA:Lipofectamine) and incubate for 30 
minutes at Room Temperature; we added the complex to the cells and incubated at 
37°C for 24 h.
RNA interference. Cells were transfected with 50 nM human TG2, SUMO-1,PIASy, 
beclin 1 and CFTR siRNA (Invitrogen) or scrambled oligonucleotides by using Lipo 
RnaiMax (Invitrogen) according to the manufacturer’s instructions. Briefly, one day 
before transfection, we plated cells in growth medium without antibiotics such that 
they will be 30-50% confluent at the time of transfection; the day of transfection we 
prepared the complex of siRNA oligonucletides and LipoRNAiMAX and incubate for 
30 minutes at Room Temperature; we added the complex to the cells and incubated 
at 37°C for 72 h.
For siRNA oligonucleotides sequences see Supplementary Information, Table 2 . 
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Adenoviral Vector. Human MnSOD cDNA was cloned into the shuttle vector 
pAd5CMVK-NpA (gift from Dr. Michael Brownlee). Briefly, one day before infection
we plated cells in growth medium without antibiotics; the next day, the cells were 
infected with MnSOD or control adenovirus for 2 hours at 37°C.
Quantitative RT-PCR. Total RNA was extracted using the RNeasy Mini Kit (Qiagen). 
The mRNA was reverse transcribed by SuperScriptTM III First Strand Synthesis 
System (Invitrogen). Quantitative RT-PCR was performed using iCycler iQ 
Multicolour Real-Time PCR Detector (Bio-Rad) with iQ TM SYBR Green supermix 
(Bio-"/*(982%;/	-actin levels in the same 
sample. The sequence of primers is reported in Table 3. The relative amounts of 
mRNA were calculated by using the comparative CT method. 
Western blot analysisCells were washed 2 times with ice PBS and then lysed in 
buffer containg 50 mM Tris- HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 5 mM EDTA, 1 
? 2   / +C ? 01 C F%4 22 / C F%4
apoprotein supplemented with protease inhibitors (Sigma), kept in ice for 40 minutes  
and centrifuged at 14,000rpm at 4°C for 20 minutes. The amounts of proteins were 
determined by a Bio-Rad protein assay to ensure equal protein loading before 
Western blot analysis. Fifty micrograms of cell lysate of each sample was 
electrophoresed through 10% or 8% polyacrylamide gels (BioRad), transferred onto 
blotting membranes (Polyscreen PVDF, NEN) and immunobloted for specific primary 
antibody in agitation at 4°C  for 12-18 hours. The primary Abs were counterstained
by a HRP-conjugated anti-IgG Ab (Amersham Biosciences) for 60 min at room 
temperature. Proteins were visualized by chemiluminescence (ECL Plus; Amersham 
Biosciences) and exposed to X-OMAT 
lm (Eastman Kodak). 
The antibodies used for immunoblot analysis are reported in Table 4.
The densitometric analysis was performed by Image J software and each data point 
is expressed as the mean ± s.d. of three independent experiments.

 
 
Immunoprecipitation.Cells were washed 2 times with ice PBS and then lysed in
buffer containg 50 mM Tris- HCl (pH 7.5), 150 mM NaCl, 0,5% NP-40, 5 mM EDTA, 1 
? 2   / +C ? 01 C F%4 22 / C F%4
apoprotein supplemented with protease inhibitors (Sigma), kept in ice for 40 minutes  
and centrifuged at 14,000rpm at 4°C for 20 minutes. Following cell lysis , 500 μg of 
whole cell-lysates were incubated in agitation at 4°C for 8-12 h with antibody specific 
primary antibody. After the addition of Protein A/G-agarose beads, the incubation 
was continued in agitation at 4°C for 1 h. After washing, the immunoprecipitated 
proteins were electrophoresed through 8% polyacrylamide gels (BioRad), transferred 
onto blotting membranes (Polyscreen PVDF, NEN) and analyzed. 


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Soluble and insoluble fraction. Cells were lysed in buffer containg 50 mM Tris- HCl 
(pH 7.5), 150 mM NaCl, 0.5% NP-40, 5 mM EDTA, 1 mM phenylmethylsulfonyl 
/+C?01CF%-22/CF%-1 apoprotein supplemented 
with protease inhibitors (Sigma) and centrifuged at 14,000rpm at 4°C for 20 minutes. 
After centrifugation the soluble (supernatant) and insoluble (pellet) fraction were used 
in Western blot analysis using anti-Beclin1. The NP-40 insoluble pellet was dissolved 
in sample buffer 5X, boiled at 95°C for 5’ and resolved onto 10% polyacrylammide 
gel.
Cell fractionation. IB3-1 cells were collected in cold buffer A (20 mM Tris-HCl (pH 
7.4), 2 mM EDTA, 20 mM 2-ME, 1X PMSF, 1 {g/ml inhibitor protease cocktail), 
homogenized in Potter-Elvehjem pestle and glass tube (Sigma-Aldrich), and 
centrifuged at 2000 rpm for 15 min at 4°C to obtain nuclear pellets. Supernatants 
were collected as cytoplasmic fractions. Nuclear pellets were washed with buffer A 
and resuspended in buffer B (2 mM Na3VO4, 400 mM NaCl, 1 mM MgCl2, 1 mM 
EGTA, HEPES 10 mM (pH 7.9), 1 mM DTT, 1X PMSF, 1 μg/ml inhibitor protease 
cocktail) and incubated on ice for 50 min with occasional mixing to extract nuclear 
proteins. Nuclear extracts were cleared by centrifugation (7000 rpm, 15 min, 4°C), 
and supernatants were collected as nuclear fraction. Then, cytoplasmic and nuclear 
whole-cell fractions were analyzed by western blot analysis
 
 
Confocal microscopy.
Human tissue sections. Five-micrometer frozen human lung tissue sections were 
xed in 
acetone for 10 min. The sections were incubated for 2 h at room temperature with primary 
Abs.  
Cell lines. Treated or untreated cells were 
xed in ice 
methanol for five minute at -20°C, washed 3 times with PBS, permeabilized with 
0.5% Triton X-100 for ten minutes at room temprature, washed 3 times with PBS and
incubated with primary antibodies over night at 4°C. 
Mice lung tissue. Seven-micrometer frozen lung tissue sections from each mice were 

xed in acetone for 10 min. The sections were incubated for 2 h at room temperature 
with primary Abs.  
The primary antibodies were counterstained by a Alexa fluor-conjugated anti-IgG Ab. 
and an LSM510 Zeiss confocal laser-scanning unit (Carl Zeiss, Germany) was used 
for detection. 
The antibodies used for immunofluorescence analysis are reported in Table 4.
  
 
 
 
ROS detection. Cell lines were pulsed with 10 μM 5(and 6)-chloromethyl-2'7'-
dichlorodihydro,uorescein diacetate acetyl ester (CM-H2DCFDA; Molecular Probes, 
Invitrogen), according to manufacturer suggestions, and analyzed with Wallac 1420 
multilabel counter (PerkinElmer). Tissue sections (5 μm) of nasal mucosa and cells 
were incubated with 10 μM CMH2DCFDA, according to manufacturer suggestions, 
and an LSM510 Zeiss confocal laser-scanning unit (Carl Zeiss, Germany) was used 
for detection. 
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In situ detection of TG2 activity and protein.
The simultaneous detection of TG2 protein and activity was performed by incubating 
live cells with bio-MDC for1hat room temperature, according to the above described 
procedure, and then with anti-TG2 CUB 7402 mAb (NeoMarkers; 1:50) for 1hat room 
temperature. This was followed by simultaneous incubation with PE-conjugated 
streptavidin (DakoCytomation; 1:50) and FITC-conjugated rabbit anti-mouse Ig 
F(ab')2 (DakoCytomation; 1:20) for 1 h. 
TG2 protein and enzyme activity 
were detected and analyzed by confocal microscopy. Brie,y, for detection of TG2 
enzyme activity, live cells were preincubated with TG2 assay buffer (965 μl of 100 
mM Tris/HCl (pH 7.4), 25 μl of 200 mM CaCl2) for 15 min and then with the same 
TG2 assay buffer added with 10 μl of 10 mM biotinylated monodansylcadaverine 
(bio-MDC; Molecular Probes) for 1hat room temperature. The reaction was stopped 
with 25 mM EDTA for 5 min. The cells were then 
xed in 4% paraformaldehyde for 
10 min. The incorporation of labeled substrate was visualized by incubation with PE-
conjugated streptavidin (Dako-Cytomation; 1:50) for 30 min. Control experiments 
included the omission of bio-MDC, as well as replacement of 200 mM CaCl2 with 200 
mM EDTA. Blocking experiments were also conducted by incubating cells with the 
active site inhibitor R283 (250 μM) for 1 h before incubation with the substrates (bio-
MDC or biotinylated peptides) and detection of TG2 enzymatic activity. Data were 
analyzed under ,uorescence examination by LSM510 Zeiss confocal laser-scanning 
unit (Carl Zeiss). 
An LSM510 Zeiss confocal laser-scanning unit (Carl Zeiss, Germany) was used for 
detection. Of TG2 activity and protein on tissue sections 
 
Electron Microscopy. Cell culture monolayers were fixed for 15 min at 4 °C with 4% 
paraformaldehyde and 2.5% glutaraldehyde in 125 mM cacodylate buffer and  
stained with uranil and lead citrate and examined in a Leo912 electron microscope. 
We used Image J software (US National Institutes of Health) to quantify the number 
of autophagosomes per cell in 15–20 different randomly taken micrographs for each 
condition
ELISA .
 
Human or murine TNF-a secretion was measured using the BD OptEIA TNF-
a ELISA kit II (BD Biosciences). Measurements were performed at least in triplicate. 
Values were normalized to 10
6
cells; results were expressed as means ± SEM. 
 
Statistical analysis. Data are reported as arithmetic mean ±s.d.. Data distribution 
was analyzed for normality and statistical analysis performed using the one-way 
ANOVA. Significant differences are indicated in the figures. All data were obtained 
from independent measurements. Data were analyzed using SPSS 13 software. 
Statistical significance was defined as P value of <0.05.
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Collagen gel mix. Liquid collagen rat-tail high concentration (9 mg/ml) was diluted to 
obtain a final concentration of 2mg/ml different percentage. We added in the mix an 
appropriate amount of medium 1X free and 10X free and we used NaOH 0,1 M to 
stabilize the pH around  physiological value (pH 7.2). The was placed in incubator at 
37°C and 5% CO2 for 30 minutes. We added 2*105 cell/ml of gel, or FITC-dextran 
(50μg/ml).
Neutrophils isolation. Peripheral blood (10 ml) was taken from healty human 
donors into BD Vacutainers containing K3EDTA. Neutrophils were freshly isolated by 
dextran sedimentation and centrifugation on Ficoll-Hypaque. The pellet of a density- 
gradient centrifugation containing neutrophil granulocytes and erythrocytes was 
diluted 1:1.3 with a high-molecular-weight dextran solution. After 2h erythrocytes had 
settled down and the neutrophil granulocytes containing supernatant was separated 
from the pellet. If necessary, red blood cells in the neutrophil-rich fraction were lysed 
with hypotonic saline. The neutrophils were washed twice with phosphate buffered 
saline (PBS) and then resuspended in RPMI 1640 containing 10% heat-treated fetal 
bovin serum (FBS). The obtained purified neutrophil granulocytes were used 
immediately after isolation.
Image analysis. The Image Pro Plus software, with a home-made macro tool, was 
used to analyze single cell motility. Math-lab software  was used to  fitting data.
Phalloidin staining. Treated or untreated cells were 
xed paraforlmadehyde 4%  for 
15 minute at room temperature, washed 3 times with PBS, permeabilized with 0.5% 
Triton X-100 for ten minutes at room temperature, washed 3 times with PBS and 
incubated with FITC-phalloidin (1:100) for 30 minutes at RT. An LSM510 Zeiss 
confocal laser-scanning unit (Carl Zeiss, Germany) was used for detection. 
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TABLE 2. Sequence of siRNA oligonucleotides
GENE NAME OLIGO-SENSE(5'-3') OLIGO-ANTISENSE (5'-3')
TG2 GCGUCGUGACCAACUACAAdTdT UUGUAGUUGGUCACGACGCdGdG
 oligo#2 CAAGACAGGUGGAGUUGAUUU pAUCAACUCCACCUGUCUUGUU
 oligo#4 AAGCUGCCGUUCUUUAAUAUU pUAUUAAAGAACGGCAGCUUUU
BECLIN-1 AAGAUUGAAGACACAGGAGGC GCCUCCUGUGUCUUCAAUCUU
CFTR oligo#1 CGUGUGUCUGUAAACUGAUGGCUAA UUAGCCAUCAGUUUACAGACACAGC
CFTR oligo#2 CCCUUCUGUUGAUUCUGCUGACAAU AUUGUCAGCAGAAUCAACAGAAGGG
CFTR oligo#3 GGCAUAGGCUUAUGCCUUCUCUUUA UAAAGAGAAGGCAUAAGCCUAUGCC
SUMO-1 oligo#1 GGAUAGCAGUGAGAUU CACUUCAAA UUUGAAGUGAAUCUCACUGCUA UCC
SUMO-1 oligo#2 GGUGUUCCAAUGAAUU CACUCAGGU ACCUGAGUGAAUUCAUUGGAAC ACC
SUMO-1 oligo#3 GGAAGAAGAUGUGAUU GAAGUUUAU AUAAACUUCAAUCACAUCUUCU UCC
TABLE 3. Sequence of primers used for Quantitative RT-PCR
GENE NAME
FOWARD PRIMER SEQUENCE (5'-
3')
REVERSE PRIMER SEQUENCE (5'-
3')
-actin ATTGCCGACAGGATGCAGAA ACATCTGCTGGAAGGTGGACAG
ULK1 GTCCAGCTTTGACAGTCAGT TCCCAGGACTCAGGATTCCA
ULK2 TGTTTCTAGGGTGTAGCTGG CACCATCTACCCCAAGACCT
ATG5 AGTATCAGACACGATCATGG TGCAAAGGCCTGACACTGGT
ATG6\BECLIN1 TGTCACCATCCAGGAACTCA CTGTTGGCACTTTCTGTGGA
ATG7 CACTGTGAGTCGTCCAGGAC CGCTCATGTCCCAGATCTCA
ATG8 CGTGGAGTCCGCGAAGATTC AGGCATGAGGACAATGCACA
ATG14L ATGAGCGTCTGGCAAATCTT CCCATCGTCCTGAGAGGTAA
Bcl2 GCTGCTGGAGGCTGGGGAGA CCCCCACAGGAACCCTCCTC
hVsps34 AAGCAGTGCCTGTAGGAGGA TGTCGATGAGCTTTGGTGAG
hVsps15 TGGGACTGGCGGTCTGCACT CGGGACGGGAAAACGCGTCA
Ambra-1 AACCCTCCACTGCGAGTTGA TCTACCTGTTCCGTGGTTCTCC
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TABLE 4. Primary antibody
ANTIBODY COMPANY
phospho-p42/p44 MAP kinases  CELL SIGNALING 
phospho-p65 CELL SIGNALING 
-actin (13E5) CELL SIGNALING 
	
 
SANTA CRUZ 
BIOTECNOLOGY 
 
SANTA CRUZ 
BIOTECNOLOGY 
Ubiquitin(FL76) 
SANTA CRUZ 
BIOTECNOLOGY 
-L-glutamyl)-L-lysine 
isopeptide (81DIC2) COVOLAB 
 
SANTA CRUZ 
BIOTECNOLOGY 
TG2 (CUB7402) NEOMARKER 
 
SANTA CRUZ 
BIOTECNOLOGY 
SUMO-1 
SANTA CRUZ 
BIOTECNOLOGY 
BECLIN-1 ABCAM 
GFP(FL) 
SANTA CRUZ 
BIOTECNOLOGY 
hVps15\p150 (Nterm) 
SANTA CRUZ 
BIOTECNOLOGY 
Bcl-2(C2) 
SANTA CRUZ 
BIOTECNOLOGY 
-6  
SANTA CRUZ 
BIOTECNOLOGY 
N-Cor 
SANTA CRUZ 
BIOTECNOLOGY 
LC3 ABCAM 
CFTR ABCAM 
AMBRA-1 ABCAM 
p62 BD BIOSCIENCE 
 BD BIOSCIENCE 
-TUBULIN SIGMA 
hVps34  SIGMA 
Atg14L ABCAM 
LAMP1 ABCAM 
EEA-1 ABCAM 
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Defective CFTR induces aggresome formation and lung 
inflammation in cystic fibrosis through ROS-mediated 
autophagy inhibition
Alessandro Luciani1,2,11, Valeria Rachela Villella2,11, Speranza Esposito2,3, Nicola Brunetti-Pierri4,5, Diego 
Medina4, Carmine Settembre4, Manuela Gavina1, Laura Pulze1, Ida Giardino6, Massimo Pettoello-Mantovani3, 
Maria D’Apolito3, Stefano Guido2, Eliezer Masliah7, Brian Spencer7, Sonia Quaratino8, Valeria Raia9,12, Andrea 
Ballabio4,10,12 and Luigi Maiuri1,3,12
Accumulation of unwanted/misfolded proteins in aggregates has 
been observed in airways of patients with cystic fibrosis (CF), 
a life-threatening genetic disorder caused by mutations in the 
gene encoding the cystic fibrosis transmembrane conductance 
regulator (CFTR). Here we show how the defective CFTR 
results in defective autophagy and decreases the clearance of 
aggresomes. Defective CFTR-induced upregulation of reactive 
oxygen species (ROS) and tissue transglutaminase (TG2) 
drive the crosslinking of beclin 1, leading to sequestration 
of phosphatidylinositol-3-kinase (PI(3)K) complex III and 
accumulation of p62, which regulates aggresome formation. 
Both CFTR knockdown and the overexpression of green 
fluorescent protein (GFP)-tagged-CFTRF508del induce beclin 1 
downregulation and defective autophagy in non-CF airway 
epithelia through the ROS–TG2 pathway. Restoration of beclin 1 
and autophagy by either beclin 1 overexpression, cystamine or 
antioxidants rescues the localization of the beclin 1 interactome 
to the endoplasmic reticulum and reverts the CF airway 
phenotype in vitro, in vivo in Scnn1b-transgenic and CftrF508del 
homozygous mice, and in human CF nasal biopsies. Restoring 
beclin 1 or knocking down p62 rescued the trafficking of 
CFTRF508del to the cell surface. These data link the CFTR defect 
to autophagy deficiency, leading to the accumulation of protein 
aggregates and to lung inflammation.
Autophagy is a cytoprotective mechanism for the degradation of misfolded/
polyubiquitylated proteins and damaged organelles through lysosome-
mediated self-digestion1,2. Autophagy is important in clearing protein 
aggregates after overload of polyubiquitylated proteins3–5. The accumula-
tion of unwanted/misfolded protein aggregates has been described in sev-
eral human disorders, such as neurodegenerative diseases6,7, myopathies8 
and cancer9. Recently we described the presence of peroxisome proliferator-
activated receptor (PPAR)-γ in aggresomes in CF airways10. CF is caused 
by mutations in the CFTR gene11 and the mutant CFTRF508del has been 
described as the prototype of a misfolded aggresome-prone protein12–14.
Sequestration of the anti-inflammatory PPAR-γ into aggresomes, 
mediated by the increased TG2 levels, contributes to the lung inflam-
mation in CF15. This is the result of ROS-mediated TG2 SUMOylation 
inducing the crosslinking, ubiquitylation and aggresome sequestration 
of several target proteins15. Because oxidative stress and accumulation 
of protein aggregates are features of CF airway epithelia10,15,16, we spec-
ulated that the accumulation of aggresomes in CF is due to defective 
autophagy.
Here we demonstrate how defective CFTR drives autophagy inhibi-
tion in mouse and human CF airway epithelia by means of the ROS–TG2 
pathway, with sequestration of beclin 1 interactome, a key player of 
autophagosome formation17–19, in the aggresomes. Rescuing beclin 1 
and autophagy restores CFTR trafficking and damps down inflamma-
tion. Our results provide evidence that defective autophagy has a critical 
function in CF pathogenesis and suggest that drugs restoring beclin 1 
and autophagy are potentially effective in the treatment of CF.
RESULTS
Human and mouse CF airway epithelia have defective autophagy
We cultured human CF airway epithelial IB3-1 or CFBE41o– cells, car-
rying F508del/W1282X and F508del/F508del mutations, respectively, 
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Figure 1 Autophagy is defective in human and mice CF airway epithelia. C38 
and IB3-1 cells transfected with GFP–LC3 plasmid in nutrient-rich or starvation 
medium. (a) Top: confocal microscopy of GFP. N, nucleus. Scale bar, 10 μm. 
Bottom: percentage of cells containing more than five GFP–LC3 punctate dots 
per cell. Means ± s.d. (n = 5). Asterisk, P < 0.001 versus C38 cells; analysis 
of variance (ANOVA). (b) Left: electron microscopy of starved C38 and IB3-1 
cells. The right-hand images are higher magnifications showing areas enriched 
in autophagosomes in C38 cells (arrows) and perinuclear mitochondria in IB3-1 
cells. N, nucleus. Scale bar, 250 nm. Right: numbers of autophagosomes per 
cell counted in 20 cells per experiment. Means ± s.d. for three independent 
experiments. Asterisk, P < 0.001 versus C38 cells; ANOVA. (c) Fluorescence-
activated cell sorting (FACS) analysis after staining with fluorescent dye DiOC6 
in starved C38 and IB3-1 cells. (d, e) Immunoblot of LC3 in starved C38 and 
IB3-1 cells (d) and IB3-1 cells (e) after incubation with E64d and pepstatin 
A. (f, g) Immunoblots (IB) of polyubiquitin (f) and p62 (g) in starved C38 
and IB3-1 cells. Uncropped images of blots are shown in Supplementary 
Information, Fig. S10. (h) Immunoblot of LC3 and p62 in control (n = 10) 
and CF (n = 10) human nasal mucosa. (i) Number of LC3-positive dots 
(per 104 mm–2 of mucosa) in control (n = 10) and CF (n = 10) human nasal 
mucosa. Means ± s.d. Asterisk, P < 0.01 versus controls; ANOVA. (j) Confocal 
microscopy of p62 in control and CF human nasal mucosa. Representative 
images from ten patients with CF. Nuclei counterstained with 4ʹ,6-diamidino-
2-phenylindole (DAPI; blue). Scale bar, 10 μm. (k) Number of LC3-positive 
dots in lung tissues from wild-type (WT) and CftrF508del mice. Means ± s.d. for 
lung tissues from ten mice per group. Asterisk, P < 0.001 versus WT mice; 
ANOVA. (l) Confocal microscopy of p62 in WT and CftrF508del homozygous mice. 
Representative staining from at least five airway epithelial areas per mouse 
(n = 10 mice per group). L, lumen. Nuclei counterstained with DAPI (blue). 
Scale bar, 10 μm. β-Actin was used as loading control for immunoblot analysis 
of cells, and αβ-tubulin for nasal mucosa. All expreriments were repeated three 
times. Densitometric analysis of blots is shown in Supplementary Information, 
Fig. S9.
2  NATURE CELL BIOLOGY  ADVANCE ONLINE PUBLICATION 
© 2010 Macmillan Publishers Limited.  All rights reserved.
A RT I C L E S
and the isogenic stably rescued C38, S9 (refs 10, 15) or bronchial epi-
thelial 16HBE14o– cells10,15, under nutrient starvation to stimulate 
autophagy20,21. Transfection of GFP–LC3, a marker of autophago-
somes21, revealed a larger number of GFP–LC3 puncta in C38 cells 
than in IB3-1 cells (P < 0.001) (Fig. 1a). Transmission electron micro-
scopy showed autophagosomes containing mitochondria and cellular 
organelles in C38 cells but rarely in IB3-1 cells (Fig. 1b; Supplementary 
Information, Fig. S1a). Increased mitochondrial membrane depolari-
zation was observed in IB3-1 cells but not in C38 cells (Fig. 1c).
An increase in LC3 II, the lipidated product of LC3 (refs 20, 21), was 
observed in C38 cells but not in IB3-1 cells under starvation (Fig. 1d). 
E64d and pepstatin A, inhibitors of the lysosomal proteases (Fig. 1e), 
and also chloroquine, a weak base disrupting lysosomal functions21 
(Supplementary Information, Fig. S1b), failed to increase LC3 II, thus 
indicating that decreased LC3 II levels were not due to lysosomal deg-
radation of LC3.
Defective autophagy in IB3-1 cells was also revealed by the increased 
pool of polyubiquitylated proteins (Fig. 1f) and the accumulation of 
p62 (Fig. 1g; Supplementary Information, Fig. S1c), a LC3-binding and 
ubiquitin-binding protein, that accumulates in intracellular aggregates 
under defective autophagy3,20,21. IB3-1 cells were also resistant to rapamy-
cin, a known inducer of autophagy20,21 (Supplementary Information, 
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Figure 2 Sequestration of beclin 1 interactome in aggresomes drives defective 
autophagy in CF airway epithelia. (a–d) Starved C38 and IB3-1 cells. (a–c) 
Confocal microscopy images of beclin 1 (green) and hVps34 (red) (a), calnexin 
(green) and hVps34 (red) (b), and beclin 1 (green) and HDAC6 (red) (c, left) 
or hVps34 (green) and HDAC6 (red) (c, right). N, nucleus. Scale bar, 10 μm. 
Yellow indicates co-localization. (d) Immunoblot of Ambra1, hVps15, hVps34, 
Atg14L and beclin 1. Uncropped images of blots are shown in Supplementary 
Information, Fig. S10. (e–i) Starved IB3-1 cells transfected with either HA-
tagged human beclin 1 or the empty vector. (e) Confocal microscopy images 
of HA (red) and calnexin (green) (top) or hVps34 (red) and calnexin (green) 
(bottom). Yellow indicates co-localization. N, nucleus. Scale bar, 10 μm. (f) 
Left: confocal images of LC3-positive dots. N, nucleus. Scale bar, 10 μm. 
Right: percentage of cells containing more than five LC3-positive dots. At least 
60 cells were counted in each experiment. Means ± s.d. for three independent 
experiments. Asterisk, P < 0.001 versus cells transfected with the empty 
vector; ANOVA. (g) Left: electron microscopy of HA–beclin 1-transfected 
IB3-1 cells shows areas enriched in autophagosomes (arrows). Scale bar, 
250 nm. Right: number of autophagosomes per cell; 20 cells were counted 
in each experiment. Means ± s.d. for three independent experiments. 
Asterisk, P < 0.001 versus cells transfected with the empty vector; ANOVA. 
(h) Immunoblot of HA and LC3. (i) Immunoblot of p62. Uncropped images 
of blots are shown in Supplementary Information, Fig. S10. (j) Immunoblot 
of beclin 1 in WT and CftrF508del mice. Representative of seven mice for each 
group. (k, l) CftrF508del mice (n = 3 per group) were administered intranasally 
with a lentiviral vector encoding beclin 1 (LV-beclin 1) or GFP (LV-GFP). (k) 
LC3-positive dots per mm2 of lung tissues. Means ± s.d. for lung tissues from 
three mice per group. (l) Confocal microscopy micrographs of p62. L, lumen. 
Representative stainings from at least five airway epithelial areas per mouse. 
Scale bar, 10 μm. β-Actin was used as loading control for immunoblot analysis 
of cells, and αβ-tubulin for mouse tissue. Densitometric analysis of blots and 
quantitative measurement of co-localizations are shown in Supplementary 
Information, Fig. S9.
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Fig. S1d). CFBE41o– cells behaved in a similar manner to IB3-1 cells, 
whereas both S9 and 16HBE14o– cells behaved in a similar manner to 
the C38 cell line (data not shown).
Defective basal autophagy was observed in human and mouse CF 
airways. Nasal polyp biopsies from patients with severe CF (n = 10) 
(Supplementary Information, Table S1)10,15,22, showed decreased levels 
of LC3 II protein and LC3 dots (per 104 mm–2 of mucosa, P < 0.01) 
(Fig. 1h, i), an increased pool of polyubiquitylated proteins (data not 
shown), and increased levels of p62 with accumulation in intraepithe-
lial aggregates in comparison with non-CF controls (n = 10) (Fig. 1h, j). 
A decrease in LC3 dots (per mm2 of tissue, P < 0.001), an increased 
pool of polyubiquitylated proteins (data not shown) and intraepithelial 
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Figure 3 TG2-mediated crosslinking of beclin 1 induces aggresome 
sequestration of beclin 1 interactome and drives defective autophagy in CF 
airway epithelial cells. (a) IB3-1 cells cultured with 250 μM cystamine or 
transfected with either 50 nM human TG2 siRNA or scrambled oligonucleotides. 
IP, immunoprecipitation; IB, immunoblot. (b) IB3-1 cells cultured with the 
proteasome inhibitor MG132 (50 μM). (c, d) IB3-1 cells transfected with either 
human TG2 siRNA or scrambled oligonucleotides followed by incubation with 
MG132. (c) Cells immunostained with anti-beclin 1 (green) and anti-HDAC-6 
(red) antibodies. Yellow indicates co-localization. N, nucleus. Scale bar, 10 μm. 
(d) FRET analysis of beclin 1-Alexa 546 (Al546) fluorescence after HDAC6-Cy5 
photobleaching. F/F0 indicates the post-bleaching/pre-bleaching fluorescence 
ratio of Al546/Cy5. (e) IB3-1 cells were transfected with either human TG2 
siRNA or scrambled oligonucleotides. Immunoblot of TG2, Ambra-1, hVps15, 
hVps34, Atg14L and beclin 1 in IB3-1 cells grown in starvation. Uncropped 
images of blots are shown in Supplementary Information, Fig. S10. (f) IB3-1 
and C38 cells were transfected with either 1 μg of pLPCX-WT-TG or pLPCX-
Cys277Ser-TG or the empty vector. Immunoblot of beclin 1. Uncropped images 
of blots are shown in Supplementary Information, Fig. S10. (g, h) IB3-1 cells 
were treated with cystamine or 10 mM EUK-134 or transfected with either 
50 nM human PIASy siRNA or scrambled oligonucleotides. (g) Percentage of 
cells containing more than five GFP–LC3 punctate dots. Means ± s.d. for three 
independent experiments. Asterisk, P < 0.001 versus control; ANOVA. (h) Left: 
electron micrographs of IB3-1 cells showing areas enriched in autophagosomes 
(arrows) on PIASy gene silencing, EUK-134 or cystamine. Scale bar, 100 nm. 
Right: number of autophagosomes per cell counted in 20 cells per experiment. 
Means ± s.d. for three independent experiments. Asterisk, P < 0.001 versus 
control; ANOVA. (i) IB3-1 cells treated with cystamine. Immunoblot of p62. 
(j) IB3-1 cells treated with cystamine or EUK-134 or transfected with human 
PIASy siRNA or scrambled oligonucleotides. Immunoblot of beclin 1 (left) 
and PIASy (right). Uncropped images of blots are shown in Supplementary 
Information, Fig. S10. The experiments were repeated three times. β-actin 
was used as loading control for all blots. Densitometric analysis of blots and 
quantitative measurement of co-localizations are shown in Supplementary 
Information, Fig. S9.
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accumulation of p62 aggregates were observed in lung tissues from 
CFTRF508del homozygous (CftrF508del) mice23 (n = 10) compared with their 
control littermates (n = 10) (Fig. 1k, l).
Sequestration of beclin 1 interactome in aggresomes drives 
defective autophagy in CF airway epithelia
We analysed the expression levels of several autophagy-related genes21,24, 
including ULK1, ULK2, ATG5, ATG6 (encoding beclin 1), ATG7, ATG14, 
Bcl-2, hVps34 (encoding vacuolar protein sorting 34), hVps15 (encod-
ing regulatory myristoylated kinase) and Ambra1, a beclin 1-interact-
ing WD40-domain protein19. Real-time PCR did not reveal decreased 
messenger RNA expression levels of any of the tested genes in IB3-1 and 
CFBE41o– cells in comparison with C38 and 16HBE14o– cells. In con-
trast, significant increased expression of ATG7, ATG14, Bcl-2 and hVps34 
was observed in CF epithelia (Supplementary Information, Table S2; 
Supplementary Information, Fig. S1e, f).
A growing body of evidence indicates that beclin 1, a tumour suppres-
sor gene17–19, interacts with the class III PI(3)K hVps34 (refs 24, 25), and 
endoplasmic-reticulum-associated class III PI(3)K activity is crucial in 
the initiation of autophagosome formation26,27. Moreover, dissociation 
of beclin 1 from Bcl-2 promotes autophagy during stress conditions 
such as starvation18,26–29.
We immunoprecipitated beclin 1 from IB3-1 and C38 cells under 
nutrient-rich conditions or starvation. Decreased Bcl-2 immunoreactiv-
ity was observed in IB3-1 cells under basal conditions and was negligible 
under starvation (Supplementary Information, Fig. S2a). Fluorescence 
resonance energy transfer (FRET) analysis confirmed decreased interac-
tion between beclin 1 and Bcl-2 (Supplementary Information, Fig. S2b), 
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Figure 4 Defective CFTR drives inhibition of autophagy by means of ROS-
mediated TG2 SUMOylation in airway epithelial cells. (a, b) C38 cells 
were transfected with either 50 nM human CFTR siRNA or scrambled 
oligonucleotides (a, b) or cultured with CFTRinh-172 (b) in the presence or 
absence of cystamine (250 μM) or EUK-134 (10 mM). (a) Immunoblot of 
beclin 1, LC3 and p62 in C38 cells on starvation. Uncropped images of blots 
are shown in Supplementary Information, Fig. S10. (b) Percentage of cells 
containing more than five GFP–LC3 punctate dots per cell. Means ± s.d. 
for three independent experiments. Asterisk, P < 0.001 versus scrambled 
oligonucleotides; circle, P < 0.01 versus CFTR siRNA or CFTRinh-172; 
ANOVA. (c–g) A549 cells were transfected with 1 μg of pGFP–-CFTRF508del 
or pGFP (empty vector), in the presence or absence of 10 mM EUK-134 or 
250 μM cystamine. (c) Immunoblot of TG2 and PIASy. (d) FRET analysis 
of TG2-Alexa 546 fluorescence after SUMO-1 Cy5 photobleaching. (e) 
Immunoblot of beclin 1 and LC3 in A549 cells after starvation. Uncropped 
images of blots are shown in Supplementary Information, Fig. S10. (f) 
Percentage of cells containing more than five GFP–LC3 punctate dots per 
cell. Means ± s.d. for three independent experiments. Asterisk, P < 0.001; 
two asterisks, P < 0.01; ANOVA. (g) Immunostaining with anti-p62 (red) 
and anti-GFP (green) antibodies in starved A549 cells. Yellow indicates 
co-localization. N, nucleus. Scale bar, 10 μm. Each experiment was 
repeated three times. β-Actin was used as loading control for immunoblot. 
Densitometric analysis of blots and quantitative measurement of co-
localizations are shown in Supplementary Information, Fig. S9.
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suggesting an intracellular environment favourable to the induction of 
autophagy.
Immunoreactivities to hVps34, hVps15 and Ambra1 were detected in 
beclin 1 immunoprecipitates from both C38 and IB3-1 cells and increased 
on starvation (Supplementary Information, Fig. S2a). Because the PI(3)
K core complex binds to either Atg14L or the ultraviolet-irradiation-
resistance-associated gene (UVRAG)24,30, involved in distinct functional 
complexes driving either autophagy or endosome-to-Golgi retrograde 
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Figure 5 Restoring beclin 1 and autophagy decreases aggresome 
accumulation in CF epithelia. (a, b) IB3-1 cells were transfected with 
either HA-tagged human beclin 1, empty vector, p62 siRNA or scrambled 
oligonucleotides followed by rosiglitazone (10 μM). (a) Cells were 
immunostained with anti-HDAC6 (red) and anti-PPAR-γ (green) antibodies. 
Yellow indicates co-localization. N, nucleus. Scale bar, 10 μm. (b) FRET 
analysis of increase in PPAR-γ–Alexa 546 fluorescence after N-CoR Cy5 
photobleaching. (c) IB3-1 cells were transfected with either HA-tagged 
human beclin 1 or the empty vector under nutrient starvation. Cells were 
immunostained with anti-LC-3 (red) and anti-CFTR (green). Yellow indicates 
co-localization. N, nucleus. Scale bar, 10 μm. (d) IB3-1 cells were cultured 
under nutrient starvation with cystamine (250 μM) in the presence or absence 
of the PI(3)K inhibitor 3-MA. Immunostaining was with anti-LAMP-1 (red) 
and anti-CFTR (green). Yellow indicates co-localization. N, nucleus. Scale 
bar, 10 μm. (e) IB3-1 cells were transfected with either 50 nM human 
beclin 1 siRNA or scrambled oligonucleotides in the presence or absence 
of 250 μM cystamine under nutrient starvation. Cells were immunostained 
with anti-p62 (red) and anti-CFTR (green) antibodies. Yellow indicates 
co-localization. N, cell nucleus. Scale bar, 10 μm. (f, g) IB3-1 cells were 
transfected with 1 μg of pGFP–CFTRF508del or the empty vector, in the 
presence or absence of 250 μM cystamine. (f) Cells were immunostained 
with anti-GM-130 (red) and anti-GFP (green) antibodies. Yellow indicates co-
localization (arrows). Scale bar, 10 μm. (g) FRET analysis of GFP fluorescence 
after HDAC6 Cy3 photobleaching. Each experiment was repeated three times. 
Quantitative measurement of co-localizations is shown in Supplementary 
Information, Fig. S9.
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trafficking30, and Atg14L seems to divert hVps/class III PI(3)K into an 
autophagic role30, we investigated the interaction between Atg14L and 
beclin 1. Atg14L immunoreactivity was detected on beclin 1 immu-
noprecipitates and increased after starvation in both C38 and IB3-1 
cells (Supplementary Information, Fig. S2a). Confocal microscopy and 
FRET analysis revealed co-localization of beclin 1 with hVps34, hVps 15, 
Ambra 1 and Atg14L (Fig. 2a; Supplementary Information, Fig. S2c, d) 
in both C38 and IB3-1 cells. hVps34 (Fig. 2b), beclin 1 and the other bec-
lin 1-interacting proteins (data not shown) co-localized with the endo-
plasmic reticulum marker calnexin in C38 cells but not in IB3-1 cells. 
In CF cells, beclin 1 and beclin 1-interacting proteins are sequestered 
in perinuclear aggregates, where they co-localize with the aggresome 
marker HDAC6 (ref. 31) (Fig. 2c; Supplementary Information, Fig. S2d) 
and also with γ-tubulin and are associated with the collapse of the vimen-
tin cage (data not shown)12,31. The absence of the beclin 1 interactome 
at the endoplasmic reticulum level18,19 might have functional relevance 
in autophagy deficiency of CF epithelia, because PI(3)K complex III is a 
specialized endoplasmic reticulum membrane platform for the assembly 
of a phagosomal initiation complex18,19.
Decreased protein levels of beclin 1, hVps34, hVps15, Ambra1 
and Atg14L (Fig. 2d), and also of UVRAG (data not shown), were 
observed in IB3-1 cells. Western blots of the insoluble protein fraction 
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Figure 6 Restoring beclin 1 and autophagy rescues CF phenotype in IB3-1 
cells. (a–d) IB3-1 cells transfected for 24 h at 37 °C with 1 μg of pGFP–
CFTRF508del or empty vector in the presence or absence of 250 μM cystamine 
or with either 50 nM human p62 siRNA or scrambled oligonucleotides. 
(a) Left: CFTR revealed with anti-GFP primary antibody in IB3-1 cell 
lysate. Top arrow, complex-glycosylated form (apparent Mr of band C about 
170K, revealed as 210K with GFP tag); bottom arrow, core-glycosylated 
form (apparent Mr of band B about 150K, revealed as 190K with GFP 
tag). Uncropped images of blots are shown in Supplementary Information, 
Fig. S10. Right: quantification of bands B (black) and C (white) 
normalized to β-actin levels. Values are means ± s.d. for three independent 
experiments. (b) Cells immunostained with an anti-GFP antibody under 
non-permeabilizing conditions. Serial confocal sections were collected 
from top to bottom of cell. (c) Side view (X–Z) of a z-stack of confocal 
images taken in b. (d) Surface biotinylation assays was performed with 
membrane-impermeable sulpho-NHS-LC-biotin. The cells were fractioned 
to obtain the plasma membrane fraction, and biotinylated proteins were 
precipitated with streptavidin beads. Immunoblot of GFP to reveal the C 
form. E-cadherin and β-actin were used as positive and negative controls, 
respectively. (e) IB3-1 cells transfected with either HA-tagged human 
beclin 1 or empty vector. Immunoblot of PIASy, TG2, phospho-p42/44 
and PPAR-γ proteins. (f) IB3-1 cells transfected with either 50 nM human 
p62 siRNA or scrambled oligonucleotides. Immunoblot of p62 and 
phospho-p42/44. Uncropped images of blots are shown in Supplementary 
Information, Fig. S10. (g) IB3-1 cells transfected with either 50 nM 
human beclin 1 siRNA or scrambled oligonucleotides in the presence or 
absence of cystamine. Immunoblot of phospho-p42/44. (h) IB3-1 cells 
transfected with either 50 nM human beclin 1 siRNA or 50 nM human 
ATG5 siRNA or scrambled oligonucleotides in the presence or absence of 
cystamine. TNF-α secretion. Each bar represents the mean ± s.d. for n = 3 
experiments. Asterisk, P < 0.01; ANOVA. Each experiment was repeated 
three times. β-Actin was used as loading control. Densitometric analysis 
of blots and quantitative measurement of co-localizations are shown in 
Supplementary Information, Fig. S9.
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revealed increased beclin 1 levels in IB3-1 cells in comparison with 
C38 cells, suggesting the retention of beclin 1 as an insoluble pro-
tein within aggregates in CF epithelia (Supplementary Information, 
Fig. S2e).
Next we overexpressed beclin 1 in IB3-1 cells. Haemagglutinin 
(HA)-tagged beclin 1 was detected at the endoplasmic reticulum level 
(Fig. 2e, top panel) and restored co-localization of hVps34 (Fig. 2e, bot-
tom panel), hVps15, Ambra1 and Atg14L (data not shown) with cal-
nexin. Moreover, HA–beclin induced an increase in LC3 dots (P < 0.001) 
(Fig. 2f) and autophagosome formation (Fig. 2g), increased LC3 II levels 
and decreased p62 accumulation (Fig. 2h, i).
Decreased beclin 1 protein levels were also observed in CF nasal 
polyp biopsies10,15,22 (n = 10) (Supplementary Information, Table S1 and 
Fig. S2f) and in airway tissues from CftrF508del mice (n = 10) (Fig. 2j), 
even though beclin 1 mRNA levels were similar to those in controls 
(data not shown). To investigate whether rescuing beclin 1 was effec-
tive in restoring autophagy in vivo in CF airways, CftrF508del mice (n = 3 
per group) were administered intranasally with a lentiviral vector 
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Figure 7 Restoring autophagy by cystamine or beclin 1 overexpression 
rescues CF phenotype in human and mice CF airways. CF human 
nasal mucosae cultured with cystamine or NAC (patients 4–10 in 
Supplementary Information, Table S1) (a–c) in the presence or absence 
of 3-MA (patients 6–10 in Supplementary Information, Table S1) (b, c). 
(a) Immunoblot of beclin 1. (b) Fluorescence microscopy quantification 
of LC3-positive dots. Results represent means ± s.d. Asterisk, P < 0.05 
between groups of treatment; ANOVA. (c) Confocal microscopy 
micrographs of p62. Nuclei counterstained with DAPI (blue). Scale 
bar, 10 μm. Representative of five patients per group. (d–i) CftrF508del 
mice treated with cystamine or PBS in the presence or absence of 3-MA 
(e–i) (n = 7 per group). (d) Immunoblot of beclin 1. (e) Quantification 
of LC3 dots (per mm2 of lung tissue). Means ± s.d. Asterisk, P < 0.01; 
ANOVA. (f) Immunoblot of TG2. Uncropped images of blots are shown 
in Supplementary Information, Fig. S10. (g) Confocal microscopy of 
SUMO-1 in lung tissues. Nuclei counterstained with DAPI (blue). Scale 
bar, 10 μm. (h) Number of CD68+ macrophages counted in 15–20 
different randomly taken sections. Means ± s.d. per mm2 of lung tissue 
from seven mice in each group. Asterisk, P < 0.01; ANOVA. (i) MPO 
activity in lung homogenates (expressed as 10–3 × optical density 
(OD) s–1). Means ± s.d. for lung tissues from seven mice in each group. 
Asterisk, P < 0.05; ANOVA. (j–m) CftrF508del mice (n = 3 per group) 
administered intranasally with a lentiviral vector encoding beclin 1 
(LV-beclin 1) or GFP (LV-GFP). (j) TG2 Immunoblot in lung tissues. 
Uncropped images of blots are shown in Supplementary Information, 
Fig. S10. (k) Confocal microscopy of TG2 activity. Representative 
stainings from at least five airway epithelial areas per mouse from three 
mice per group. L, lumen. Scale bar, 10 μm. (l) Number of CD68+ 
macrophages counted in 15–20 different randomly taken sections. 
Means ± s.d. per mm2 of lung tissue. Asterisk, P < 0.01; ANOVA. 
(m) MPO activity in lung homogenates (expressed as 10–3 × OD s–1). 
Means ± s.d. for lung tissues. Asterisk, P < 0.05; ANOVA. Anti-β-Tubulin 
was used as loading control for immunoblot analysis. Densitometric 
analysis of blots is shown in Supplementary Information, Fig. S9.
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encoding beclin 1 under the control of the ubiquitous CMV pro-
moter32,33 or a lentiviral vector expressing GFP under the control of 
the same promoter (LV-GFP) (Supplementary Information, Fig. S2g). 
Overexpression of beclin 1 from the lentivirus induced a significant 
increase in LC3 dots (P < 0.001) and decreased p62 accumulation in 
comparison with CftrF508del mice treated with LV-GFP (Fig. 2k, l).
TG2-mediated crosslinking induces sequestration of beclin 1 
in aggresomes and drives defective autophagy in CF airway 
epithelial cells
These findings suggest that there is post-transcriptional regulation 
of beclin 1 expression in CF airways. Because the beclin 1 protein 
sequence contains QP and QXXP motifs, which are specific target sites 
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Figure 8 NAC restores autophagy and ameliorates CF lung phenotype in 
CF mice. CftrF508del mice (a–d) and Scnn1b-Tg mice (e–k) treated with NAC 
or PBS (n = 10 per group). (a) Confocal microscopy of LC3 (top) and p62 
(bottom) in lung tissues from CftrF508del mice. Nuclei counterstained with DAPI 
(blue). Scale bar, 10 μm. Representative images of ten PBS-treated and ten 
NAC-treated mice. (b) Quantification of LC3 dots (per mm2 of tissue) in lung 
tissues from CftrF508del mice. Means ± s.d. Asterisk, P < 0.001 versus PBS-
treated mice; ANOVA. (c) Number of macrophages per mm2 of lung tissue 
from CftrF508del mice (CD68-positive cells in 15–20 different randomly taken 
sections for each mouse lung for each condition); means ± s.d. for three 
separate experiments. Asterisk, P < 0.05 versus PBS-treated mice; ANOVA. 
(d) MPO activity in lung homogenates from CftrF508del mice (expressed as 
10–3 × OD s–1). Means ± s.d. Asterisk, P < 0.05 versus PBS-treated mice; 
ANOVA. (e) Confocal microscopy of LC3-positive dots in lung tissues from 
PBS-treated or NAC-treated Scnn1b-Tg mice. Nuclei counterstained with 
DAPI (blue). Scale bar, 10 μm. (f) Number of LC3-positive dots in lung 
tissues from Scnn1b-Tg mice. Means ± s.d. Asterisk, P < 0.01 versus PBS-
treated mice; ANOVA. (g) FRET analysis of TG2-Alexa 546 fluorescence after 
SUMO-1 Cy5 photobleaching in lung tissues from PBS-treated WT mice 
and PBS-treated or NAC-treated Scnn1b-Tg mice. (h) Immunoblot of TG2 
and phospho-p42/44 in lung tissues from PBS-treated WT mice and PBS-
treated or NAC-treated Scnn1b-Tg mice. αβ-Tubulin was used as loading 
control. (i) Lung histology of PBS-treated and NAC-treated Scnn1b-Tg mice. 
Haematoxylin staining. Scale bar, 150 μm. Black arrows indicate decrease 
in lung infiltration in NAC-treated in comparison with PBS-treated mice 
(arrowheads). (j) Left: confocal microscopy of COX-2 staining (left) in PBS-
treated and NAC-treated Scnn1b-Tg mice. Nuclei counterstained with DAPI 
(blue). Scale bar, 150 μm. Right; number of COX-2-positive cells per mm2 of 
lung tissue in PBS-treated and NAC-treated Scnn1b-Tg mice. Means ± s.d. 
Asterisk, P < 0.05 versus PBS-treated mice; ANOVA. (k) MPO activity in lung 
homogenates from PBS-treated and NAC-treated Scnn1b-Tg mice (expressed 
as 10–3 × OD s–1). Means ± s.d. Asterisk, P < 0.05 versus PBS-treated 
mice; ANOVA. Densitometric analysis of the blot is shown in Supplementary 
Information, Fig. S9.
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for TG2 activity34 (Supplementary Information, Fig. S3a), and TG2 is 
an autophagy inhibitor in pancreatic adenocarcinoma cells35, we tested 
the hypothesis that beclin 1 might undergo TG2-mediated crosslinking. 
Immunoprecipitates of beclin 1 from IB3-1 cells were blotted with an 
Nε(γ-l-glutamyl)-l-lysine isopeptide crosslink catalysed by TG2 (ref. 34). 
We observed high-molecular-mass bands in the Mr 130,000–250,000 
(130K–250K) range that were decreased by knockdown of TG2 as well 
as by the TG2 inhibitor cystamine34 (Fig. 3a; Supplementary Information, 
Fig. S3b) or the calcium chelator bis-(o-aminophenoxy)ethane-N,N,Nʹ,Nʹ-
tetra-acetic acid acetoxymethyl ester (BAPTA-AM)10,15 (data not shown) 
and enhanced by the proteasome inhibitor MG132 (Fig. 3b).
TG2 short interfering RNA (siRNA) or cystamine decreased bec-
lin1/HDAC6 co-localization and aggresome sequestration (Fig. 3c, d), 
restored the soluble forms of beclin 1 and beclin 1 interactor proteins 
(Fig. 3e), decreased the amount of beclin 1 in the insoluble protein frac-
tion (Supplementary Information, Fig. S3c) and increased the number of 
Atg16L-positive puncta (Supplementary Information, Fig. S3d), which 
associate transiently with the surface of forming autophagosomes24,36. 
They also increased LC3 dots (P < 0.001) and autophagosome forma-
tion (Fig. 3g, h; Supplementary Information, Fig. S3e) and decreased the 
accumulation of p62 in IB3-1 cells (Fig. 3i). To prove the role of TG2 
further, we transfected autophagy-competent C38 cells with pLPCX-TG2, 
a plasmid expressing wild-type TG2 or mutant Cys277Ser-TG2 including 
the amino-acid substitution Cys277Ser in the catalytic site. Wild-type 
TG2 induced a decrease in beclin 1 protein in C38 cells, whereas mutant 
TG2 did not (Fig. 3f). Overexpression of mutant TG2 restored beclin 1 
protein levels in IB3-1 cells (Fig. 3f).
These results indicate that TG2-mediated crosslinking drives defective 
autophagy in CF epithelial cells.
ROS-mediated TG2 SUMOylation is responsible for defective 
autophagy in CF epithelia
Because increased ROS sustain high TG2 levels through TG2 
SUMOylation mediated by PIASy (protein inhibitor of activated STAT 
y)15, we incubated IB3-1 cells with superoxide dismutase (SOD)–catalase 
mimetic EUK-134 or knocked-down PIASy15. We observed decreased 
beclin 1 crosslinking and aggresome sequestration (data not shown), 
increased LC3 dots (P < 0.001) (Fig. 3g), autophagosome formation 
(Fig. 3h) and beclin 1 upregulation (Fig. 3j); overexpression of man-
ganese superoxide dismutase (MnSOD)15 and the ROS scavenger 
N-acetylcysteine (NAC) showed similar effects to those of EUK-134 
(data not shown). NAC, EUK-134 or PIASy knockdown were all as effec-
tive as TG2 knockdown in restoring protein levels of soluble beclin 1, 
Atg14L, hVps34, hVps15 and Ambra1 (data not shown). These results 
indicate that ROS-mediated TG2 SUMOylation is responsible for defec-
tive autophagy in CF epithelia.
Defective CFTR inhibits autophagy through ROS-mediated TG2 
SUMOylation
We tested whether defective autophagy is a consequence of the CF 
genetic defect, because ROS-mediated TG2 SUMOylation is induced on 
inhibition of CFTR10,15. CFTR knockdown (Supplementary Information, 
Fig. S4a) in autophagy-competent C38 cells decreased beclin 1 and LC3 II 
protein levels (Fig. 4a), LC3 dots (P < 0.001) (Fig. 4b) and increased p62 
levels (Fig. 4a). Similar effects were observed on inhibition of CFTR 
by the small molecule CFTR inhibitor-172 (CFTRinh-172)10,15 (P < 0.001) 
(Fig. 4b). These effects were prevented by cystamine and by EUK-134 
(P < 0.01) (Fig. 4a, b) or NAC (data not shown). Transfection of C38 cells 
with HA–beclin on CFTR inhibition abrogated the effects on autophagy 
of CFTRinh-172 (data not shown). 16HBE14o– cells behaved similarly to 
C38 cells (data not shown).
Overexpression of GFP–CFTRF508del in A549 lung adenocarcinoma cell 
lines31 increased intracellular ROS and Ca2+ concentrations and eIF-2α 
phosphorylation (Supplementary Information, Fig. S4b–d), thus indicat-
ing CFTRF508del-induced activation of the unfolded protein response and 
endoplasmic reticulum stress36,37. GFP–CFTRF508del also increased PIASy 
and TG2 levels (Fig. 4c) and TG2 SUMOylation (Fig. 4d), and decreased 
beclin 1 and LC3 II protein levels (Fig. 4e) and LC3 dots (P < 0.001) 
(Fig. 4f). EUK-134 and cystamine (Fig. 4d–f) or NAC (data not shown) 
prevented these effects. Overexpression of mutant CFTR also induced 
p62 accumulation and co-localization of p62 with GFP–CFTRF508del in 
aggregates (Fig. 4g). These results indicate that defective CFTR has a 
pivotal role in driving beclin 1 downregulation and defective autophagy 
in CF airways through the ROS–TG2 pathway.
Restoring beclin 1 and autophagy decreases aggresome 
accumulation in CF epithelia
Next we investigated whether restoring beclin 1 levels might influ-
ence the aggresome-prone behaviour of CF epithelia. HA–beclin 1 
decreased the aggresome sequestration of PPAR-γ (Fig. 5a; 
Supplementary Information, Fig. S5a) and allowed PPAR-γ to interact 
with the nuclear co-repressor (N-CoR)15 in response to the PPAR-γ 
agonist rosiglitazone (Fig. 5b). Both HA–beclin 1 and cystamine 
induced CFTR co-localization with LC3 (Fig. 5c) and with the lyso-
somal marker LAMP-1 (Fig. 5d). They also decreased CFTR/HDAC-6 
co-localization and 3-MA (3-methyl adenine) prevented the effects 
of cystamine (Fig. 5d; Supplementary Information, Fig. S5b). Both 
beclin 1 knockdown and 3-MA also inhibited the effects of cystamine 
in decreasing CFTR (Fig. 5e) and PPAR-γ (data not shown) seques-
tration in aggresomes and co-localization with p62 (Fig. 5e). These 
results suggest that the effects of cystamine are due to its ability to 
rescue beclin 1 and autophagy.
We investigated the role of p62 in driving aggresome formation in CF 
epithelia. p62 is a regulator of packing and targeting polyubiquitylated pro-
teins and aggregates to autophagosomes for lysosomal degradation3,4 and 
is involved in the formation of protein aggregates in cancer cells38,39. p62 
knockdown in autophagy-deficient IB3-1 cells decreased PPAR-γ and the 
inhibitory protein IkB-α aggresomes (data not shown), restored the interac-
tion between PPAR-γ and N-CoR15 (Fig. 5b), decreased the accumulation of 
CFTR aggregates (Supplementary Information, Fig. S5c) and decreased the 
co-localization of CFTR with HDAC6 (data not shown). This suggests that, 
in CF epithelia, p62 mediates the effects of defective autophagy in driving 
aggresome accumulation of misfolded or modified proteins.
Defective autophagy with p62 accumulation compromises the delivery 
of ubiquitylated substrates to the proteasome40. However, upregulation of 
autophagy has been reported as a compensatory response to proteasome 
inhibition40, thus revealing crosstalk between the proteasome-based and 
the autophagy-based degradasomes40. We incubated IB3-1 cells with 
the proteasome inhibitor MG132 and demonstrated that MG132 was 
not effective in enhancing soluble beclin 1 protein or increasing LC3 
dots, but enhanced beclin 1 sequestration in HDAC6-positive aggregates 
(Supplementary Information, Fig. S5d–f).
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Rescuing beclin 1 and autophagy restores CFTR trafficking in 
CF epithelia
These results indicate that HA–beclin 1, cystamine and p62 knockdown 
all favoured the clearance of CFTRF508del aggregates. They also raise the 
question of whether rescuing beclin 1 and autophagy in IB3-1 cells might 
restore mutant CFTR maturation and trafficking to the Golgi and ulti-
mately to the cellular surface.
The F508del mutation results in a temperature-sensitive folding defect 
of CFTR and premature degradation by the endoplasmic-reticulum-asso-
ciated degradation system (ERAD)41,42. Functional CFTR can be increased 
by growth at a lower temperature or incubation with chemical chaper-
ones, which favour the escape of CFTRF508del from ERAD41–47.
We transfected autophagy-deficient IB3-1 cells for 24 h with GFP–
CFTRF508del in the presence or absence of cystamine at 37 °C or p62 knock-
down. Either cystamine or p62 knockdown (data not shown) induced 
an increase in GFP–CFTRF508del co-localization with the Golgi marker 
GM-130 (Fig. 5f) and decreased the sequestration of CFTR in aggre-
somes (Fig. 5g). Western blotting of the whole protein extracts revealed 
increased mature complex-glycosylated CFTRF508del (band C, apparent 
Mr about 170K)46 after treatment with cystamine or p62 knockdown in 
comparison with cells transfected with GFP–CFTRF508del alone (Fig. 6a), 
with an increased ratio between the complex-glycosylated band C and 
its core-glycosylated counterpart band B (apparent Mr about 150K)46, 
the predominant form in untreated cells46 (Fig. 6a). These results also 
revealed a greater increase in band B in cystamine-treated cells or after 
p62 knockdown (Fig. 6a). Western blots of the insoluble protein frac-
tion revealed higher amounts of CFTRF508del band B that were decreased 
after treatment with cystamine or p62 knockdown (Supplementary 
Information, Fig. S6a), indicating the sequestration of CFTRF508del within 
insoluble aggregates.
Confocal microscopy revealed an increase in GFP–CFTRF508del at the 
plasma membrane after treatment with cystamine (Fig. 6b, c) as well as 
on p62 knockdown (data not shown) in comparison with IB3-1 cells 
transfected with GFP–CFTRF508del alone (Fig. 6b, c). To confirm the pres-
ence of complex-glycosylated CFTR at the cell surface, plasma membrane 
fractions were isolated from GFP–CFTRF508del-transfected IB3-1 cells by 
biotinylation assay and streptavidin pull-down, as reported previously47. 
Band C of GFP–CFTRF508del was pulled down specifically on streptavidin 
beads after cystamine treatment (Fig. 6d, Supplementary Information, 
Fig. S6b) or p62 knockdown (data not shown).
These results indicate that restoring intracellular homeostasis by res-
cuing beclin 1 and autophagy by cystamine or reducing p62 accumula-
tion inhibits sequestration of mutant CFTR in aggresomes and allows 
its maturation and trafficking to the cell membrane.
Restoring beclin 1 rescues the CF inflammatory phenotype
Next we investigated whether defective autophagy might have a function 
in inflammation in CF. HA–beclin 1 rescued pro-inflammatory phe-
notype of IB3-1 cells as it decreased p42/44 phosphorylation (Fig. 6e), 
increased the levels of Mr 55K PPAR-γ protein (Fig. 6e) and decreased 
tumour necrosis factor (TNF)-α secretion in medium (P < 0.01) 
(Supplementary Information, Fig. S6c). We also investigated whether 
defective autophagy might in turn sustain TG2 activation. HA–beclin 1 
decreased ROS (P < 0.01) and TG2 SUMOylation (Supplementary 
Information, Fig. S6d, e), and also PIASy and TG2 protein levels 
(Fig. 6e). Moreover, p62 knockdown in autophagy-deficient IB3-1 cells 
decreased p42/44 phosphorylation (Fig. 6f) and TG2 SUMOylation 
(Supplementary Information, Fig. S6f) and increased the levels of Mr 55K 
PPAR-γ protein (data not shown). In contrast, MG132 did not decrease 
TNF-α secretion in medium (P < 0.01) (Supplementary Information, 
Fig. S5g) or p42/44 phosphorylation (data not shown).
Because targeting TG2 restores inflammation in human and mice 
CF airways15, we investigated whether these effects were mediated by 
the rescue of autophagy. We incubated IB3-1 cells with cystamine or 
the antioxidants EUK-134 and NAC in the presence or absence of bec-
lin 1 knockdown. The effects of cystamine or antioxidants (data not 
shown) in controlling p42/44 phosphorylation (Fig. 6g) and TNF-α 
secretion (Fig. 6h) were neutralized on beclin 1 knockdown (Fig. 6g, h; 
Supplementary Information, Fig. S6g). The effects of cystamine on 
TG2 SUMOylation and inflammation were also neutralized by either 
3-MA48 (data not shown) or ATG5 knockdown (Fig. 6i, Supplementary 
Information, Fig. S6h).
This indicates that rescue of beclin 1 and autophagy mediates the 
effects of cystamine and antioxidant molecules in CF epithelia.
Targeting the ROS–TG2 pathway ameliorates the CF phenotype 
through restoration of autophagy in human and mouse CF airways
To validate these results in human CF airways, we cultured nasal 
polyp biopsies with cystamine or EUK-134 (refs 10, 15, 22). In all CF 
biopsies tested (n = 7) (Supplementary Information, patients #4-10 
of Supplementary Information, Table S1), both NAC and cystamine 
increased beclin 1 protein and LC3 dots (P < 0.05), decreased p62 
aggregates (Fig. 7a–c, top panel, Supplementary Information, Fig. S7a), 
decreased TG2 SUMOylation and enhanced PPAR-γ/N-CoR interac-
tion; these effects were prevented by 3-MA48 (Fig. 7b, c; Supplementary 
Information, Fig. S7b, c).
To confirm the biological relevance of these findings in vivo, we 
treated CftrF508del homozygous mice with cystamine15 in the presence or 
absence of 3-MA or PBS (n = 7 for each group). Cystamine has been 
proved to be effective in vivo in a mouse model of Huntington’s dis-
ease49, and also to control inflammation in CftrF508del homozygous mice 
15,23. In all mice tested, cystamine increased beclin 1 protein (Fig. 7d) 
and LC3 dots (P < 0.01) (Fig. 7e), thus indicating rescue of autophagy. 
These effects were neutralized in lung homogenates by 3-MA (Fig. 7e), 
which also prevented the effects of cystamine in reducing TG2 protein 
(Fig. 7f), SUMO-1 protein expression15 (Fig. 7g), TG2 SUMOylation 
(Supplementary Information, Fig. S7d), macrophage lung infiltration 
(per mm2 of tissue, versus PBS-treated mice; P < 0.01) (Fig. 7h) and mye-
loperoxidase (MPO) activity, a marker of neutrophilic recruitment and 
activation status23 (Fig. 7i). On its own, 3-MA did not induce changes in 
lung phenotype in CftrF508del homozygous mice (data not shown).
To investigate whether beclin 1 overexpression was effective in damping 
down CF lung inflammation in vivo, we evaluated inflammation markers 
in LV-beclin 1-treated CftrF508del homozygous mice. Intranasal adminis-
tration of LV-beclin 1 was effective in restoring autophagy in CftrF508del 
homozygous mice, as shown in Fig. 2. We demonstrate that LV-mediated 
beclin 1 overexpression induced a decrease in TG2 protein and activity 
(Fig. 7j, k) and decreased macrophage lung infiltration and MPO activ-
ity in lung homogenates (Fig. 7l, m), in comparison with LV-GFP-treated 
mice (Fig. 7j–m).
These results indicate that targeting ROS–TG2 axis ameliorates the human 
and mouse CF airway phenotype by restoring beclin 1 and autophagy.
NATURE CELL BIOLOGY  ADVANCE ONLINE PUBLICATION   11
© 2010 Macmillan Publishers Limited.  All rights reserved.
A RT I C L E S
Antioxidant treatment restores autophagy and ameliorates the 
CF lung phenotype in mouse CF airways
To study the effects of NAC in vivo, we treated CftrF508del mice with daily 
intraperitoneal injections of NAC50 (n = 10) or PBS (n = 10). NAC-treated 
mice showed an increase in LC3-positive vesicles (Fig. 8a) and punctate 
dots (P < 0.001) (Fig. 8b), and a decrease in p62 accumulation (Fig. 8a), 
macrophage infiltration (P < 0.05) (Fig. 8c) and MPO activity (P < 0.05) 
in the lungs (Fig. 8d).
We tested the effects of NAC in Scnn1b-Tg mice, another well-estab-
lished mouse model of CF, with overexpression of the β-ENaC subunit51 
and Na+ hyperabsorption, which induce a severe CF-like lung disease 
including inflammation51,52. Similarly to the Cftrf508del mice, Scnn1b-Tg 
show a spontaneous lung inflammatory phenotype regardless of the 
presence of bacterial infections15,23,51,52. Scnn1b-Tg lung tissues showed 
decreased LC3-positive vesicles and LC3 dots and p62 accumulation, 
and increased TG2 activity, in comparison with their control littermates 
(Supplementary Information, Fig. S7e–g). NAC-treated Scnn1b-Tg mice 
(n = 10) showed increased LC3-positive vesicles and LC3 dots (P < 0.01) 
(Fig. 8e, f) with decreased p62 aggregates (data not shown) and a decrease 
in TG2 SUMOylation (Fig. 8g), TG2 protein levels and p42/44 phospho-
rylation (Fig. 8h) in comparison with PBS-treated mice. Treatment with 
NAC also decreased lung infiltration by leukocytes (Fig. 8i), decreased the 
number of cyclo-oxygenase-1 (COX-2)-positive cells (per mm2 of tissue, 
P < 0.05 versus PBS-treated mice) (Fig. 8j) and decreased MPO activity in 
lung homogenates (P < 0.05 vs. PBS-treated mice) (Fig. 8k).
Finally, we found that cystamine increased LC3 dots and decreased 
inflammatory lung infiltration (data not shown) in Scnn1b-Tg mice. Neither 
cystamine nor NAC induced changes in wild-type mice (data not shown).
These results indicate that NAC rescues beclin 1 and autophagy and 
ameliorates the airway phenotype in vivo in CF mouse models.
DISCUSSION
Defective autophagy is a critical mechanism in several chronic human 
diseases53 such as neurodegeneration54 and cancer55. Here we have shown 
that defective autophagy due to decreased levels of beclin 1 protein, a 
key molecule involved in autophagosome formation17,19,24,25,30, drives lung 
inflammation in CF.
Decreased beclin 1 expression has been described in the affected brain 
regions in early Alzheimer’s disease, and defective autophagy has been 
linked to amyloid-β accumulation56. A feature that is common to this neu-
rodegenerative disease and CF is the aberrant intracellular accumulation of 
misfolded proteins within the affected tissues57,58. In CF airways, misfolded 
or damaged proteins such as misfolded CFTR31 and PPAR-γ10 accumulate 
in aggresomes. Here we demonstrate that in CF epithelia TG2-mediated 
crosslinking and sequestration of beclin 1 dislodge the PI(3)K platform 
from the endoplasmic reticulum, thus inhibiting the initiation of autophagy. 
TG2-driven defective autophagy in turn increases ROS and TG2 levels, thus 
generating a cycle leading to a deleterious pro-oxidative and pro-inflamma-
tory environment (Supplementary Information, Fig. S8a, b).
Autophagy inhibition with p62 accumulation3,4,5,38,39 increases the lev-
els of proteasome substrates3 and compromises the ubiquitin proteasome 
system3,59, thus favouring aggresome formation4,5. TG2 contributes to 
proteasome overload and aggresome formation in CF airways by induc-
ing the crosslinking and aggregation of several substrate proteins10,15. TG2 
therefore functions as a rheostat of the post-translational network and 
the ubiquitin proteasome system under disease conditions and switches 
off the post-translational regulatory mechanisms. As a consequence of 
this function, TG2 is involved in the pathogenesis of neurodegenerative 
diseases due to protein aggregates60.
Our study highlights an unpredicted role of p62 in CF. p62 is a 
stress-induced protein that also regulates the formation and disposal 
of the intracellular aggregates3,4,5,38–40. Either restoring beclin 1 by 
cystamine or reducing p62 levels allows CFTRF508del maturation and 
trafficking to the cell surface, probably interrupting the cycle that 
disregulates the intracellular chaperone system.
CF airway tissues are characterized by a pro-inflammatory phenotype 
with constitutive ceramide accumulation61 and activation of NF-κB second-
ary to defective CFTR function62. We have previously reported that CFTR 
inhibition results in the upregulation of ROS and their downstream events, 
leading to inflammation10,15. Here we show that CFTR knockdown drives 
defective autophagy, as it occurs in human and mouse epithelia that are 
either homozygotes for F508del or compound heterozygotes for two severe 
CFTR mutations. Because under the latter conditions negligible amounts of 
functional CFTR are detected at the cell surface45,63,64, our results highlight 
an unforeseen role of CFTR in the regulation of autophagy in CF.
We show that targeting TG2 SUMOylation with antioxidant molecules 
as well as inhibiting TG2 with cystamine rescue the CF lung phenotype 
by means of autophagy induction in both human and mouse CF airways. 
Our results provide a new mechanism linking the CFTR defect with 
inflammation, through the ROS–TG2-mediated inhibition of autophagy 
(Supplementary Information, Fig. S8a, b). We have therefore provided a 
novel rationale and a mechanism of action for both NAC65 and cystamine 
in the treatment of patients with CF.
Our study suggests that the restoration of beclin 1 and autophagy may 
be a novel approach to the treatment of CF and may pave the way for the 
development of a new class of drugs that, by enhancing beclin 1 levels, 
could be effective treatments for CF.
METHODS
Methods and any associated references are available in the online version 
of the paper at http://www.nature.com/naturecellbiology/
Note: Supplementary Information is available on the Nature Cell Biology website.
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METHODS
Cell lines. IB3-1 human CF bronchial epithelial, C38 or S9 cells, normal bronchial 
epithelial 16HBE14o– or lung carcinoma A549 cell lines (LGC Promochem, Milan, 
Italy) were cultured as recommended by the American Type Culture Collection. 
CFBE41o– human CF bronchial epithelial cells (a gift from D. C. Gruenert) were 
cultured in MEM Earl’s salt l-glutamine (200 mM l-glutamine) medium sup-
plemented with 10% FBS and the appro priate amount of penicillin/streptomy-
cin. Cell lines were incubated for 24 h with cystamine (250 μM; Sigma Aldrich), 
NAC (10 mM; Vinci Biochem), EUK-134 (50 μg ml–1; Vinci Biochem), rapamycin 
(100 nM; Sigma Aldrich), chloroquine (25 μM; Sigma Aldrich), E64d (50 μg ml–1 
for 4 h) and pepstatin A (50 μg ml–1 for 4 h), rosiglitazone (10 μM for 4 h; Vinci 
Biochem); BAPTA-AM (25 μg ml–1 for 4 h; Calbiochem) and proteasome inhibi-
tor MG132 (50 μM for 6 h; Calbiochem). IB3-1 cells were also incubated for 24 h 
with 3-MA (20 mM; Calbiochem) followed by cystamine. C38 and 16HBE cells 
were incubated for 48 h with CFTRinh-172 (20 μM; Calbiochem)10,15 followed by 
cystamine or EUK-134.
Human subjects and ex vivo cultures of nasal polyp mucosal biopsies. Ten patients 
with CF carrying severe CFTR mutations (Supplementary Information, Table S1) 
and ten consecutive patients without CF (mean age 21 years, range 16–32 years) 
undergoing surgical treatment for non-allergic nasal polyposis were enrolled. Nasal 
polyp biopsies from seven patients in each group (patients 4–10 in Supplementary 
Information, Table S1) were cultured for 4 h with or without EUK-134 (50 μg ml–1), 
NAC (10 mM) or cystamine (400 μM). Nasal polyp biopsies from five patients with 
CF (patients 6–10 in Supplementary Information, Table S1) were also incubated 
with NAC or cystamine in the presence or absence of 3-MA (3 mM)20, followed by 
incubation wth rosiglitazone (10 mM for 4 h).
Mice and treatments. Young adult female CF mice homozygous for the F508del 
mutation (abbreviated CftrF508del)23 in the 129/FVB outbred background (obtained 
from Bob Scholte, Erasmus Medical Center Rotterdam, The Netherlands), young 
adult Scnn1b-Tg mice51 and their wild-type littermates were housed in static 
isolator cages at the animal care specific pathogen-free facility of Charles River 
(Varese, Italy). We treated CftrF508del homozygous mice and Scnn1b-Tg mice by 
intraperitoneal injection with a daily dose of 100 μl of 0.01 M cystamine in PBS 
solution for 7 days (ref. 16) (n = 7 for each group of treatment) or NAC with a 
daily dose of 100 mg per kg body weight in PBS solution for 5 days or with PBS 
solution (n = 10 for each group of treatment). CftrF508del mice were also treated 
with cystamine in the presence or absence of 3-MA (intraperitoneal injection of 
50 mg kg–1 in 100 μl of PBS for 7 days) or 3-MA alone (n = 7 for each group of 
treatment). Airway administrations of lentiviral vectors expressing mouse bec-
lin 1 or GFP32 were performed in anaesthetized CftrF508del homozygous mice aged 
4–8 weeks, as described previously33. In brief, mice received a single dose of 4 μl 
of 1% l-α-lysophosphatidylcholine (LPC; Sigma) in PBS into the nasal airway by 
inhalation-driven instillation 1 h before delivery of the GFP or beclin 1 lentiviral 
vectors at a dose of 1.2 × 107 transducing units per mouse delivered into the nose 
(two 10-μl aliquots over several minutes). Mice were killed 5 days after vector 
administration, and lung tissues were collected for analyses.
Histology. We excised and immediately fixed mouse lungs in buffered 4% para-
formaldehyde; they were then embedded in paraffin and sectioned to a thickness 
of 5 μm. We performed haematoxylin staining on serial sections.
Plasmids. The pGFP–CFTRF508del expression vector (provided by Ron R. Kopito), 
pEGFP–LC3 and pcDNA3-HA–beclin 1 expression vector (a gift from N. 
Mizushima), pLPCX-TG and pLPCX-TGCys277Ser (a gift from G. M. Fimia) 
and the corresponding empty expression vectors were used for transfection 
experiments.
Transfection and RNA interference. Cells were transfected with TG2 (ref. 15), 
PIASy (ref. 15), beclin 1 and p62 (Oligonucleotide Synthesis Core Facility, CEINGE 
s.c.a.r.l. Naples, Italy), CFTR and ATG5 siRNA (Invitrogen) or scrambled oligo-
nucleotides by using Lipo RnaiMax (Invitrogen) in accordance with the manufac-
turer’s instructions. siRNA oligonucleotide sequences are shown in Supplementary 
Information, Table S2a. Cell lines were also transfected with pcDNA3-HA–beclin 1 
expression vectors, pEGFP–LC3, human TG2 or Cys277Ser TG2 or antisense 
cDNAs in pLPCLX vector and GFP–CFTRF508del, by using Lipofectamine 2000 
(Invitrogen) in accordance with the manufacturer’s instructions.
Lentiviruses. The lentiviral vectors expressing mouse beclin 1 or GFP have been 
described previously33.
Adenoviral vector. Human MnSOD cDNA was cloned into the shuttle vector 
pAd5CMVK-NpA (a gift from Michael Brownlee). Cell lines were infected for 
2 h with MnSOD or control adenovirus (ref. 15).
Quantitative RT–PCR. Total RNA was extracted with the RNeasy Mini Kit 
(Qiagen). The mRNA was reverse transcribed with a SuperScriptTM III First 
Strand Synthesis System (Invitrogen). Quantitative RT–PCR was performed with 
an iCycler iQ Multicolour Real-Time PCR Detector (Bio-Rad) with iQ TM SYBR 
Green supermix (Bio-Rad). Expression levels of genes were normalized to β-actin 
levels in the same sample. The sequence of primers is reported in Supplementary 
Information, Table S2b. The relative amounts of mRNA were calculated by using 
the comparative Ct method.
Immunoblot analysis. Immunoblot analysis was performed as described 
previously10,15. The antibodies used for immunoblot analysis are reported 
in Supplementary Information, Table S3. Densitometric analysis was per-
formed with Image J software; each data point is expressed as a mean ± s.d. 
for three independent experiments. The data are shown in Supplementary 
Information.
Immunoprecipitation. Whole-cell lysates were incubated at 4 °C for 8–12 h with 
antibody anti-beclin 1 (Santa Cruz Biotechnology). After the addition of Protein 
A/G-agarose beads, the incubation was continued for 1 h. After being washed, 
the immunoprecipitated proteins were subjected to electrophoresis through 8% 
polyacrylamide gels (Bio-Rad), transferred to blotting membranes (Polyscreen 
poly(vinylidene difluoride); NEN) and analysed.
Soluble and insoluble fractions. Cells were lysed in buffer containg 50 mM Tris-
HCl pH 7.5, 150 mM NaCl, 0.5% Nonidet P40, 5 mM EDTA, 1 mM phenylmeth-
ylsulphonyl fluoride, 50 mM NaF, 10 μg ml–1 leupeptin and 10 μg ml–1 apoprotein 
supplemented with protease inhibitors (Sigma) and centrifuged at 16,000g at 4 °C 
for 20 min. After centrifugation the soluble (supernatant) and insoluble (pel-
let) fraction were used in western blot analysis with anti-beclin 1 or anti-GFP 
antibody. The pellet insoluble in Nonidet P40 was dissolved five times in sample 
buffer, boiled at 95 °C for 5 min and resolved on a 10% polyacrylamide gel.
Cell-surface biotinylation assay. Cell-surface proteins were biotinylated with 
sulphosuccinimidyl-6-(biotinamido) hexanoate (sulpho-NHS-LC-biotin, 1 
mg ml–1 in PBS, pH 8.2; Pierce), as described47. IB3-1 cells were homogenized in 
a Potter–Elvehjem pestle and glass tube (Sigma) and centrifuged at 2,300g for 15 
min at 4 °C to obtain nuclear pellets. Supernatants containing the cytoplasmic 
fractions and plasma membrane were centrifuged for 1 h at 16,000g at 4 °C; the 
pellet was the intact membrane and was solubilized in buffer A containing 1% 
Triton X-100. This was then centrifuged for 1 h at 60,000g in the ultracentrifuge. 
The supernatants were collected as the plasma membrane fraction. Equivalent 
amounts of protein (500 μg) were used for streptavidin–agarose pull-down 
(Pierce). Biotinylated proteins were immunoblotted against GFP or E-cadherin 
or β-actin antibodies. Incubation without biotin was used as control.
Immunofluorescence analysis. Immunofluorescence analysis was performed 
as described previously10,15. Cell or tissue sections were incubated with pri-
mary antibodies. The antibodies used for immunofluorescence analysis are 
reported in Supplementary Information, Table S3. TG2 enzymatic activity in 
human or mice lung sections was detected by incubating unfixed sections with 
biotin-mono-dansyl cadaverine for 1 h at room temperature, as described previ-
ously10,15. Image J software (US National Institutes of Health) was used to quan-
tify the number of GFP–LC3-positive cells containing more than five GFP–LC3 
puncta or cells with more than LC3 dots per cell. At least 60 cells were counted 
in each experiment and the values are means ± s.d. for five independent experi-
ments. Correlation coefficient analysis was used as value of co-localization as 
described previously66.
FRET microscopy. For acceptor photobleaching, FRET microscopy analysis was 
performed as described previously10,15. The antibodies used for FRET microscopy 
are reported in Supplementary Information, Table S3. Cy5 was bleached at not 
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more than 10% of its initial fluorescence, by 200 2.56-ms pulses of 5-mW 633-nm 
laser per pixel, sampling 0.01 mm2 of the specimen. Alexa 546 fluorescence was 
detected before and after Cy5 photobleaching.
Electron microscopy. Cell culture monolayers were fixed for 15 min at 4 °C with 
4% paraformaldehyde and 2.5% glutaraldehyde in 125 mM cacodylate buffer and 
stained with uranyl acetate and lead citrate and examined in a Leo912 electron 
microscope. We used Image J software (US National Institutes of Health) to quan-
tify the number of autophagosomes per cell in 15–20 different randomly taken 
micrographs for each condition.
Mitochondrial membrane potential measurements. We incubated 106 PBS-
washed cells in 40 nM DiOC6 (Sigma) and 1 mg ml–1 propidium iodide (Sigma) 
for 15 min at 37 °C. After being washed, cells were suspended in 1 ml of PBS 
(pH 7.4) and were subsequently analysed by flow cytometry.
MPO activity. MPO activity in lung homogenates was assessed at 490 nm over 
10 min and expressed as 10–3 × OD s–1, as described previously24.
ROS detection. Cells were pulsed with 10 μM 5-(and-6)-chloromethyl-2ʹ,7ʹ- 
dichlorodihydrofluorescein diacetate acetyl ester (CM-H2DCFDA; Molecular 
Probes) and analysed with a Wallac 1420 multilabel counter as described 
previously10,15.
Calcium imaging. We loaded A549 cells transfected with CFTRF508del or vector 
control with Fura-2 (30 min at 37 °C) in calcium imaging buffer in accordance 
with the manufacturer’s instructions (Invitrogen, Molecular probes). 
Enzyme-linked immunosorbent assay (ELISA). Human TNF-α secretion 
was measured with a BD OptEIATM TNF-α ELISA kit II (BD Biosciences, 
NJ, USA). Values were normalized to 106 cells; results are expressed as 
means ± s.d.
Statistical analysis. Data are reported as arithmetic means ± s.d. The data dis-
tribution was analysed for normality and statistical analysis was performed with 
a one-way ANOVA. Significant differences are indicated in the figures. All data 
were obtained from independent measurements. Data were analysed with SPSS 
13 software. Statistical significance was defined as P < 0.05.
66. Luciani, A. et al. Lysosomal accumulation of gliadin p31-43 peptide induces oxida-
tive stress and tissue transglutaminase-mediated PPARγ downregulation in intestinal 
epithelial cells and coeliac mucosa. Gut 59, 311–319 (2010).
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Figure S1 Defective autophagy in human CF airway epithelia. (a) Electron 
microscopy analysis of  non-starved C38 and IB3-1 cells. Bar, 250 nm. (b) 
Immunoblot of LC3 in starved IB3-1 cells in the presence or absence of 
chloroquine. β-actin was used as loading control. (c) Confocal microscopy 
micrographs of p62 in starved C38 and IB3-1 cells. N, nucleus. Scale bar, 
10  m. (d) Immunoblot of LC3 in C38 and IB3-1 cells in the presence or 
absence of rapamycin. β-actin was used as loading control. (e-f) Real-time 
PCR of ULK-1, ULK-2, ARTG5, ATG6, ATG7, ATG8, ATG14L, BCL-2, Vps34, 
Vps15 and Ambra-1  mRNA in C38 and IB3-1 cells (e) or 16HBE14  and 
CFBE 41 (f).
   
   

   



© 2010 Macmillan Publishers Limited.  All rights reserved.
S U P P L E M E N TA RY  I N F O R M AT I O N
2  WWW.NATURE.COM/NATURECELLBIOLOGY
Figure S2 Beclin 1 and beclin 1 interactor proteins in CF airways. (a,b ) IB3-1 
and C38 cells were grown in nutrient-rich or starvation medium. (a, left) 
Immunoprecipitated (IP) beclin 1 species from whole cell extracts from IB3-1 
or C38 cells were subjected to immunoblotting with the antibodies against 
Ambra 1, hVps15, hVps34, Atg14L, Bcl-2, and beclin1. For full scan see 
Supplemtary Information, Fig.S10. (a, right) Densitometric analysis of the 
band intensity (mean ± s.d. of three independent experiments): fold increase 
after starvation versus cells cultured in nutrient-rich conditions. (b) FRET 
analysis of beclin 1-Alexa 546 fluorescence after Bcl-2-Cy5 photobleaching. 
F/F0 indicates post-bleaching/pre-bleaching fluorescence ratio of Al546/
Cy5. (c) Starved IB3-1 and C38 cells. FRET analysis of beclin 1-Alexa 546 
fluorescence after hVps34-Cy5, hVps15-Cy5, Ambra-1-Cy5 and ATG14L-Cy5 
photobleaching. F/F0 indicates post-bleaching/pre-bleaching fluorescence 
ratio of Al546/Cy5.  (d) Confocal microscopy micrographs of IB3-1 cells of 
ATG14L (red) and beclin 1 (green) (left panel) or ATG14L (red) and HDAC-6 
(green) (right panel) antibodies. Yellow indicates co-localization. N, nucleus. 
Scale bar, 10 μm. (e) Immunoblot of Beclin1 of soluble and insoluble detergent 
(NP-40) fractions in starved C38 and IB3-1. (f) Beclin 1 immunoblot in control 
and CF human nasal mucosa. αβ-tubulin was used as loading control. (g) GFP 
and mouse beclin 1 expression in airway tissues from CftrF508del homozygous 
mice after intranasal administration of a lentiviral vector encoding beclin 1(LV-
beclin1) or expressing the GFP (LV-GFP). L, Lumen. Scale bar, 10 μm.
 	 
 	 	 



 	 
  
 	 
 	 	 




 	 
  




 	 
   
 	 
 	 	 




 	 

 	 
 	 	 

 	 
 	 


 





 	 
 
 	 
 	 	 
 	  	

 	 
 

   
 
	



 

 	 

 	  	



	



 	 
 	  	
Fo
ld
 in
cr
ea
se
© 2010 Macmillan Publishers Limited.  All rights reserved.
S U P P L E M E N TA RY  I N F O R M AT I O N
WWW.NATURE.COM/NATURECELLBIOLOGY 3
Figure S3 Effects of TG on autophagy in airway epithelia. (a) Sites for TG2 
activity on beclin 1 sequence. (b) Immunoprecipitated (IP) beclin 1 species 
from whole cell extracts of IB3-1 is immunoreactive for the anti-isopeptide 
antibody. Immunoprecipitated (IP) without antibody from whole cell extracts of 
IB3-1 was used as control (c) Immunoblot analysis of beclin1 of soluble and 
insoluble detergent (NP-40) fractions in starved IB3-1 in presence or asbsence 
of cystamine. (d-f) IB3-1 cells were transfected with either TG2 siRNA or 
scrambled oligonucleotides upon starvation. (d) left panel, confocal microscopy 
micrographs Atg16L (red). DAPI (blue), nuclear counterstaining. Scale bar, 
10 μm. right panel, quantification of the number of Atg16L dots/cell. Mean 
± s.d. of three independent experiments (*,p<0.01 vs cells transfected with 
control siRNA; ANOVA). (e) left panel, confocal microscopy micrographs of LC3 
(green). DAPI (blue), nuclear counterstaining. Scale bar, 10 μm. right panel, 
percentage of cells containing more than five LC3 positive punctate dots. 
Mean ± s.d. of three independent experiments (*, p<0.001 vs cells transfected 
control siRNA; ANOVA). (f) left panel, electron micrographs of starved IB3-1 
cells showing areas enriched in autophagosomes (arrow) upon TG2 siRNA. 
Scale bar, 100 nm. righ panel, number of autophagosomes per cell, counted 
in 20 cells per experiment. Mean ± s.d. of three independent experiments. (*, 
p<0.001 vs siRNA control cells; ANOVA).
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Figure S4 GFP-F508del-CFTR increases ROS and Calcium levels and activates 
UPR in A549 cells. (a). Immunoblot analysis of CFTR in C38 cells transfected 
with either human CFTR siRNA or scrambled oligonucleotides. β-actin was 
used as loading control. (b-d ) A549 cells were transfected with 1 g of pGFP-
F508del-CFTR, or pGFP. (b) Increase of intracellular ROS in GFP-F508del 
CFTR transfected A549 cells (each bar represents the mean±s.d. of three 
indipendent experiments). *, p<0.001 vs empty vector. DCF, 5-(and-6)-
chloromethyl-2’7’-dichlorodihydrofluorescein diacetate acetyl ester (CM-
H2DCFDA). (c) Ca2+ imaging of GFP-F508del CFTR transfected A549 cells 
loaded with FURA-2. Pseudocolor ratiometric images. Colors correspond to the 
scale of [Ca2+]i increase. Red, high [Ca2+]i contents. Quantification of results 
from three indipendent experiments is shown in the histogram. *, p<0.001 vs 
empty vector. N, nuclei. (d) Immunoblot analysis of p-eIF-2  in GFP-F508del 
CFTR transfected A549 cells. β-actin was used as loading control.
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Figure S5 Beclin 1 overexpression and p62 knock down rescue aggresome 
formation. (a) IB3-1 cells transfected with either HA-tagged human 
beclin 1 or empty vector or with p62 siRNA or scrambled oligonucleotides 
followed by rosiglitazone. Confocal microscopy analysis of PPAR  (green). 
DAPI (blue), nuclear counterstaining. Scale bar, 10  m (b) IB3-1 
cells transfected with HA-beclin 1, or empty vector, or with cystamine 
in presence or absence of 3-MA. FRET analysis of CFTR-Alexa 546 
fluorescence after HDAC6 -Cy5 photobleaching. F/F0 indicates post-
bleaching/pre-bleaching fluorescence ratio of Al546/Cy5. (c) IB3-1 cells 
transfected with 50 nM human p62 siRNA or scrambled oligonucleotudes. 
Confocal microscopy analysis CFTR (green).  DAPI (blue), nuclear 
counterstaining. Scale bar, 10  m. (d) Starved IB3-1 cells cultured with 
MG132. top panel, immunoblot of Beclin1. bottom panel, densitometric 
analysis normalized to β-actin (mean ± s.d. of three independent 
experiments). (e ) Confocal microscopy analysis of CFTR (green) and 
HDAC-6 (red). Yellow colour indicates co-localization. N, nucleus. Scale 
bar, 10  m. (f ) IB3-1 cells transfected with plasmid expressing GFP-LC3. 
left panel, confocal laser microscopy. Scale bar, 10  m. right panel, 
percentage of cells containing more than five GFP-LC3 punctate dots per 
cell. Mean ± s.d. of five independent experiments. (g) TNF-  secretion in 
IB3-1 cells after MG132 treatment. Each bar represents the mean ± s.d. of 
three independent experiments. *, p<0.01 vs control ANOVA.
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Figure S6 Cystamine and p62 knock down restores F508del-CFTR trafficking 
and inflammatory phenotype in CF airway epithelia(a) IB3-1 cells were 
transfected with 1μg of pGFP-F508del-CFTR in presence of either  human 
p-62 siRNA or scrambled oligonucleotides. The cells were lyzed with detergent 
(NP-40) to obtain soluble and insoluble fractions. left panel, immunoblot 
analysis of GFP. B: core-glycosylated form (MW approximately 150 kDa, 
revealed as 190kDa as GFP-tagged). right panel, densitometric analysis (mean 
± s.d. of three independent experiments). (b) Immunoblot of E-cadherin as 
control of membrane fractioning. (c-d) IB3-1 cells transfected with either 
human HA-tagged-beclin 1 or empty vector. (c) TNF-α secretion. Each bar 
represents the mean ± s.d. of three independent experiments. *, p<0.01 
vs the empty vector, ANOVA. (d) Intracellular ROS content [CM-H2DCFDA 
(DCF) detection by a Wallac 1420 multilabel counter]. Each bar represents 
the mean ± s.d. of three independent experiments.*, p<0.01 compared to 
the empty vector (e) IB3-1 cells transfected with either human p62 siRNA or 
scrambled oligonucleotides. FRET analysis of TG2-Alexa 546 fluorescence 
after SUMO-1-Cy5 photobleaching. F/F0 indicates post-bleaching/pre-
bleaching fluorescence ratio of Al546/Cy5. (f) IB3-1 cells were transfected 
with either human HA-tagged-beclin 1 or empty vector. FRET analysis of TG2-
Alexa 546 fluorescence after SUMO-1 Cy5 photobleaching. (g) IB3-1 cells 
were transfected with either human Beclin 1 or scrambled oligonucleotides. 
Immunoblot analysis of beclin1. β-actin was used as loading control. (h) IB3-1 
cells transfected with 50 nM human ATG5 siRNA or scrambled oligonucleotides 
or cultured with cystamine in presence or absence of 3MA. FRET analysis of 
TG2-Alexa 546 fluorescence after SUMO-1-Cy5 photobleaching. F/F0 indicates 
post-bleaching/pre-bleaching fluorescence ratio of Al546/Cy5.
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Figure S7 Defective autophagy in human nasal mucosa and in CF mouse 
models. (a) Confocal microscopy micrographs of p62 in control and CF 
human nasal polyp mucosa. DAPI (blue), nuclear counterstaining. Scale 
bar, 10  m. Representative of five control and five CF patients (b) FRET 
analysis of TG2-Alexa 546 fluorescence after SUMO-1 Cy5 photobleaching 
in human nasal mucosae treated with cystamine or NAC in presence or 
absence of 3-MA. Representative of five cultured CF human nasal polyp 
mucosa (patients #6-10, Supplementary Table 1 online). (c) FRET analysis 
of PPAR -Alexa 546 fluorescence after N-CoR-Cy5 photobleaching in 
in human nasal mucosae treated with cystamine or NAC in presence or 
absence of 3-MA followed by rosiglitazone (d) FRET analysis of TG2-Alexa 
546 fluorescence after SUMO-1 Cy5 photobleaching in lung tissues from 
CftrF508del homozygous mice treated with cystamine or PBS in presence or 
absence of 3-MA (representative of seven CftrF508del mice). (e) Fluorescence-
microscopy quantitation of LC3 dots in lung tissues from WT and Scnn1b-Tg 
mice (10 mice per group). Mean ±s.d. *, p<0.01 compared to WT mice. (f) 
Confocal microscopy micrographs of p62 in WT and Scnn1b-Tg mice. DAPI 
(blue), nuclear counterstaining. Scale bar, 10  m. (g) Confocal microscopy 
micrographs of TG2 activity in WT and Scnn1b-Tg mice. DAPI (blue), 
nuclear counterstaining. Scale bar, 100  m.
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Figure S8 Schematic representation of the main findings of the study. a: 
Defective autophagy in CF airway epithelia. (a) Defetive CFTR and mutant 
CFTR-induced ER stress both increase ROS levels and drive TG2 SUMOylation 
and persistence of high TG2 protein levels. (b) ROS-driven TG2 SUMOylation 
induces cross-linking, ubiquitination, and aggresome sequestration of PPAR  
and IK-B . TG2 also cross-links beclin 1 and favours its sequestration 
in aggresomes. Cross-linked beclin 1 dislocates PI3K complex III away 
from the Endoplasmic Reticulum (ER) leading to sequestration of beclin 1 
interactome into aggresomes. (c) This leads to inhibition of autophagy. (d) 
Defective autophagy induces accumulation of damaged mitochondria and 
p62 accumulation that leads to proteasome overload, favours the formation 
of protein aggregates, impairs CFTR trafficking leading to sequestration 
of F508del-CFTR in HDAC6+/p62+ aggresomes. (e) Defective autophagy 
generates a vicious cycle (black arrows) with increasing ROS and TG2 levels 
and (f) inflammation. b: Effects of cystamine treatment. (a) Cystamine inhibits 
TG2 cross-linking activity and also decreases TG2 SUMOylation, by reducing 
ROS levels, favouring TG2 ubiquitination and proteasome degradation. (b) This 
avoids cross-linking of beclin 1 leading to restoration of beclin 1 interactome 
at the ER levels and allows autophagosome formation and autophagy upon 
starvation. (c)  Restoration of beclin 1 and autophagy decreases p62 and 
aggresome formation and also leads to (d) restoration of PPAR  and IK-B , 
thus dampening inflammation. The inhibition of aggresome sequestration of 
misfolded/modified proteins also allows F508delCFTR to traffic to the Golgi 
network and plasma membrane.
© 2010 Macmillan Publishers Limited.  All rights reserved.
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Figure S9 Densitometric analysis of blot experiments and quantitation of confocal microscopy micrographs.
© 2010 Macmillan Publishers Limited.  All rights reserved.
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Figure S10 Full scan of key blot experiments

 


 



 

 


	
	
 
	
 


 
 	

 	
	
 	
 	


	
	

 	

	


	

© 2010 Macmillan Publishers Limited.  All rights reserved.
S U P P L E M E N TA RY  I N F O R M AT I O N
WWW.NATURE.COM/NATURECELLBIOLOGY 11
Supplementary Tables  
Supplementary Table 1: Clinical characteristics of Cystic Fibrosis patients.
Supplementary Table 2: Sequence of primers used for Quantitative RT-PCR and sequence of siRNA oligonucleotides
Supplementary Table 3: Primary antibodies
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Supplementary Table 2:  
 
Sequence of primers used for Quantitative RT-PCR 
GENE NAME FOWARD PRIMER SEQUENCE (5'-3') REVERSE PRIMER SEQUENCE (5'-3') 
β-actin  ATTGCCGACAGGATGCAGAA ACATCTGCTGGAAGGTGGACAG 
ULK1 GTCCAGCTTTGACAGTCAGT TCCCAGGACTCAGGATTCCA 
ULK2 TGTTTCTAGGGTGTAGCTGG CACCATCTACCCCAAGACCT 
ATG5 AGTATCAGACACGATCATGG TGCAAAGGCCTGACACTGGT 
ATG6\BECLIN1 TGTCACCATCCAGGAACTCA CTGTTGGCACTTTCTGTGGA 
ATG7 CACTGTGAGTCGTCCAGGAC CGCTCATGTCCCAGATCTCA 
ATG8 CGTGGAGTCCGCGAAGATTC AGGCATGAGGACAATGCACA 
ATG14L ATGAGCGTCTGGCAAATCTT CCCATCGTCCTGAGAGGTAA 
Bcl2 GCTGCTGGAGGCTGGGGAGA CCCCCACAGGAACCCTCCTC 
hVsps34 AAGCAGTGCCTGTAGGAGGA TGTCGATGAGCTTTGGTGAG 
hVsps15 TGGGACTGGCGGTCTGCACT CGGGACGGGAAAACGCGTCA 
Ambra-1 AACCCTCCACTGCGAGTTGA TCTACCTGTTCCGTGGTTCTCC 
 
Sequence of siRNA oligonucleotides 
GENE NAME OLIGO-SENSE(5'-3') OLIGO-ANTISENSE (5'-3') 
Control UACCGUCUCCACUUGAUCGdTdT CGAUCAAGUGGAGACGGUAdTdT 
TG2 GCGUCGUGACCAACUACAAdTdT UUGUAGUUGGUCACGACGCdGdG 
PIASγ oligo#2 CAAGACAGGUGGAGUUGAUUU pAUCAACUCCACCUGUCUUGUU 
PIASγ oligo#4 AAGCUGCCGUUCUUUAAUAUU pUAUUAAAGAACGGCAGCUUUU 
BECLIN-1 AAGAUUGAAGACACAGGAGGC GCCUCCUGUGUCUUCAAUCUU 
p62 UACAAAUUUAACAGGAUGGdTdT CCAUCCUGUUAAAUUUGUAdTdT 
CFTR oligo#1  CGUGUGUCUGUAAACUGAUGGCUAA UUAGCCAUCAGUUUACAGACACAGC 
CFTR oligo#2 CCCUUCUGUUGAUUCUGCUGACAAU AUUGUCAGCAGAAUCAACAGAAGGG 
CFTR oligo#3 GGCAUAGGCUUAUGCCUUCUCUUUA UAAAGAGAAGGCAUAAGCCUAUGCC 
ATG5 oligo#1 GGUUUGGACGAAUUCCAACUUGUUU AAACAAGUUGGAAUUCGUCCAAACC 
ATG5 oligo#2 GAUCACAAGCAACUCUGGAUGGGAU AUCCCAUCCAGAGUUGCUUGUGAUC 
ATG5 oligo#3 CAAAGAAGUUUGUCCUUCUGCUAUU AAUAGCAGAAGGACAAACUUCUUUG 
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Supplementary Table 3: Primary Antibodies 
ANTIBODY COMPANY APPLICATION 
phospho-p42/p44 MAP kinases  CELL SIGNALING IB 
E-cadherin  CELL SIGNALING IB 
β-actin (13E5) CELL SIGNALING IB 
PPARγ (E8) SANTA CRUZ BIOTECNOLOGY IB 
PIASγ(H75) SANTA CRUZ BIOTECNOLOGY IB 
Ubiquitin(FL76) SANTA CRUZ BIOTECNOLOGY IB, IF 
TG2 (H237) SANTA CRUZ BIOTECNOLOGY IB 
TG2 (CUB7402) NEOMARKER IB 
GFP(FL) SANTA CRUZ BIOTECNOLOGY IB, IF 
hVps15\p150 (Nterm) SANTA CRUZ BIOTECNOLOGY IB, IF 
Bcl-2(C2) SANTA CRUZ BIOTECNOLOGY IB, IF 
HDAC-6  SANTA CRUZ BIOTECNOLOGY IF 
SUMO-1 SANTA CRUZ BIOTECNOLOGY IF 
COX-2 SANTA CRUZ BIOTECNOLOGY IF 
BECLIN-1 ABCAM IB,IF 
LC3 ABCAM IB,IF 
phospho-eIF2α ABCAM IB 
CFTR ABCAM IB,IF 
AMBRA-1 ABCAM IB 
p62 BD BIOSCIENCE IB,IF 
HA BD BIOSCIENCE IB 
αβ-TUBULIN SIGMA IB 
hVps34  SIGMA IB,IF 
Atg14L SIGMA IB,IF 
LAMP1 SIGMA IF 
Nε(γ-L-glutamyl)-L-lysine isopeptide (81DIC2) COVOLAB IB 
CD68 ACRIS IF 
Alexa 546anti-TG2  / Cy5-anti anti-SUMO-1 (Molecular Probes, INVITROGEN) FRET 
Alexa 546anti-beclin 1 / Cy5-anti anti-HDAC6  (Molecular Probes, INVITROGEN) FRET 
Alexa 546anti-PPARγ/ Cy5-anti anti-N-CoR (Molecular Probes, INVITROGEN)/SANTA CRUZ FRET 
Alexa 546anti-Bcl-2/ Cy5-anti anti-Beclin  (Molecular Probes, INVITROGEN) FRET 
Alexa 546anti-Beclin 1 / Cy5-anti Vps34  (Molecular Probes, INVITROGEN) FRET 
Alexa 546anti-Beclin 1 / Cy5-anti Vps34  (Molecular Probes, INVITROGEN) FRET 
Alexa 546anti-Beclin 1 / Cy5-anti Vps15  (Molecular Probes, INVITROGEN) FRET 
Alexa 546anti-Beclin 1 / Cy5-anti Ambra-1  (Molecular Probes, INVITROGEN) FRET 
Alexa 
546anti-Beclin 1  / Cy5-anti ATG14L  (Molecular Probes, INVITROGEN) 
FRET 
Alexa 546anti-CFTR / Cy5-anti HDAC-6 (Molecular Probes, INVITROGEN) FRET 
Alexa 546-anti GFP / Cy5-anti HDAC-6 (Molecular Probes, INVITROGEN) FRET 
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Lysosomal accumulation of gliadin p31e43 peptide
induces oxidative stress and tissue
transglutaminase-mediated PPARg downregulation
in intestinal epithelial cells and coeliac mucosa
Luigi Maiuri,1 Alessandro Luciani,1,2 Valeria Rachela Villella,3 Angela Vasaturo,3
Ida Giardino,4 Massimo Pettoello-Mantovani,1 Stefano Guido,2,3 Olivier N Cexus,5
Nick Peake,5 Marco Londei,6 Sonia Quaratino5
ABSTRACT
Background An unresolved question in coeliac disease is
to understand how some toxic gliadin peptides, in
particular p31e43, can initiate an innate response and
lead to tissue transglutaminase (TG2) upregulation in
coeliac intestine and gliadin sensitive epithelial cell lines.
Aim We addressed whether the epithelial uptake of
p31e43 induces an intracellular pro-oxidative
envoronment favouring TG2 activation and leading to the
innate immune response.
Methods The time course of intracellular delivery to
lysosomes of p31e43, pa-2 or pa-9 gliadin peptides was
analysed in T84 and Caco-2 epithelial cells. The effects of
peptide challenge on oxidative stress, TG2 and
peroxisome proliferator-activated receptor (PPAR)g
ubiquitination and p42/44emitogen activated protein
(MAP) kinase or tyrosine phosphorylation were
investigated in cell lines and cultured coeliac disease
biopsies with/without anti-oxidant treatment or TG2 gene
silencing by immunoprecipitation, western blot, confocal
microscopy and Fluorenscence Transfer Resonance
Energy (FRET) analysis.
Results After 24 h of challenge p31e43, but not pa-2 or
pa-9, is still retained within LAMP1-positive perinuclear
vesicles and leads to increased levels of reactive oxygen
species (ROS) that inhibit TG2 ubiquitination and lead to
increases of TG2 protein levels and activation. TG2
induces cross-linking, ubiquitination and proteasome
degradation of PPARg. Treatment with the antioxidant
EUK-134 as well as TG2 gene silencing restored PPARg
levels and reversed all monitored signs of innate
activation, as indicated by the dramatic reduction of
tyrosine and p42/p44 phosphorylation.
Conclusion p31e43 accumulation in lysosomes leads to
epithelial activation via the ROSeTG2 axis. TG2 works as
a rheostat of ubiquitination and proteasome degradation
and drives inﬂammation via PPARg downregulation.
INTRODUCTION
Coeliac disease is a relatively common pathology
that affects 1% of the population, and is precipi-
tated by the ingestion of gluten proteins.1e3 In
predisposed individuals, gliadin acts as a stimulator
of innate responses, in turn setting the type and
intensity of the adaptive immune response4 leading
to a powerful activation of lamina propria gliadin-
speciﬁc Tcells.5e7 Several fragments of gliadin have
been found to be ‘toxic’ for predisposed individuals
and it has also been suggested that different portion(s)
of gliadin, ostensibly not those recognised by Tcells,
modulates this innate activation of coeliac small
intestine.7 8 Among these, p31e43 induces the
expression of early markers of epithelial activation
and leads to enterocyte apoptosis4 both in coeliac
intestine and in sensitive intestinal epithelial cell
lines.4
The mechanisms by which p31e43 initiates an
innate immune response in coeliac duodenum are,
however, still elusive. It has been reported that
p31e43 can delay epidermal growth factor receptor
(EGFR) inactivation through interference with the
endocytic pathway,9 this suggesting that gliadin
fragments could amplify the effects of trace
amounts of EGF. Moreover, p31e43 induces early
tissue transglutaminase (TG2) upregulation
compared to immunodominant gliadin peptides.10
This indicates that TG2 is not only central to the
adaptive response to gliadin as the main deami-
dating enzyme of the immunodominant epitopes,
but is also a key player in the initiation of inﬂam-
mation in coeliac disease.10 However, it is still
unknown how p31e43 induces early TG2 activa-
tion in both coeliac intestine and ‘gliadin-sensitive’
intestinal epithelial cells.9 10
TG2 expression is regulated by retinoids, steroid
hormones, peptide growth factors and cytokines,
which also lead to a time-dependent decrease in
TG2 ubiquitination,11 indicating that post-trans-
lational control mechanisms also play a role in TG2
regulation. We have demonstrated that in cystic
ﬁbrosis (CF) airway epithelia,12 sustained TG2
activation is driven by the increased levels of reac-
tive oxygen species (ROS) caused by the CFTR
genetic defect.12 We therefore investigated whether
p31e43 was able to drive an intracellular pro-
oxidative environment and demonstrate that
p31e43 leads to an increase of ROS levels in coeliac
duodenum as well as T84 and Caco-2 intestinal
epithelial cells.
To understand how p31e43 challenge induces
oxidative stress, we analysed the delivery of this
peptide to the intracellular degradation systems. It has
been reported that the epithelial translocation of the
gliadin immunostimulatory peptide 33-mer occurs by
transcytosis after partial degradation through a rab5
endocytic compartment.13 Increased transepithelial
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translocation of the 33-mer was demonstrated in active coeliac
disease compared to healthy controls. Moreover, incomplete degra-
dation of the 33-mer and protected transport of the peptide 31e49
occurs in patients with untreated coeliac disease, thus favouring
their respective immunostimulatory and toxic effects.14 Here we
show that p31e43 is retained within the lysosomes as compared to
the more rapid disappearance of the immunodominant peptides
pa-2 or pa-9 from the intracellular compartments. Blocking p31e43
endocytosis prevents the increase of ROS.
We have previously reported that in CF airways sustained
TG2 activation drives inﬂammation by inducing cross-linking,
ubiquitination and proteasome degradation, of the anti-inﬂam-
matory peroxisome proliferator-activated receptor (PPAR)g,12
a negative regulator of inﬂammatory gene expression.15 16
Blocking TG2 through speciﬁc gene silencing12 or the speciﬁc
TG2 inhibitors restores a physiological control of inﬂammation
in CF airways.12
We therefore addressed whether the p31e43-induced innate
response was mediated by the ROSeTG2 axis via PPARg
downregulation.
METHODS
Peptide preparation
Biotinylated gliadin peptides p31e43, pa-9 (57e68) or pa-2
(62e75), control human thyroid peroxidase pTPO (535e551)
and pTPO (536e547), peptide LGQQQPFAAVQPY (referred to
below as pZ), and scrambled peptides with amino acid compo-
sition similar to p31e43 (QQGQPFPQPQLQY (referred to below
as pX), GLQQFQPPPPQQY (referred to below as pY)) were
synthesised by Primm (Milan, Italy) and the purity was deter-
mined by reverse-phase HPLC.
Cell lines
Human colon adenocarcinoma T84 or human colorectal carci-
noma Caco-2 cell lines were cultured as recommended by
American Type Culture Collection (ATCC).
Cell cultures
The cells were challenged with p31e43 for 24 h in the presence
or absence of the ROS scavenger EUK-134 (50 mg/ml; Alexis
Biochemicals, Florence, Italy), glutathione (GSH) (10 mmol/l;
Sigma, Milan, Italy)17 or the TG inhibitor cystamine (400 mmol/l;
Sigma). To study internalisation of peptides, cells were chal-
lenged for 15, 30, 60 or 90 min, 3 or 24 h at 378C with the
biotinylated peptides (20 mg/ml). To inhibit endocytosis, the cells
were pre-treated with the cholesterol-binding agent methyl-b-
cyclo-dextrin (M-b-CD, 10 mmol/l; Sigma) or ﬁlipin (5 mg/ml;
Sigma) and then challenged with biotinylated peptides. Cell lines
were also incubated for 6 h with the PPARg agonist rosiglitazone
(10 mmol/l; Alexis Biochemicals) and then challenged with
p31e43. The PPARg antagonist GW9662 (1 mmol/l; Alexis
Biochemicals) was added for 24 h to p31e43 in the presence or
absence of TG2 siRNA oligos. The proteosome inhibitor MG132
(50 mmol/l; Calbiochem, Milan, Italy) was added 6 h before
p31e43 in the presence or absence of TG2 siRNA oligos or
EUK134.
Patients
Duodenal multiple endoscopic biopsies were performed for
diagnostic purposes in seven treated patients with coeliac disease
(mean age, 25 years; range, 16e41 years), and ﬁve non-coeliac
controls affected by oesophagitis (22.4 years; range,
18e29 years). Informed consent was obtained from all individ-
uals, and the study was performed according to the Ethics
Committee of Regione Campania Health Authority. One spec-
imen from each patient was used for diagnosis; the other samples
were cultured in vitro as described.4
In vitro organ culture of biopsy specimens from patients with
coeliac disease and from controls
Duodenal biopsy specimens were cultured as previously
reported4 for 3 or 24 h with medium alone, p31e43, pa-9, pa-2,
pTPO (20 mg/ml) in the presence or absence of cystamine
(400 mmol/l). Duodenal biopsy specimens were also incubated for
6 h with the PPARg agonist rosiglitazone (10 mmol/l; Alexis
Biochemicals) and then re-challenged for 3 h with p31e43.
RNA interference
The cells were transfected with 50 nmol/l human TG2 and
scrambled small interfering RNAs (siRNAs) duplex using
Hiperfect Transfection Reagent (Qiagen, Milan, Italy) at 378C for
72 h as previously described.12
Adenoviral vector
Human manganese superoxide dismutase (MnSOD) cDNA was
cloned into the shuttle vector pAd5CMVK-NpA.18 MnSOD
adenovirus was a gift from Michael Brownlee (Albert Einstein
College ofMedicine, New York). T84 cell lines were infected with
MnSOD or the control adenovirus for 2 h, as previously
described.18
Immunolocalisations
Tissue sections were individually incubated with the antibodies
anti-phospho-tyrosine (PY99 mAb, 1:80, mouse IgG2b; Santa
Cruz Biotechnology, Santa Cruz, California, USA), anti-PPARg
(clone E8, sc-7273, 1:100, mouse IgG1; clone H100, sc-7196,
1:100, rabbit polyclonal IgG; Santa Cruz Biotechnology) and
control antibodies.4 12 Cell lines were incubated with the anti-
bodies against phospho-tyrosine, Early Endosome Antigen-1
(EEA-1; 1:100, rabbit polyclonal IgG; Abcam, Cambridge, UK),
Rab7 (1:200, rabbit polyclonal IgG; Abcam), ARF-1 (1:100, rabbit
polyclonal IgG; Abcam), LAMP-1 (1:100, rabbit polyclonal IgG;
Abcam). Two-colour and indirect immunoﬂuorescence were used
for the detection of the tested markers by using an LSM510 Zeiss
confocal laser scanning unit (Zeiss, Jena, Germany).12 The
correlation coefﬁcient analysis was used as value of co-local-
isation between peptides and EEA-1 or LAMP-1 as described.19
In situ detection of TG2 enzymatic activity
The detection of in situ TG2 activity was performed by detec-
tion of biotinylated mono-dansyl-cadaverine (MDC) incorpora-
tion by Alexa-546 streptavidin as previously described.4 12
FRET microscopy
For acceptor photobleaching 4-mm frozen tissue sections of biopsy
samples were ﬁxed with buffered 2% paraformaldehyde and
permeabilised with 0.5% Triton X-100. Upon ﬁxation, tissues were
immunostained with Alexa 546/anti-PPARg (Santa Cruz
Biotechnology, Santa Cruz, California, USA) and Cy5/anti-Ne(g-L-
glutamyl)-L-lysine isopeptide (Covolab, Cambridge, UK). Alexa 546
ﬂuorescence was detected before and after Cy5 photobleaching.
Immunoblot and immunoprecipitation
Blots were incubated with anti-phospho-tyrosine (PY99 mAb,
1:500), anti-phospho-p42/p44 MAP kinases (Cell Signaling
Technology, Danvers, Massachusetts, USA), PPARg (clone E8 sc-
7273; Santa Cruz Biotechnology, Santa Cruz, California, USA),
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TG2 (clone CUB7402, 1:100; NeoMarkers, Fremont, California,
USA), Ne(g-L-glutamyl)-L-lysine isopeptide (clone 81DIC2;
Covalab), ubiquitin (1:100 clone FL-76, rabbit polyclonal IgG;
Santa Cruz Biotechnology), as previously described.12
Immunoprecipitations with anti-TG2 CUB 7402 mAb, anti-
phospho-tyrosine and anti-PPARgwere carried out as previously
described.12
ROS detection
Cell lines were pulsed with 10 mmol/l 5-(and-6)-chloromethyl-
29,79-dichlorodihydroﬂuorescein diacetate acetyl ester (CM-
H2DCFDA) (Molecular Probes, Invitrogen, Milan, Italy) and
analysed as previously described.12
Statistical analysis
Cells challenged with peptides were compared with those
cultured in medium alone, and with those cultured in the
presence of the tested inhibitors. All experiments were
performed at least in triplicate. Data distribution was analysed,
and statistical differences were evaluated using ANOVA
TukeyeKramer test and SPSS 12 software. A p value of <0.05
was considered signiﬁcant.
Detailed methods are described in the online supplementary
information section.
RESULTS
p31e43 is retained within the lysosomes in T84 epithelial cells
T84 cells were incubated with biotinylated p31e43, p-a2, p-a9
(20 mg/ml) for 15, 30, 60, 90 min, 3 h and 24 h at 378C. The
peptides were rapidly detected (upon 15 min) in intracellular
vesicles (ﬁgure 1A). Prolonged incubation (after 90 min to 24 h)
increased the amount of p31e43 (ﬁgure 1A), but not of p-a9
(ﬁgure 1A) or p-a2 (data not shown), which resided in perinuclear
vesicles. Soon after 15 min of challenge, peptides co-localised
with EEA-1 (ﬁgure 1B), a marker of early endosomes,13 whereas
after 60 min they co-localised with Rab7-positive late endosomes
(data not shown).20 These data are in agreement with those
described for the gliadin peptide 33-mer.13 Co-staining with anti-
body against Arf1 (data not shown) did not reveal translocation
of the peptides to the Golgi complex. After 90 min the internalised
peptides co-localised with Lysosomal Associated Membrane
Protein-1 (LAMP-1) (ﬁgure 1C), a marker of lysosomes.20 The
peptide/EEA-1 or peptide/LAMP-1 correlation coefﬁcients of the
spatial intensity distributions yielded a fairly high correlation
coefﬁcient (ﬁgure 1D), indicating that gliadin peptides are
internalised and transported through early and late endocytic
endosomes to lysosomes. No internalisation of peptides or co-
localisation with LAMP-1 were observed when T84 cells were
pre-incubated with M-b-CD, which inhibits clathrin-mediated
endocytosis,20 or ﬁlipin, a speciﬁc inhibitor of lipid raft- or
caveolae-dependent endocytosis20 (data not shown). This
suggests that endocytosis is essential for the delivery of gliadin
peptides to the lysosomes for degradation.
Increasing appearance of the internalised p31e43 in LAMP-1-
positive vesicles, mainly limited to perinucelar localisation, was
observed after 3e24 h of challenge (ﬁgure 1E,F). At these late
time points p-a9 (ﬁgure 1E,F) or pa-2 (data not shown) were only
faintly detected in LAMP-1-positive structures. The coefﬁcients
of p-a2 or p-a9 co-localisation with LAMP-1 were signiﬁcantly
lower compared to p31e43 (ﬁgure 1G), thus indicating that
p31e43, but not p-a9 or p-a2 is retained within the lysosomes.
Caco-2 cells showed the same behaviour as T84 after peptide
challenge (data not shown). The control pTPO (535e551) (data
not shown), pTPO (536e547) and pZ, as well as scrambled pX
and pY peptides, behaved like pa-9 and pa-2 in both T84
(supplementary ﬁgure 1) and Caco-2 cell lines (data not shown).
p31e43 induces increase of ROS in T84 epithelial cells
T84 cells were pulsed with 10 mmol/l CM-H2DCFDA in the
presence of the tested peptides and the levels of ROS were
monitored after 90 min, 3 h and 24 h of challenge. The intracel-
lular transport of gliadin peptides through early and late endo-
cytic endosomes did not induce ROS generation (data not
shown). Moreover, after 90 min of challenge neither p31e43 nor
pa-9, both detected in LAMP-1 positive vesicles (ﬁgure 1C),
induced signiﬁcant increase of ROS (ﬁgure 2A). At the later time
points (3e24 h of challenge), p31e43, but not pa-9 (ﬁgure 2A),
pa-2, pTPO (535e551) (data not shown) or peptides pTPO
(536e547), pX, pY and pZ (supplementary ﬁgure 1) induced
a time-dependent signiﬁcant increase of ROS levels, suggesting
that the prolonged persistence of p31e43 in LAMP-1 positive
vesicles (ﬁgure 1E,F) generates a pro-oxidative environment. No
increase of ROS was observed after challenge with p31e43 upon
M-b-CD or ﬁlipin treatment (ﬁgure 2B).
The generation of a pro-oxidative environment induces acti-
vation of different stress sensitive signalling pathways.9 12 21
Since the challenge with p31e43 induces phosphorylation of the
extracellular signal-regulated kinases 1/2 (Erk1/2, p42/44
mitogen-activated protein kinases, MAPK),9 we investigated
whether p31e43-induced ROS-mediated p42/44 MAPK phos-
phorylation in T84 cells. We demonstrated that p42e44 MAPK
phosphorylation induced by the challenge with p31e43 was
prevented by the incubation with the catalaseesuperoxide
dismutase (SOD) mimetic EUK-13412 (ﬁgure 2C), as well as by
GSH17 or byMnSOD over-expression18 (supplementary ﬁgure 2).
This further indicates that the generation of a pro-oxidative
environment is critical to p31e43 biological activity in T84 cells.
p31e43 induces ROS-dependent inhibition of TG2 ubiquitination
To investigate whether the increased levels of ROS may account
for the p31e43-induced increase of TG2 levels,12 we incubated
p31e43-challenged T84 cells with EUK-134. We demonstrated
that EUK-134 was effective in controlling the increase of TG2
protein levels (ﬁgure 3A) and TG2 activity (data not shown)
induced by p31e43. The same effects as EUK-134 were observed
after incubation with GSH or upon MnSOD over-expression
(supplementary ﬁgure 2). No increase of TG2 was observed after
challenge with p31e43 upon M-b-CD or ﬁlipin treatment (data
not shown). This indicates that p31e43 internalisation is critical
for the induction of ROS-mediated TG2 activation.
Since post-translational modiﬁcations of TG2, such as ubiq-
uitination, play a role in regulating the levels of TG2 protein11
we investigated whether TG2 ubiquitination was inﬂuenced by
ROS generation induced by p31e43. We incubated T84 cells with
p31e43 in the presence or absence of EUK-134 upon inhibition of
proteasome function by MG132,12 then immunoprecipitated
TG2 protein and detected ubiquitin co-reactivity. The ubiquitin
immunoreactivity on TG2 immunoprecipitates was enhanced
upon treatment with EUK-134 (ﬁgure 3B). No effects of p31e43
on TG2 ubiquitination were observed when T84 cells were
pre-treated with M-b-CD or ﬁlipin (data not shown).
p31e43-induced TG2 drives PPARg cross-linking and
proteasome degradation in T84 cells
We investigated whether the p31e43-induced TG2 activation
was effective in inducing PPARg cross-linking and proteasome
degradation as we have reported in CF airways.12
We immunoprecipitated PPARg species from T84 cell lysates
after challenge with p31e43 and detected the immunoreactivity
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Figure 1 p31e43, but not pa-9, accumulates within the lysosomes in T84 cells. (A) Incubation of T84 cells with biotinylated p31e43 and pa-9 from
15 min to 24 h at 378C and detection by confocal microscopy upon incubation with Alexa 488-conjugated streptavidin. After 15 min both p31e43 and
p-a9 were detected in intracellular peripheral vesicles. Prolonged incubation (90 min to 24 h) increased the amount of p31e43, but not of p-a9, in
perinuclear vesicles. (B) Co-localisation of p31e43 and p-a9 (green) with EEA-1 (red) in T84 cells upon 15 min of challenge. Both peptides were detected
in EEA1-positive vesicles (yellow). (C) Co-localisation of p31e43 and p-a9 (green) with LAMP-1 (red) in T84 cells after 90 min of challenge. Both
peptides were detected in LAMP1-positive vesicles (yellow). (D) Quantitative measurement of peptides/EEA-1 or peptides/LAMP-1 co-localisations
shown in B and C, respectively. Each bar represents the mean plus SEM of three independent experiments. (EeF) Co-localisation of p31e43 and p-a9
(green) with LAMP-1 (red) in T84 cells after 3 h and 24 of challenge. p31e43, but not pa-9, was detected in LAMP-1 positive vesicles (yellow).
(G) Quantitative measurement of peptides/LAMP-1 co-localisations shown in E and F, respectively. Each bar represents the mean plus SEM of three
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with an isopeptide cross-link speciﬁcally catalysed by TG2.22
We observed isopeptide immunoreactivity in PPARg immuno-
precipitates (ﬁgure 4A). No PPARg cross-linking was observed in
T84 cells challenged with pa-9 or pa-2 (data not shown). TG2
siRNA12 was highly effective in preventing PPARg cross-linking
upon p31e43 exposure (ﬁgure 4A). Moreover, pre-treatment
with the TG2 inhibitor cystamine,23 as well as with the EUK-
134, also prevented TG2-mediated cross-linking of PPARg (data
not shown). These results indicate that p31e43 induces post-
translational modiﬁcations of PPARg via the ROSeTG2 axis.
We also investigated whether the cross-linking of PPARg
might favour ubiquitination and PPARg proteasome degradation
with reduction of the 55 kDa PPARg form. Indeed, a striking
increase of ubiquinated PPARg was observed in p31e43-stimu-
lated T84 cells treated with the proteasome inhibitor MG132
(ﬁgure 4B). Negligible amounts of ubiquitinated PPARg were
observed in p31e43-stimulated T84 cells upon TG2 gene
silencing (ﬁgure 4B) as well as after TG2 inhibition by cystamine
or after treatment with EUK-134 (data not shown). Moreover,
a reduction of the 55-kDa PPARg form was observed in T84 cells
upon p31e43 challenge (ﬁgure 4C) and TG2 siRNA was highly
effective in preventing p31e43-induced PPARg downregulation
(ﬁgure 4C and supplementary ﬁgure 3). The incubation with the
TG2 inhibitor cystamine (400 mmol/l), showed the same effects
as TG2 knock-down (ﬁgure 4C). No PPARg cross-linking or
proteasome degradation was observed in T84 cells upon inhibi-
tion of p31e43 endocytosis by M-b-CD or ﬁlipin (data not
shown). These results indicate that the internalisation and
lysosomal delivery of p31e43 induces PPARg downregulation via
the ROSeTG2 axis.
independent experiments. (AeC,E,F), representative results of three independent experiments. Confocal microscopy, DAPI (blue) nuclear
counterstaining. Scale bar, 10 mm. DAPI, 49-diamidine-29-phenylindol dihydrochloride; EEA-1, Early Endosome Antigen 1; LAMP-1, Lysosomial
Associated Membrane Protein 1.
Figure 2 p31e43 induces increase of
ROS levels in T84 cells. (A) Increase of
intracellular ROS in p31e43 stimulated
T84 cells. Each bar represents the mean
plus SEM of three independent
experiments. *p<0.01 versus samples
cultured with medium or with p-a9. (B)
Inhibition of p31e43 endocytosis by
methyl-b-cyclo-dextrin or ﬁlipin inhibited
p31e43-induced increase of ROS. Each
bar represents the mean plus SEM of
three independent experiments.
*p<0.017 versus samples cultured with
p31e43. (C) Immunoblot analysis
showed a decrease of p31e43-induced
p42/p44 phosphorylation upon treatment
with the ROS scavenger EUK-134.
Representative result of three different
experiments. DCF, 5-(and-6)-
chloromethyl-2‘,7’
-dichlorodihydroﬂuorescein diacetate
acetyl ester; ROS, reactive oxygen
species.
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The ROSeTG2ePPARg axis is a master regulator of the
epithelial activation to gliadin peptides
To demonstrate that the biological activity of p31e43 was
mediated by the downregulation of PPARg, we pre-incubated
T84 cells with the PPARg agonist rosiglitazone12 for 6 h and then
challenged with p31e43. As a matter of fact, PPARg ligation by
agonists favours PPARg interaction with the nuclear receptor co-
repressor (N-CoR) histone deacetylase 3 (HDAC3) complex and
thereby blocks its ubiquitination, thus maintaining a repressor
condition.23 We monitored the effects of p31e43 on epithelial
tyrosine phosphorylation, as revealed by PY-99 antibody, a well-
established marker of epithelial activation in T84 cells and in
human coeliac disease intestinal mucosa.4 We found that the pre-
incubation with rosiglitazone antagonised p31e43-induced
tyrosine phosphorylation in T84 cells (ﬁgure 4D).
Moreover we incubated p31e43-challenged T84 cells with the
PPARg antagonist GW966212 upon TG2 siRNA. The incubation
with GW9662 antagonised the downregulatory effect of the TG2
siRNA on tyrosine phosphorylation induced by p31e43, as
detected by immunoprecipitation studies (ﬁgure 4E) and confocal
microscopy (ﬁgure 4F). These data indicate that p31e43 may
induce epithelial activation via the ROSeTG2ePPARg axis.
p31e43 induces TG2-mediated PPARg cross-linking and reduced
protein expression in coeliac duodenum
To investigate whether TG2-mediated PPARg cross-linking and
downregulation occurs in human coeliac intestine, we chal-
lenged coeliac biopsies with p31e43, pa-2 or pa-9 in presence or
absence of cystamine, a well known TG2 inhibitor already used
in vivo in a mouse model of Huntington’s disease to control
TG2-related manifestations.23 FRET analysis showed that
PPARg interacted with the isopeptide cross-link also in human
coeliac disease biopsies (ﬁgure 5A). Confocal microscopy showed
that PPARg protein was reduced in coeliac biopsies after chal-
lenge with p31e43 (ﬁgure 5B) but not with pa-2 or pa-9 (data
not shown). Moreover treatment of cultured biopsies with
cystamine was highly effective in preventing p31e43-induced
PPARg downregulation (ﬁgure 5B). No PPARgeisopeptide
interaction (data not shown) or p31e43 induced PPARg down-
regulation was observed in non-coeliac control biopsies (ﬁgure
5C), in agreement with our previous data showing that p31e43
fails to induce TG2 upregulation in non-coeliac duodenum.10
Moreover, upon challenge with p31e43 coeliac biopsies showed
intense immunoreactivity to the anti-phospho-tyrosine anti-
body PY99 (ﬁgure 5D). Pretreatment with rosiglitazone
completely reversed the p31e43-induced phospho-tyrosine
immunoreactivity (ﬁgure 5D).
DISCUSSION
An innate response triggered by several ‘toxic’ gliadin
fragments4 7 8 is involved in both modulating mucosal
damage24e26 as well as in setting the type and intensity of the
adaptive immune response in coeliac disease.4 Furthermore, a series
of studies has indicated that several gliadin fragments activate, in a
non-disease-speciﬁc manner, bothmouse and human DC cells,27 28
a speciﬁc type of DC detected in the intestines of patients with
coeliac disease29 and some epithelial cells lines derived from
different species.30 31 10 These results have raised a series of
questions and the most pressing is to understand why only CD
tissues react to this non-T-cell antigenic portion of gliadin.4
Here we demonstrate that ‘gliadin sensitive’ epithelial cells
upregulate intracellular ROS upon challenge with p31e43 but
not with immunodominant gliadin peptides. These results indi-
cate that p31e43 induces cellular stress. Among the factors able
to trigger cellular stress is the accumulation of improperly
handled substances within the intracellular compartments.32e35
A string of studies has suggested that some a-gliadin peptides, in
particular p31e43(9)13 as well as 33-mer,14 possess the ability to
penetrate cells.13 It has been demonstrated that gliadin peptides
may be internalised by endocytic uptake and activate some signal
transduction pathways.9 Here we demonstrate that p31e43 is
delivered to the lysosomes but is retained as late as 24 h after
challenge in LAMP1-positive vesicles mainly located in the peri-
nuclear region. The engulfment of lysosomes with p31e43 may
induce cellular stress with the generation of a pro-oxidative
environment. The relationship between lysosomal garbage and
the perturbation of cellular homeostasis has been described in
a number of human pathologies such as lysosomal storage
diseases,33 36 37 neurodegenerative diseases32 34 and even in
ageing.35 However, in T84 or Caco-2 cells as well as in coeliac
intestine, the lysosomal machinery of peptide degradation is not
generally perturbed since other peptides, such as pTPO and even
the gliadin immunodominant pa-2 or pa-9 peptides, are no
longer detectable within intracellular organelles after 90 min of
challenge. Whatever the mechanism involved in such a puzzling
interaction between some gliadin peptides and ‘sensitive’
epithelia, these results further indicate that a complex alteration
of the cross-talk between the intestine and its local environment
is crucial for the development of coeliac disease.
Our results demonstrate that p31e43 induces TG2 activation
via ROS generation. The increased levels of ROS reduce TG2
degradation by the ubiquitineproteasome system, thus leading
to increased TG2 protein levels. TG2 is a multifunctional enzyme
with a vast array of biological functions.38 Increased tissue levels
of TG2 have been described in a number of human diseases, such
as neurodegenerative diseases,39 40 CF12 and even in cancers.41
The upregulation of TG2 has recently been associated with an
increased metastatic activity41 or drug resistence.41 One of the
TG2 effects is the cross-linking, with consequent functional
sequestration and proteasome degradation of several intracellular
proteins such as a-synuclein in Parkinson’s disease,39 huntingtin
in Huntington’s disease.42 We have previously reported that in
Figure 3 ROS-mediated inhibition of TG2 ubiquitination in T84 cells
upon p31e43 challenge. (A) Immunoblot analysis of TG2 protein. ROS
scavenger EUK-134 inhibited p31e43-induced increase of TG2 protein in
T84 cells. (B) Ubiquitin immunoreactivity in TG2 immunoprecipitates.
Incubation with EUK-134 increased TG2 ubiquitination upon MG132
treatment in T84 cells. Immunoprecipitation (IP): anti-TG2 antibody;
immunoblot (IB): anti-ubiquitin antibody Representative results of three
independent experiments. ROS, reactive oxygen species; TG2, tissue
transglutaminase.
316 Gut 2010;59:311e319. doi:10.1136/gut.2009.183608
Coeliac disease
 group.bmj.com on June 25, 2010 - Published by gut.bmj.comDownloaded from 
CF TG2 drives the characteristic chronic inﬂammation via
PPARg downregulation.12
Here we demonstrate that in T84 cells, as well as in coeliac
duodenum, p31e43 induces PPARg downregulation via ROS-
mediated TG2. Therefore, an uncontrolled activation of the
ROSeTG2 axis, either constitutive, as a consequence of genetic
alterations as in CF,12 or induced by triggering factors such as
p31e43 in a susceptible target (coeliac mucosa and T84 epithelial
cells), leads to PPARg downregulation with a derangement of the
appropriate control of inﬂammation. PPARg is a hormone
receptor produced by several cell types, including epithelial cells,
which negatively regulates inﬂammatory gene expression by
‘transrepressing’ inﬂammatory responses15 and even by modu-
lating oxidative stress.43 44 PPARg has been identiﬁed as a major
functional receptor mediating the aminosalicylate activity45 46
and PPARg agonists have been exploited in therapeutic
approaches to control inﬂammation in chronic intestinal
inﬂammatory diseases such as ulcerative colitis47 48 and in
experimental models of colitis.49 PPARg plays a key role in the
regulation of the intestinal ‘inﬂammatory’ homeostasis since is
activated by dietary ligands,50 as well as commensal bacteria.51 In
this paper we provide the ﬁrst evidence that TG2-mediated
PPARg downregulation plays a key role in the pathogenesis of
coeliac disease. The effects of p31e43 are speciﬁc for coeliac
intestine and ‘gliadin-sensitive’ cell lines.30 31 10 This might be
related to a coeliac disease-speciﬁc peptide internalisation or
reﬂect a still unknown coeliac disease-speciﬁc perturbation of the
machinery of peptide degradation.
The activation of the ROSeTG2 axis is therefore a key
pathway of inﬂammation. TG2 works as a rheostat of ubiquiti-
nation and proteasome degradation in inﬂammation, particularly
in the context of coeliac disease. Indeed, in one case, increased
PPARg ubiquitination and degradation leads to increased
inﬂammation, whilst increased TG2 ubiquitination and degra-
dation leads to a reduced inﬂammatory response. A derangement
of TG2 regulation may lead to the ampliﬁcation of the effects of
the stress. The induction of an epithelial pro-inﬂammatory
phenotype may alter the ﬁrst mucosal defence against ‘toxic’
agents and lead to a wide perturbation of the regulatory mech-
anisms at the mucosal surface. The increased secretion of
Figure 4 p31e43 challenge induces TG2-mediated PPARg cross-linking and proteasome degradation in T84 cells. (A) Immunoprecipitates of PPARg
species from whole-cell extracts of T84 cells after challenge with p31e43 were immunoreactive for the anti-isopeptide cross-link antibody. High MW
bands ranging from 72 to 130 kDa are evident after p31e43 challenge and signiﬁcantly reduced upon TG2 siRNA treatment. Immunoprecipitation (IP):
anti-PPARg antibody; immunoblot (IB): anti-isopeptide antibody. (B) Effect of the MG132 treatment on PPARg ubiquitination upon TG2 siRNA in
p31e43-challenged T84cells. Immunoprecipitated PPARg species from whole-cell extracts of T84 cells immunoreactive for the anti-ubiquitin antibody
were evident after challenge with p31e43 upon MG132 treatment. The simultaneous incubation with TG2 siRNA oligos induced a pronounced decrease
of ubiquitinated PPARg protein. Immunoprecipitation (IP): anti-PPARg antibody; immunoblot (IB): anti-ubiquitin antibody. (C) Immunoblot analysis of
PPARg protein in p31e43-challenged T84 cells. TG2 siRNA as well as cystamine inhibited p31e43-induced PPARg downregulation. Quantitative
analysis (mean, SD) of three different experiments is reported in supplementary ﬁgure 3. (D) Confocal microscopy showed a decrease of p31e43-
induced tyrosine phosphorylation in T84 cells upon rosiglitazone pre-treatment. (E) Phospho-tyrosine immunoreactivity of PY-99 immunoprecipitates of
T84 cells after incubation with p31e43 upon TG2 siRNA in the presence or absence of GW9662. Decrease of PY99 immunoreactivity upon TG2 gene
silencing. GW9662 inhibits TG2 siRNA-induced decrease of tyrosine phosphorylation. (F) Confocal microscopy shows an increase of p31e43-induced
tyrosine phosphorylation in T84 cells upon TG2 gene silencing followed by GW9662. (D,E) Confocal microscopy, phospho-tyrosine (PY-99 antibody,
green), DAPI (blue) nuclear counterstaining. Scale bar, 10 mm (AeF), are the results of three reproducible experiments. DAPI, 49-diamidine-29-
phenylindol dihydrochloride; PPARg, peroxisome proliferator-activated receptor g; TG2, tissue transglutaminase.
Gut 2010;59:311e319. doi:10.1136/gut.2009.183608 317
Coeliac disease
 group.bmj.com on June 25, 2010 - Published by gut.bmj.comDownloaded from 
inﬂammatory cytokines may, in turn, derange intestinal perme-
ability52 and enhance the toxic effects of environmental triggers.
TG2 may be considered as a main player of the innate response to
stress inducers, thus setting the tone of whole mucosal response.
Targeting the ROSeTG2 axis might represent a new pathogenic-
based approach to antagonise the unwanted effects of gluten in
coeliac disease.
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approved clinical trial and registry. However,
it is a fact and needs to be pointed out, that
only one third of our identiﬁed IAR (80 of
205) participated in the recommended
screening programme. A pilot study on 32 of
these IAR using standard questionnaires and
interviews (Beck Depression Inventory (BDI)
and Brief Symptom Inventory (BSI)) around
counselling (days 7, 0, +30) conducted by
a psychiatrist revealed, that these IAR were
critically biased by cognitive coping strategies
(unpublished data). Pancreatic cancer (PC)
screening is clearly different from other cancer
screening programmes, given the disastrous
prognosis of PC, the unknown true pene-
trance in the different settings of hereditary
PC, the lack of a major gene defect, the lack of
reliable imaging or biomarkers, the lack of
evidence to improve prognosis or to save lives
by any screening, and the high risk of
morbidity and mortality of potential preven-
tive surgery. Some authors even advocate that
at present ‘doing nothing’ provides the
greatest remaining quality of life-adjusted
years and the lowest costs.6
We fully agree that we need to gain much
more knowledge about hereditary PC to
draw a deﬁnite conclusion about the true
value of PC screening in IAR. However,
based on our data, we strongly believe, in
accordance with the recommendations of
the Fourth International Symposium of
Inherited Diseases of the Pancreas,5 that all
screening procedures should be performed as
part of peer-reviewed protocols combined
with a scientiﬁc appraisal of the screening
methods and human subject protection. At
present there is no data, that would justify
a general PC screening even of high risk
individuals outside of such protocols as
suggested by Harinck et al. In contrast, it
has to be feared that uncritical use and
interpretation of screening results obtained
with the presently available tools on
a healthcare basis may cause unnecessary
physical harm and psychological distress.
On the other hand over-estimation of the
power of our present screening tools may
lead to a deceptive, unjustiﬁed and poten-
tially dangerous level of safety, if done
uncritically and uncontrolled. The message
of our paper thus is not ‘to do nothing’, but
to carefully evaluate screening methods for
IAR from familial pancreatic cancer (FPC)
families in the setting of board approved
clinical trials, to continuously improve our
knowledge and strategies.
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SUMOylation of Tissue Transglutaminase as Link between
Oxidative Stress and Inﬂammation1
Alessandro Luciani,*† Valeria Rachela Villella,‡ Angela Vasaturo,‡ Ida Giardino,§
Valeria Raia,¶ Massimo Pettoello-Mantovani,* Maria D’Apolito,* Stefano Guido,†‡
Teresinha Leal, Sonia Quaratino,# and Luigi Maiuri2*,**
Cystic ﬁbrosis (CF) is a monogenic disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene.
CF is characterized by chronic bacterial lung infections and inﬂammation, and we have previously reported that tissue trans-
glutaminase (TG2), a multifunctional enzyme critical to several diseases, is constitutively up-regulated in CF airways and drives
chronic inﬂammation. Here, we demonstrate that the generation of an oxidative stress induced by CFTR-defective function leads
to protein inhibitor of activated STAT (PIAS)y-mediated TG2 SUMOylation and inhibits TG2 ubiquitination and proteasome
degradation, leading to sustained TG2 activation. This prevents peroxisome proliferator-activated receptor (PPAR) and IkB
SUMOylation, leading to NF-B activation and to an uncontrolled inﬂammatory response. Cellular homeostasis can be restored
by small ubiquitin-like modiﬁer (SUMO)-1 or PIASy gene silencing, which induce TG2 ubiquitination and proteasome degrada-
tion, restore PPAR SUMOylation, and prevent IkB cross-linking and degradation, thus switching off inﬂammation. Manganese
superoxide dismutase overexpression as well as the treatment with the synthetic superoxide dismutase mimetic EUK-134 control
PIASy-TG2 interaction and TG2 SUMOylation. TG2 inhibition switches off inﬂammation in vitro as well as in vivo in a homozy-
gous F508del-CFTR mouse model. Thus, TG2 may function as a link between oxidative stress and inﬂammation by driving the
decision as to whether a protein should undergo SUMO-mediated regulation or degradation. Targeting TG2-SUMO interactions
might represent a new option to control disease evolution in CF patients as well as in other chronic inﬂammatory diseases,
neurodegenerative pathologies, and cancer. The Journal of Immunology, 2009, 183: 0000–0000.
C ystic ﬁbrosis (CF)3 is the most common life-threateninginherited disease among the Caucasian population world-wide with considerable morbidity and reduced life ex-
pectancy (1). The birth prevalence of CF is estimated to be in
3500–4500, with 200–300 new cases each year in single geo-
graphic areas (1). CF is caused by mutations in the CF transmem-
brane conductance regulator (CFTR) gene, which encodes a
cAMP-regulated chloride channel expressed at the apical mem-
brane of epithelial cells in the airways, pancreas, testis, and other
tissues (Online Mendelian Inheritance in Man no. 219700) (1, 2).
The most common CFTR mutation producing CF is deletion of
phenylalanine at residue 508 (F508del) in its amino acid sequence
(1, 2). The misfolded F508del-CFTR protein is degraded and fails
to reach the cell membrane, leading to defective chloride channel
function (3–6).
As a prototype of a monogenic disease, gene therapy is ideally
placed to treat CF patients, although this approach has so far not
proved to be beneﬁcial (7). Alternative therapeutic approaches
have therefore been considered, such as small-molecule correctors
of defective F508del-CFTR folding/cellular processing (“correc-
tors”) and channel gatings (“potentiators”) (8, 9).
Although CF is a systemic disease, the main cause of death is
due to chronic airway inﬂammation and persistent and untreatable
pulmonary infections, with Pseudomonas aeruginosa colonizing
most of the patients (10–12). As inﬂammation has a central role in
the pathogenesis of CF (13), new antiinﬂammatory drugs provided
some encouraging results in recent clinical trials. However, con-
ﬂicting results have been reported on whether CF airways undergo
proinﬂammatory response in the absence of bacterial infections
(14–16). Several studies have shown that both cytokine proﬁle
secretion and NF-B activation are similar in CF and normal cells
(17, 18). However, mounting evidence suggests that inﬂammation
may occur before infection, and CFTR-defective cells have an in-
trinsically proinﬂammatory phenotype (19–23). Recently, it has
been shown that CFTR is a negative regulator of NF-B-mediated
innate immune response, and its localization to lipid rafts is in-
volved in control of inﬂammation (24).
We have previously investigated the molecular mechanisms that
regulate this “intrinsic” proinﬂammatory proﬁle and made a link
between CFTR-defective function and inﬂammation (22). We have
shown that nasal polyp mucosa from CF patients as well as human
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CFTR-defective cell lines constitutively up-regulate tissue trans-
glutaminase (TG2), a multifunctional protein expressed in several
tissues (25). The increased TG2 activity drives inﬂammation
through down-regulation of the antiinﬂammatory peroxisome pro-
liferator-activated receptor (PPAR), a negative regulator of in-
ﬂammatory gene expression (26).
TG2 is an enzyme with a vast array of biological functions (27).
It catalyzes cross-links or deamidation of target proteins in the
presence of high Ca2 levels (27), whereas at low Ca2 concen-
trations it may function as a G protein or a protein disulﬁde
isomerase (27), thus contributing to the functionality of the mitho-
condrial respiratory chain complexes. We have shown that in CF
airways high levels of reactive oxygen species (ROS) lead to an
increase of TG2 activity, TG2-mediated PPAR cross-linking,
ubiquitination, and proteasome degradation, thus driving inﬂam-
mation (22). Blocking TG2 through speciﬁc gene-silencing or TG2
inhibitors increases PPAR protein and reverses inﬂammation
(22). The mechanisms by which the genetic CF defect leads to
TG2 up-regulation and inﬂammation, however, are still unknown.
TG2 is regulated by retinoids, steroid hormones, peptide growth
factors, and cytokines that also lead to a time-dependent decrease
in TG2 ubiquitination (25). Increased TG2 tissue levels have been
observed in neurodegenerative diseases (28), including Alzhei-
mer’s, Huntington’s, and Parkinson’s diseases, as well as in
chronic inﬂammatory conditions such as celiac disease (29). In-
creased tissue levels of TG2 have also been detected in cancer such
as glioblastomas, malignant melanomas, and pancreatic ductal ad-
enocarcinomas (30), and they are often associated with an in-
creased metastatic activity or acquisition of drug resistance (30).
In this paper we investigated whether posttranslational modiﬁ-
cations result in the persistence of high levels of TG2 protein in CF
airways. We focused on small ubiquitin like-modiﬁer (SUMO)
posttranslational modiﬁcation, since this has been deﬁned as a cen-
tral way of regulating key cellular functions and stability of pro-
teins (31, 32). Since protein inhibitor of activated STAT (PIAS)y,
a member of the PIAS family (33), has recently been deﬁned as the
ﬁrst SUMO ligase for NF-B essential modulator (NEMO) (33),
and PIASy-NEMO interaction is mediated by ROS (33), we also
investigated whether PIASy-TG2 interaction could mediate ROS-
driven posttranslational modiﬁcations of TG2. We demonstrate
that in CF airway epithelia the pro-oxidative intracellular milieu
leads to PIASy-mediated TG2 SUMOylation and uncontrolled
TG2 activation. This prevents PPAR and IkB SUMOylation,
leading to NF-B activation and persistent inﬂammation. More-
over SUMO-1 or PIASy gene silencing can switch off inﬂamma-
tion, favoring TG2 degradation and restoring cellular homeostasis.
We demonstrate increased ROS levels and TG2 SUMOylation
also in vivo, in a mouse model homozygous for the F508del-CFTR
mutation, and show that TG2 inhibition blocks lung inﬂammation
in vivo.
These results indicate TG2 as a missing link between oxidative
stress and inﬂammation and ﬂag TG2 as a new attractive target to
control the evolution of chronic airway inﬂammation in CF.
Materials and Methods
Cell lines and cultures
Human CF bronchial epithelial cell line IB3-1, carrying F508del/W1282X
CFTR mutation, isogenic stably rescued C38, normal bronchial epithelial
16HBE, or lung carcinoma A549 cell lines (LGC Standards) were cultured
as recommended by American Type Culture Collection. IB3-1 cell lines
were incubated for 24 h with EUK-134 (50 g/ml; Alexis Biochemicals),
TG inhibitor R283 (250 M), KCC009 (250 M), or cystamine (400 M;
Sigma-Aldrich) followed or not by rosiglitazone for 6 h (10 M; Alexis
Biochemicals). A549 and 16HBE cell lines were incubated for 1 h with
H2O2 (33) (2 mM; Sigma-Aldrich) and for 24 h with rotenone (1 M;
Sigma-Aldrich) or buthionine sulfoximine (10 M; Sigma-Aldrich) in the
presence or absence of EUK-134 as well as with CFTR-inh172 (20, 22) (20
M; Calbiochem). A549 and 16HBE cell lines were also cultured under
hypoxic conditions in a humidiﬁed hypoxia chamber (Cop Laboratories)
for 1 h at 1% O2 (5% CO2 balance N2), and temperature was maintained
at 37°C (34).
RNA interference
IB3-1 cells were transfected with 50 nM human SUMO-1 or scrambled small
interfering RNA (siRNA) duplex using Lipofectamine RNAiMAX at
37°C for 72 h. The SUMO-1 duplex siRNA was a pool of three se-
quences: siRNA no. 1, SUMO-1, sense, 5-GGAUAGCAGUGAGAUU
CACUUCAAA-3, antisense, 5-UUUGAAGUGAAUCUCACUGCUA
UCC-3; siRNA no. 2, SUMO-1, sense, 5-GGUGUUCCAAUGAAUU
CACUCAGGU-3, antisense, 5-ACCUGAGUGAAUUCAUUGGAAC
ACC-3; siRNA no. 3, SUMO-1, sense, 5-GGAAGAAGAUGUGAUU
GAAGUUUAU-3, antisense 5-AUAAACUUCAAUCACAUCUUCU
UCC-3. siRNA-mediated knockdown of PIASy was performed using
speciﬁc siRNA oligos, as previously described (33). TG2 gene silencing
was performed as previously reported (22).
Adenoviral vector
Human manganese superoxide dismutase (MnSOD) cDNA was cloned into
the shuttle vector pAd5CMVK-NpA (35). MnSOD adenovirus was a gift
from Michael Brownlee (Albert Einstein College of Medicine, New York,
NY). IB3-1, A549, and 16HBE cell lines were infected with MnSOD or
control adenovirus for 2 h, as previously described (35).
TG2 overexpression
A549 cells were transfected with wild-type TG2 cloned into the pLPCX
vector (pLPCX-TG2) (a gift from Dr. G. M. Fimia, National Institute for
Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientiﬁco,“L.
Spallanzani”, Rome, Italy) and empty vector (pLPCX), as control, using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol,
and incubated at 37°C for 48 h.
Cell fractionation
IB3-1 cells were collected in cold buffer A (20 mM Tris-HCl (pH 7.4), 2
mM EDTA, 20 mM 2-ME, 1 PMSF, 1 g/ml inhibitor protease cocktail),
homogenized in Potter-Elvehjem pestle and glass tube (Sigma-Aldrich),
and centrifuged at 2000 rpm for 15 min at 4°C to obtain nuclear pellets.
Supernatants were collected as cytoplasmic fractions. Nuclear pellets were
washed with buffer A and resuspended in buffer B (2 mM Na3VO4, 400
mM NaCl, 1 mM MgCl2, 1 mM EGTA, HEPES 10 mM (pH 7.9), 1 mM
DTT, 1 PMSF, 1 g/ml inhibitor protease cocktail) and incubated on ice
for 50 min with occasional mixing to extract nuclear proteins. Nuclear
extracts were cleared by centrifugation (7000 rpm, 15 min, 4°C), and su-
pernatants were collected as nuclear fraction. Then, cytoplasmic and nu-
clear whole-cell fractions were analyzed by immunoblotting.
Immunoblot
The blots were incubated with anti-phospho-p42/p44 MAP kinases (rabbit
polyclonal IgG, 1/500; Cell Signaling Technology), PPAR (clone E8 sc-
7273, mouse monoclonal IgG1, 1/500; Santa Cruz Biotechnology), TG2
(clone CUB7402, mouse monoclonal IgG1, 1/500; NeoMarkers), ubiquitin
(clone FL-76 sc9133, rabbit polyclonal IgG, 1/500; Santa Cruz Biotech-
nology), SUMO-1 (clone FL-101 sc9060, 1/500; Santa Cruz Biotechnol-
ogy), phopsho-p65(Ser536) (rabbit polyclonal, 1/500; Cell Signaling Tech-
nology), PIASy (clone H75 sc50437, rabbit polyclonal IgG, 1/1000; Santa
Cruz Biotechnology), IB (clone H4 sc1643, mouse monoclonal IgG1,
1/1000; Santa Cruz Biotechnology), -actin (clone 13E5, rabbit polyclonal
IgG, 1/2000; Cell Signaling Technology), and -tubulin (rabbit poly-
clonal IgG, 1/2000; Cell Signaling Technology). The primary Abs were
counterstained by a HRP-conjugated anti-IgG Ab (Amersham Biosciences)
for 60 min at room temperature. Proteins were visualized by chemilumi-
nescence (ECL Plus; Amersham Biosciences) and exposed to X-OMAT
ﬁlm (Eastman Kodak). The amounts of proteins were determined by a
Bio-Rad protein assay to ensure equal protein loading before Western blot
analysis. Fifty micrograms of cell lysate was loaded in each lane.
Immunoprecipitation
Treated and untreated cells were harvested, lysed, and 500 g of cell lysate
was immunoprecipitated by overnight incubation at 4°C on a mixer with an
appropriate dilution of speciﬁc Ab (anti-TG2 CUB 7402 mAb, anti-PIASy,
anti-PPAR, anti-IB) in cold lysis buffer. The samples were then incu-
bated with protein G-Sepharose at 4°C for 2 h with constant mixing. After
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washing, the immunoprecipitated proteins were electrophoresed through
10% polyacrylamide gels (Bio-Rad), transferred onto blotting membranes
(PolyScreen polyvinylidene diﬂuoride; NEN), and analyzed.
Patients and ex vivo cultures of nasal polyp mucosal biopsies
Seven consecutive CF patients carrying the common CFTR mutations
(F508del/F508del, F508del/W1282X, F508del/N1303K, or F508del/
G542X) (mean age, 19 years; range, 13–29 years) with chronic sinusitis
and nasal polyposis and seven consecutive non-CF patients (mean age, 21
years; range, 16–32 years) with idiopathic polyposis underwent surgical
treatment. Informed consent was obtained from all subjects and the ethical
committee of Regione Campania Health Authority approved the study. CF
nasal polyp biopsies were cultured for 4 h, as previously reported (22), with
or without ROS scavenger EUK 134 (50 g/ml). Control nasal polyp bi-
opsies were also cultured for 1 h with H2O2 (2 mM; Sigma-Aldrich).
Mice
Young adult female CF mice homozygous for the F508del mutation in
the 129/FVB outbred background (36) and their wild-type littermates were
housed in static isolator cages at the animal care speciﬁc pathogen-free
facility of the University of Louvain following recommendations of the
Federation of European Laboratory Animal Science Associations (37). To
prevent intestinal obstruction CF mice were weaned to a liquid diet (Pep-
tamen; Nestle´ Nutrition). Peptamen was replaced daily. The genotype of
each animal was checked at 21 days of age, as previously described (36).
These studies and procedures were approved by the local Ethics Committee
for Animal Welfare and conformed to the European Community regula-
tions for animal use in research (CEE no. 86/609). CF (n  7) and normal
homozygous wild-type mice (n  7), 10 to 14 wk of age, were treated i.p.
(38) for 7 days with a daily dose of 100 l of 0.01 M cystamine or PBS
solution. Mice were then killed by i.p. injection of 20 mg of sodium pen-
tobarbital (Abbott Laboratories).
ROS detection
Cell lines were pulsed with 10 M 5-(and-6)-chloromethyl-27-dichlo-
rodihydroﬂuorescein diacetate acetyl ester (CM-H2DCFDA) (Molecular
Probes/Invitrogen) according to the manufacturer’s suggestions. The cells
were analyzed with a Wallac 1420 multilabel counter (PerkinElmer) or
detected by a LSM510 Zeiss confocal laser scanning unit. Seven-microme-
ter frozen lung tissue sections from each mouse were pulsed with 10 M
CM-H2DCFDA and analyzed by confocal microscopy.
Confocal microscopy
Cell lines. Treated or untreated cells were ﬁxed in methanol, permeabil-
ized with 0.5% Triton X-100, and incubated with Abs against PPAR
(1/100 dilution; Santa Cruz Biotechnology), SUMO-1 (1/100; Santa Cruz
Biotechnology), TG2 (1/100; NeoMarkers), PIASy (1/100; Santa Cruz
Biotechnology), and nuclear co-repressor (N-CoR, 1/200; Santa Cruz Bio-
technology) according to the previously described procedure (22).
Human tissue sections. Five-micrometer frozen human lung tissue sec-
tions were ﬁxed in acetone for 10 min. The sections were incubated for 2 h
at room temperature with Abs against SUMO-1 (1/100; Santa Cruz Bio-
technology), PIASy (1/100; Santa Cruz Biotechnology), and TG2 (1/100;
NeoMarkers) as previously described (22).
Mice lung tissue. Seven-micrometer frozen lung tissue sections from each
mice were ﬁxed in acetone for 10 min. The sections were incubated for 2 h
at room temperature with the following Abs: anti-phospho-p42/p44 MAP
kinases (1/200; Cell Signaling Technology), PPAR (clone H100 sc-7196,
rabbit polyclonal IgG, 1/100; Santa Cruz Biotechnology), TG2 (clone
H237 sc20261, rabbit polyclonal IgG, 1/100; Santa Cruz Biotechnology),
and SUMO-1 (clone S-18 sc31852, goat polyclonal IgG, 1/100). This was
followed by incubation with Alexa 488 donkey anti-rabbit (used for de-
tection of phospho-p42–44, PPAR, and TG2 protein, 1/200; Invitrogen)
or 546 donkey anti-goat (used for detection of SUMO-1 protein, 1/200;
Invitrogen). Data were analyzed under ﬂuorescence examination by con-
focal microscopy as previously described (22).
In situ detection of TG2 enzymatic activity
TG2 activity in cell lines was detected by incubating live cells with bio-
tinylated monodansylcadaverine for 1 h at 37°C (16). The incorporation of
labeled substrate was visualized by incubation with Alexa 546-conjugated
streptavidin (1/100; Molecular Probes/Invitrogen) for 30 min (22). TG2
FIGURE 1. TG2 SUMOylation in CF airway epithelial cells. A, Immu-
noblot analysis of SUMO-1 expression in CF IB3-1 and C38 cells. -actin
levels were used as loading control. B, FRET analysis of SUMO-1-TG2
interaction in IB3-1 and C38 cells. C, Immunoprecipitated (IP) TG2 spe-
cies from whole-cell extracts of IB3-1 cells are immunoreactive for the
anti-SUMO-1 Ab. D, Immunoblot analysis of TG2 immunoprecipitates
with anti-TG2 Abs. Two TG2 bands are detected in IB3-1 cells. E, Immu-
noblot analysis of TG2 expression in CF IB3-1 and C38 cells. -actin
levels were used as loading control.
FIGURE 2. PIASy mediates TG2 SUMOylation in CF airway epithelial
cells. A–C, IB3-1 cells were transduced with either human MnSOD or
antisense cDNAs in pAd5CMVK vector. A, Immunoblot analysis of TG2
(left) or PIASy (right) immunoprecipitates (IP) with anti-PIASy (left) or
anti-TG2 (right) Abs, respectively. B, Immunoblot analysis with anti-
SUMO-1 Ab of TG2 immunoprecipitates. C, Immunoblot analysis of
SUMO-1, PIASy, and TG2 protein. -actin levels were used as loading
control. D, IB3-1 cells were transfected with either 50 nM human PIASy
siRNA or control siRNA. FRET analysis of SUMO-1-TG2 interaction.
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enzymatic activity on human or mice lung sections was detected by
incubating unﬁxed sections with biotinylated monodansylcadaverine for
1 h at room temperature, as previously described (22).
Fluorescence resonance energy transfer (FRET) microscopy
For acceptor photobleaching, cells were ﬁxed with buffered 2% paraformald-
heyde and permeabilized with 0.5% Triton X-100. Upon ﬁxation, cells were
immunostained with Alexa 546-anti-TG2 (Molecular Probes/Invitrogen)/
Cy5-anti-SUMO-1 (Santa Cruz Biotechnology) or Alexa 546-anti-TG2/
Cy5-anti-PIASy (Santa Cruz Biotechnology). Seven-micrometer frozen
lung tissue sections from each mouse were ﬁxed with buffered 2%
paraformaldheyde. Upon ﬁxation, tissue sections were immunostained
with Alexa 546-anti-TG2/Cy5-anti-SUMO-1 (Santa Cruz Biotechnol-
ogy). Cells or tissue sections were then mounted for performing FRET
assay by confocal microscopy. Cy5 was bleached at 10% of its initial
ﬂuorescence, by 200 pulses (2.56 ms) of 5 mW 633 nm laser per pixel,
sampling 0.01 mm2 of the specimen. Alexa 546 ﬂuorescence was de-
tected before and after Cy5 photobleaching (39).
ELISA
Human or murine TNF- secretion was measured using the BD OptEIA
TNF- ELISA kit II (BD Biosciences). Measurements were performed at
least in triplicate. Values were normalized to 106 cells; results were ex-
pressed as means  SEM.
Statistical analysis
All experiments were performed at least in triplicate. Data distribution
was analyzed, and statistical differences were evaluated by using
ANOVA Tukey-Kramer test by SPSS 12 software. Results of experi-
ments on mice were expressed as means  SEM. Between-group com-
parisons were evaluated by one-way ANOVA, and post hoc compari-
sons were made using ANOVA Tukey-Kramer test. A p value of 0.05
was considered signiﬁcant.
Results
PIASy-mediated TG2 SUMOylation increases TG2 protein
levels in CF airway epithelial cells
To investigate whether posttranslational modiﬁcations could result
in the persistence of high levels of TG2 protein, we ﬁrst analyzed
IB3-1 CF epithelial cell lines carrying F508-del/W1282X CFTR
mutations and the isogenic stably rescued C38 cells. Western blots
revealed that SUMO-1 was increased in IB3-1 cells as compared
with C38 cell lines (Fig. 1A). Furthermore, acceptor photobleach-
ing FRET revealed that SUMO-1 interacted with TG2 in IB3-1
cells (Fig. 1B), and SUMO-1 immunoreactivity was detected on
FIGURE 3. Decrease of TG2 protein levels and TG2 activity by ei-
ther SUMO or PIASy gene silencing. A–C, IB3-1 cells were transfected
with either 50 nM human SUMO-1 siRNA or control siRNA. A, Im-
munoblot analysis with anti-ubiquitin Ab of TG2 immunoprecipitates
upon SUMO-1 gene silencing followed by a 6-h incubation with 50 M
proteasome inhibitor MG132. B, Immunoblot analysis of SUMO-1 and
TG2 protein in IB3-1 cells upon SUMO-1 gene silencing. -actin levels
were used as loading control. C, TG2 activity (white) in IB3-1 cells
upon SUMO-1 gene silencing. Confocal microscopy, scale bar, 10 m.
D–F, IB3-1 cells were transfected with either 50 nM human PIASy
siRNA or control siRNA. D, Immunoblot analysis with anti-ubiquitin
Ab of TG2 immunoprecipitates upon PIASy gene silencing followed by
a 6-h incubation with 50 M proteasome inhibitor MG132. E, Immu-
noblot analysis of PIASy and TG2 protein upon PIASy gene silencing.
-actin levels were used as loading control. F, TG2 activity (white) in
IB3-1 cells upon PIASy gene silencing. Confocal microscopy, scale
bar, 10 m.
FIGURE 4. ROS-mediated PIASy-TG2 interaction in human nasal
polyp mucosa. A, Confocal images of PIAS (green) and TG2 protein (red)
in CF nasal polyp mucosa. The same pattern is observed after a 4-h incu-
bation with medium alone. B, Confocal images of PIAS and TG2 in CF
nasal polyp mucosa cultured for 4 h with EUK-134. C, Confocal images of
PIAS (green) and TG2 protein (red) in control nasal polyp mucosa. D,
Confocal images of PIAS and TG2 in control nasal polyp mucosa cul-
tured for 1 h with 2 mM H2O2. A–D, Overlay shows the merged images.
DAPI (4,6-diamidino-2-phenylindole) (blue), nuclear counterstaining.
Scale bar, 10 m.
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TG2 immunoprecipitates (Fig. 1C). When TG2 immunoprecipi-
tates from IB3-1 cells were probed with the anti-TG2 Ab, two TG2
bands were detected, with the upper band corresponding to the
SUMOylated TG2 (Fig. 1D). Moreover, TG2 protein levels were
higher in IB3-1 than in C38 cell lysates (Fig. 1E). Sequence anal-
ysis and SUMO motif screening revealed three SUMO acceptor
sites (_kxE) (32) in TG2 sequence (supplemental Fig. 1).4
We investigated whether PIASy could mediate TG2 SUMO-
ylation. We found that PIASy and TG2 coimmunoprecipitated in
IB3-1 cells (Fig. 2A). Since PIASy SUMO-1 E3-ligase activity is
inﬂuenced by ROS (33), we investigated whether the CF intracel-
lular prooxidative environment (22) could mediated TG2-PIASy
interaction and TG2 SUMOylation. The overexpression of human
MnSOD (35) controlled PIASy-TG2 coimmunoprecipitation (Fig.
2A) as well as SUMO-TG2 coimmunoprecipitation (Fig. 2B), thus
reducing TG2 protein levels (Fig. 2C). Furthermore, MnSOD over-
expression reduced PIASy protein levels (Fig. 2C). The antioxi-
dant synthetic SOD mimetic EUK-134 (22) showed the same
effects as MnSOD (supplemental Fig. 2). We conﬁrmed the in-
volvement of PIASy in TG2 SUMOylation by PIASy gene silenc-
ing. We reduced PIASy cellular expression by 90%, using
PIASy siRNA. Indeed, PIASy siRNA inhibited TG2-SUMO-1
interaction (Fig. 2D) and TG2-SUMO-1 coimmunoprecipitation
(data not shown). This suggests that the increase of ROS levels
induces PIASy-TG2 interaction and TG2 SUMOylation.
SUMOylation may induce protein stabilization by blocking
ubiquitination of the same lysine residues (40). We demonstrated
that SUMO gene silencing by SUMO-1-speciﬁc siRNA increased
TG2 ubiquitination upon proteasome inhibition by MG132 (Fig.
3A), thus allowing TG2 to be targeted to proteasome for degrada-
tion. This induced decreases of TG2 protein (Fig. 3B) and TG2
activity (Fig. 3C). PIASy siRNA showed the same effects as4 The online version of this article contains supplemental material.
FIGURE 5. Deregulation of ROS
machinery mediates TG2 SUMOyla-
tion in 16HBE and A549 cells. A and B,
16HBE cell lines were cultured with or
without CFTRinh-172 in the presence
or absence of MnSOD overexpression.
A, FRET analysis reveals SUMO-1-
TG2 interaction after CFTR inhibition
that was controlled by MnSOD overex-
pression. B, Immunoblot analysis of
PIASy protein. -actin levels were used
as loading control. C and D, A549 cells
were cultured with or without rotenone.
C, Immunoprecipitated (IP) TG2 spe-
cies from whole-cell extracts are immu-
noreactive for the anti-SUMO-1 Ab
upon rotenone treatment. D, FRET
analysis reveals SUMO-1-TG2 interac-
tion after incubation with rotenone.
MnSOD overexpression controls rote-
none-induced TG2 SUMOylation.
E–G, A549 cells were cultured with
H2O2 or under hypoxic conditions. E,
Immunoblot analysis of PIASy protein
after H2O2 treatment. -actin levels
were used as loading control. F, Immu-
noblot analysis of TG2 immunoprecipi-
tates (IP) with anti-PIASy Ab after
H2O2 treatment in presence or absence
of MnSOD overexpression. G, FRET
analysis reveals SUMO-1-TG2 interac-
tion after H2O2 treatment as well as
when A549 cells were cultured upon
hypoxic conditions. The effects of hyp-
oxia on TG2 SUMOylation are con-
trolled by MnSOD overexpression.
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SUMO-1 siRNA on TG2 ubiquitination (Fig. 3D) and TG2 protein
levels (Fig. 3E) and activity (Fig. 3F).
To investigate whether TG2-PIASy interaction and TG2 SUMO-
ylation may take place in human airways of CF patients and
whether it was induced by the oxidative stress, we used a well-
established tissue culture model of biopsies of human CF nasal
polyps (22, 41). We have already validated this experimental
model (22, 41) and reported that increased TG2 levels are a feature
of CF nasal polyp mucosa and that the inhibition of TG2 is effec-
tive in controlling mucosal inﬂammation by restoring normal lev-
els of PPAR protein (22). We found that TG2-PIASy colocalized
in human CF airways (Fig. 4A) and that this interaction was in-
hibited upon treatment with the EUK-134 (Fig. 4B). EUK-134 re-
duced TG2 expression at epithelial but not in the subepithelial
compartment (Fig. 4B, arrow), where PIASy did not colocalize
with TG2 protein (arrow in Fig. 4A). After EUK-134 treatment the
distribution of TG2 in CF nasal polyp biopsies was similar to that
observed in non-CF controls (22). This suggests that the inhibition
of TG2-PIASy interaction restores the physiological levels and
distribution of TG2 in CF airways (22). Furthermore, in CF nasal
polyp mucosa TG2 colocalizes with SUMO-1, and the incubation
with EUK-134 inhibited TG2-SUMO-1 colocalization (data not
shown). Non-CF control nasal polyp mucosa showed very faint
TG2, PIASy, or SUMO-1 expression at the epithelial level (Fig. 4,
C and D). In nasal control biopsies the treatment with H2O2 was
highly effective in increasing epithelial SUMO-1 and TG2 expres-
sion and their colocalization (Fig. 4D).
FIGURE 6. SUMO-1 or PIASy gene silencing control inﬂammation in
CF airway epithelial cells. IB3-1 cells were transfected with either 50 nM
human SUMO-1 siRNA, PIASy siRNA, or control siRNA. A, Immunoblot
analysis of p42–44 phosphorylation upon PIASy siRNA (left) and SUMO-1
siRNA (right).-actin levels were used as loading control.B, TNF- protein upon
SUMO-1 or PIASy gene silencing (each bar represents the mean plus SEM of
three separate experiments, each with n  3; , p  0.008 vs control siRNA).
FIGURE 7. TG2 inhibition modulates
PPAR and IkB pathways in CF airway
epithelia. A and B, IB3-I cells were incu-
bated for 6 h with rosiglitazone in presence
or absence of TG2 gene silencing. A, Im-
munoprecipitated (IP) PPAR from whole-
cell extracts are immunoreactive for the
anti-SUMO-1 Ab upon TG2 siRNA. B,
Confocal images of IB3-1 cells immuno-
stained with N-CoR (green). DAPI (4,6-
diamidino-2-phenylindole) nuclear coun-
terstaining. Scale bar, 10 m. C and D,
IB3-1 cells were transfected with either 50
nM human TG2 siRNA or control siRNA.
C, Immunoprecipitated IkB species from
whole-cell extracts are immunoreactive for
the anti-SUMO-1 Ab upon TG2 siRNA. D,
Immunoblot analysis of IkB expression
upon TG2 gene silencing. E, Immunoblot
analysis of phospho-p65(Ser536) in cytoplas-
mic (C) and nuclear (N) cell fractions upon
TG2 gene silencing. F, IB3-1 cells were in-
cubated with rosiglitazone in the presence or
absence of 400 M cystamine. Increased
immunoreactivity of immunoprecipitated
PPAR species from whole-cell extracts for
the anti-SUMO-1 Ab after cystamine treat-
ment is shown. G, Increased immunoreactiv-
ity of immunoprecipitated IkB species from
whole-cell extracts of IB3-1 cells for the anti-
SUMO-1 Ab after cystamine treatment. H
and I, IB3-1 cells were transfected with wild-
type TG2 cloned into the pLPCX vector
(pLPCX-TG2) or empty vector (pLPCX).
Decrease of SUMO-1 immunoreactivity of
immunoprecipitated PPAR (H) or IkB (I)
species from whole-cell extracts after TG2
overexpression.
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Deregulation of ROS machinery mediates TG2 SUMOylation in
human airway epithelial cell lines
Since we have previously demonstrated that the inhibition of
CFTR function by CFTR-172inh leads to increases of ROS levels
and TG2 activation (22), we investigated whether a deregulation of
ROS machinery could mediate TG2 SUMOylation in airway epi-
thelia. We inhibited CFTR function by CFTR-172inh in 16HBE
cell lines and demonstrated that PIASy-TG2 interaction (data not
shown) and TG2 SUMOylation (Fig. 5A) were induced upon
CFTR inhibition, which up-regulates intracellular ROS (22).
MnSOD overexpression was highly effective in controlling CFTR-
172inh-induced TG2 SUMOylation (Fig. 5A). The same effects
were observed in A549 epithelial cell lines (data not shown).
CFTR-172inh also increased PIASy protein levels (Fig. 5B).
Moreover, rotenone, the most commonly used complex I inhibitor
that increases ROS production in mitochondria (42), induced TG2-
SUMO-1 coimmunoprecipitation (Fig. 5C) and interaction (Fig.
5D) in A549 cells. The effects of rotenone (1 M) were neutralized
by MnSOD overexpression (Fig. 5D) as well as by EUK-134 (data
not shown). Buthionine sulfoximine, an inhibitor of the glutathione
pathway (42), showed the same effects as those observed after
treatment with rotenone (supplemental Fig. 2).
The treatment of A549 cells with H2O2 induced increased
PIASy protein levels (Fig. 5E) as well as PIASy-TG2 interaction
(Fig. 5F) and TG2 SUMOylation (Fig. 5G). These effects were
controlled by MnSOD overexpression (Fig. 5F). Moreover, when
A549 cells were cultured under hypoxic conditions (34), increased
TG2 SUMOylation was observed (Fig. 5G). The effects of hypoxia
were likely mediated by ROS (43) since MnSOD overexpression
controlled hypoxia-induced TG2 SUMOylation (Fig. 5G).
These data suggest that TG2 SUMOylation occurs as a conse-
quence of the deregulation of the oxidative control machinery.
SUMO-1 or PIASy gene silencing controls inﬂammation in CF
airway epithelial cells
TG2 SUMOylation might provide the missing link between cel-
lular stress and inﬂammation. We tested whether the control of
TG2 SUMOylation might modulate TG2-driven inﬂammation we
have described in CF epithelia (22). We demonstrated that gene
silencing of either PIASy or SUMO by speciﬁc siRNAs induced
a signiﬁcant decrease of p42–44 phosphorylation (Fig. 6A) and
TNF- release (Fig. 6B) in IB3-1 cells.
TG2 inhibition modulates PPAR and IkB SUMOylation in
CF airway epithelia
Since PPAR may undergo SUMOylation in response to a PPAR
agonist (22, 44), thus interacting with N-CoR-histone deacetylase
3 (HDAC3) complex and thereby blocks its ubiquitination (44), we
investigated whether increased TG2 protein levels might interfere
with PPAR SUMOylation. We demonstrated that blocking TG2
through speciﬁc gene silencing (22) increased SUMO-1 immuno-
reactivity in PPAR immunoprecipitates in response to rosiglita-
zone (Fig. 7A), enhanced N-CoR protein and its nuclear localiza-
tion (Fig. 7B), and favored N-CoR-PPAR interaction (data not
shown). TG2 might also mediate NF-B activation (45) by fa-
voring cross-linking, ubiquitination, and proteasome degrada-
tion of IkB, a key NF-B modulator (45) and known TG2
substrate (45). Conversely, SUMO enhancers induce SUMOy-
lation and stabilization of IkB, thus preventing NF-B acti-
vation (34). We demonstrated that in IB3-1 cells the inhibition
of TG2 by gene silencing increased SUMO-1 immunoreactivity
in IkB immunoprecipitates (Fig. 7C) and increased IkB pro-
tein levels (Fig. 7D). Moreover, reduced p-65 NF-B was de-
tected in nuclear extracts of IB3-1 cells after TG2 inhibition
(Fig. 7E). TG2 speciﬁc inhibitors such as cystamine (38) (Fig.
7, F and G), R283, or KCC009 (22) (data not shown) showed
the same effects as TG2 gene silencing. Furthermore, TG2 over-
expression in A549 cells was effective in reducing PPAR and
IkB SUMOylation (Fig. 7, H and I). TG2 SUMOylation may
therefore switch off the intracellular regulatory machinery, pre-
venting PPAR SUMOylation, IkB stabilization, and leading
to an uncontrolled inﬂammatory response.
TG2 inhibition controls inﬂammation in F508del-CFTR
homozygous mice
To test the effects of TG2 inhibition in vivo, we treated CF mutant
mice homozygous for F508del-CFTR mutation (36) and their con-
trol littermates (36) with cystamine, previously reported to inhibit
TG2 and ameliorate disease manifestations in a mouse model of
FIGURE 8. TG2 inhibition by cystamine controls airway inﬂammation
in F508del-CFTR homozygous mice. A, Increase of intracellular ROS
(DCF immunoﬂuorescence) in F508del-CFTR mice as compared with
wild-type (WT) littermates. Confocal microscopy. Scale bar, 10 m. B,
FRET analysis of TG2-SUMO-1 interaction in homozygous F508del-
CFTR mice and WT littermates. C–E, Homozygous F508del-CFTR mice
treated with cystamine (daily i.p. injection of 100 l of 0.01 M in PBS/7
days) or PBS. The pattern observed after PBS treatment was similar to that
observed in untreated mice. C, Confocal images identiﬁed increased TG2
activity, low expression of PPAR protein with localization in perinuclear
aggregates, and increased p42–44 phopshorylation in lung tissues of PBS-
treated CF mice as compared with control littermates. Cystamine reduces
TG2 activity and phospho-p42–44 and restores high epithelial expression
and nuclear localization of PPAR as observed in WT mice. D, High
magniﬁcation of C. Confocal microscopy, CyTRAK Orange nuclear coun-
terstaining, yellow indicates nuclear localization. One representative case
of seven mice for each group is shown. E, TNF- protein in mouse lung
homogenates (mean plus SEM of three separate experiments, each with
n  7; , p  0.017 vs PBS-treated mice).
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Huntington’s disease (38). We treated CF and wild-type mice with
a daily injection of cystamine (i.p. injection of 100 l of 0.01 M
in PBS for 7 days) or PBS (i.p. injection of 100 l of PBS for 7
days). After treatment with PBS the expression and distribution of
the tested markers remained unaltered as compared with the pat-
tern observed in untreated CF mice. Before treatment, as well as
after treatment with PBS, all seven tested CF mice showed in-
crease of ROS (Fig. 8A) and SUMO-TG2 interaction (Fig. 8B), as
well as TG2 activity (Fig. 8, C and D; D is a high magniﬁcation of
C), as compared with control littermates. PPAR was also reduced
and sequestered in aggresomes (Fig. 8, C and D), whereas phos-
phorylation of p42–44 (Fig. 8C) and increase of TNF- protein
were observed (Fig. 8E). In all CF mice, the treatment with cys-
tamine controlled TG2 activity (Fig. 8, C and D), increased
PPAR levels and its nuclear localization (Fig. 8, C and D), and
reduced p42–44 phosphorylation (Fig. 8C) and TNF- protein lev-
els (Fig. 8E), thus restoring the pattern observed in their control
littermates. Cystamine did not induce any changes in wild-type
mice (data not shown).
Discussion
In this report we have underpinned the relationship between CFTR
defective function, oxidative stress, and chronic airway inﬂamma-
tion in CF. We have identiﬁed TG2 SUMOylation as a pivot in
driving the proinﬂammatory CF phenotype.
The cellular response to stress involves a ﬁnely tuned posttrans-
lational network that provides proteins with functional ability at
the right time and place, and its perturbations have been shown to
contribute to the etiology of various human diseases (46).
SUMOylation has been deﬁned as a key player of the posttrans-
lational network to regulate key cellular functions, including tran-
scription, nuclear translocation, stress response, and chromatin
structure, as well as of diversifying localization and even stability
of the modiﬁed proteins (31, 32, 46). SUMOylation is accom-
plished via an enzymatic cascade involving, among others, E3 li-
gases, that catalyze the transfer of SUMO from the conjugating
enzyme UBC9 to a substrate (31). E3 ligases have gained a central
role in the SUMO machinery, since they regulate SUMOylation in
response to different stresses (31). Herein we demonstrate that in
CF airway epithelia the increased levels of ROS lead to TG2
SUMOylation via interaction of TG2 with PIASy, an E3 ligase
already reported to mediate NEMO SUMOylation upon genotoxic
stress through ROS generation (33). Oxidative stress increases
PIASy protein levels and favors TG2 SUMOylation that leads to
the persistence of high TG2 tissue levels by down-regulating TG2
ubiquitination and proteasome degradation.
Our results also indicate that TG2 SUMOylation is a general
response to oxidative stress inducers since the impairment of the
intracellular ROS balance, either by perturbing mitochondrial ox-
idative regulation by rotenone or by interfering with gluthatione
pathway, is also effective in inducing TG2 SUMOylation and en-
hancing TG2 activity in airway epithelia. The persistence of high
levels of TG2 might in turn increase the intracellular ROS since
TG2 may also contribute to the functionality of the mitochondrial
respiratory chain (27). Moreover, the PPAR down-regulation
might also interfere with the appropriate control of the redox ma-
chinery since it can also modulate oxidative stress (47). Thus, TG2
FIGURE 9. Schematic represen-
tation of the main ﬁnding of the pa-
per. a, Increased intracellular levels
of ROS favor PIASy-TG2 interac-
tion. b, PIASy-TG2 interaction
leads to TG2 sumoylation and in-
hibits TG2 ubiquitination and pro-
teasome degradation, thus leading
to uncontrolled TG2 activation. c,
TG2 favors PPAR cross-linking
and proteasome degradation and in-
hibits PPAR SUMOylation and
PPAR-NCoR complex interaction,
thus inhibiting transrepressing ac-
tivity. d, TG2 induces IkB cross-
linking and proteasome degrada-
tion, favoring NF-B activation and
nuclear translocation.
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may sustain a vicious cycle that leads to a progressive and uncon-
trolled impairment of the cellular homeostasis.
TG2 SUMOylation may therefore switch off the posttransla-
tional regulatory mechanisms in response to the oxidative stress.
Most proteins involved in the pathogenesis of chronic human dis-
eases, as huntingtin, ataxin-1, tau, and -synuclein, were reported
to be SUMO (48) as well as TG2 substrates (49). PPAR, which
may be targeted by TG2 to cross-linking and proteasome deg-
radation (22), may also be targeted by SUMO-1 and undergo
SUMOylation in response to a PPAR agonists, such as rosiglita-
zone (22, 44). SUMOylated PPAR interacts with the N-CoR-
histone deacetylase 3 (HDAC3) complex and thereby blocks its
ubiquitination, thus maintaining a repressor condition (44). Herein
we demonstrated that sustained TG2 activation inhibits PPAR
SUMOylation and its interaction with the N-CoR (44), thus favor-
ing inﬂammation. Moreover TG2-mediated cross-linking and deg-
radation of IkB, a known TG2 substrate (45), inhibits IkB
SUMOylation and favors NF-B activation. Therefore, TG2 may
function as a link between oxidative stress and inﬂammation by
driving the decision as to whether a protein should undergo
SUMO-mediated regulation or degradation (Fig. 9).
The rheostat role of TG2 makes this enzyme an attractive
target to restore cellular homeostasis and dampen chronic in-
ﬂammation in CF airways. The regulation of the high levels of
TG2 protein or the inhibition of sustained TG2 enzyme activa-
tion may represent a new attractive approach to control disease
evolution in CF patients.
To provide the rationale and the proof-of-principle for the pu-
tative use of TG2 inhibitors in CF patients, we checked whether
the mechanisms described in cell lines also take place in human CF
airways. The inﬂammatory response is a complex event involving
different cell types interacting within their natural environment.
We took advantage of a well-established model of in vitro cultures
of explants of CF nasal polyps, which are routinely removed sur-
gically and represent CF chronic airway inﬂammation (22, 41). We
demonstrated that ROS-mediated PIASy-TG2 as well as SUMO-
1-TG2 interactions take place in human CF airways.
To evaluate whether we can translate our in vitro ﬁndings into
an appropriate animal model and conﬁrm their biological rele-
vance in vivo we have studied CF mutant mice homozygous for
F508del-CFTR (36). We have demonstrated TG2-SUMO colocal-
ization and increased TG2 activity in lung tissues from F508del-
CFTR homozygous mice. In the lungs of these mice, PPAR is
also reduced and sequestered in aggresomes, and inﬂammation is
present. We treated these CF mice with daily i.p. injections of
cystamine, already used in a mouse model of Huntington’s disease
(38). Cystamine is known to inactivate TG2 through a disulﬁde-
exchange reaction and is a substrate for TG2 (38). We have shown
that daily injections of cystamine inhibit TG2 activation, increase
PPAR protein expression, and control inﬂammation.
Our results highlight TG2 as an unforeseen unifying link be-
tween genetic defect, deregulation of cellular homeostasis, and in-
ﬂammation (Fig. 9). They also indicate TG2 as a candidate target
for the design of a pathogenic-based therapy in CF and add to the
rationale for attempting inhibition of TG2 in CF patients. This
study also suggests that targeting TG2 SUMOylation through
inhibition of TG2-SUMO interactions might be helpful to con-
trol the unwanted persistence of TG2, thus favoring TG2 ubiq-
uitination and proteasome degradation. Therefore, TG2 inhibi-
tion might represent a new attractive option to control the
evolution of chronic inﬂammatory diseases, neurodegenerative
diseases, and even cancer.
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Tissue Transglutaminase Activation Modulates Inﬂammation
in Cystic Fibrosis via PPAR Down-Regulation1
Luigi Maiuri,2*† Alessandro Luciani,†‡ Ida Giardino,§ Valeria Raia,¶ Valeria R. Villella,
Maria D’Apolito,† Massimo Pettoello-Mantovani,† Stefano Guido, Carolina Ciacci,‡
Mariano Cimmino,# Olivier N. Cexus,** Marco Londei,††‡‡ and Sonia Quaratino2**††
Cystic ﬁbrosis (CF), the most common life-threatening inherited disease in Caucasians, is due to mutations in the CF transmem-
brane conductance regulator (CFTR) gene and is characterized by airways chronic inﬂammation and pulmonary infections. The
inﬂammatory response is not secondary to the pulmonary infections. Indeed, several studies have shown an increased proinﬂam-
matory activity in the CF tissues, regardless of bacterial infections, because inﬂammation is similarly observed in CFTR-defective
cell lines kept in sterile conditions. Despite recent studies that have indicated that CF airway epithelial cells can spontaneously
initiate the inﬂammatory cascade, we still do not have a clear insight of the molecular mechanisms involved in this increased
inﬂammatory response. In this study, to understand these mechanisms, we investigated ex vivo cultures of nasal polyp
mucosal explants of CF patients and controls, CFTR-defective IB3-1 bronchial epithelial cells, C38 isogenic CFTR corrected,
and 16HBE normal bronchial epithelial cell lines. We have shown that a defective CFTR induces a remarkable up-regulation
of tissue transglutaminase (TG2) in both tissues and cell lines. The increased TG2 activity leads to functional sequestration
of the anti-inﬂammatory peroxisome proliferator-activated receptor  and increase of the classic parameters of inﬂamma-
tion, such as TNF-, tyrosine phosphorylation, and MAPKs. Speciﬁc inhibition of TG2 was able to reinstate normal levels
of peroxisome proliferator-activated receptor- and dampen down inﬂammation both in CF tissues and CFTR-defective
cells. Our results highlight an unpredicted central role of TG2 in the mechanistic pathway of CF inﬂammation, also opening
a possible new wave of therapies for sufferers of chronic inﬂammatory diseases. The Journal of Immunology, 2008, 180:
7697–7705.
T he breach of the innate immune system and a chronicallyinfected and inﬂamed lung are the characteristic featuresof cystic ﬁbrosis (CF)3 (1). It has been estimated that

30,000 children and adults in the U.S. (70,000 worldwide) are
affected by CF, with a frequency of 
1 in 2,500 livebirths (1).
The direct link between CF transmembrane conductance regu-
lator (CFTR) dysfunction and airway infection has been shown.
Defects in the CFTR result in an impaired clearance of lung patho-
gens, especially Pseudomonas aeruginosa (2, 3). Infections are
then further exacerbated by the poor mucociliary clearance due to
ciliary dysfunction and the hyperabsorption of water by the air-
ways epithelium (4).
The mechanisms by which CFTR mutations might contribute to
airways inﬂammation are, however, still elusive. Defects of the
CFTR are also associated with a marked increase of proinﬂamma-
tory cytokines, such as TNF-, IL-6, IL-1, IL-17 (5, 6), and the
potent neutrophil chemoattractant and activator IL-8, which re-
cruits large numbers of neutrophils into the airways (1). Chronic
inﬂammation, however, is not merely the consequence of repeti-
tive infections, because CFTR-defective cell lines spontaneously
develop similar proinﬂammatory features when kept in vitro in
sterile conditions (7, 8). Indeed, CFTR-defective cells have been
reported to have an intrinsically proinﬂammatory phenotype, and
despite different intracellular pathways that have been considered,
none to date has been demonstrated to be associated (7, 8).
To underpin the molecular link between a defected CFTR and
the excessive inﬂammatory responses typical of CF airways here
we have studied nasal polyp mucosa from CF patients (9) as well
as CFTR-defective bronchial epithelial cell lines (2, 10). The ra-
tionale to extend the study to the cell lines was to speciﬁcally
target the role of the defective CFTR on peroxisome proliferator-
activated receptor- (PPAR) in sterile conditions, excluding the
inﬂuence that recurrent infections might have on the epithelium
and the generation of inﬂammation.
We have highlighted how a defected CFTR induces high levels
of tissue transglutaminase (TG2) in the airways. TG2 has a pivotal
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role in the initiation of inﬂammation by sequestering PPAR, a
nuclear hormone receptor expressed in monocytes, macrophages,
and epithelial cells that negatively regulates inﬂammatory gene
expression by transrepressing inﬂammatory responses (11). This
work also suggests that TG2 inhibition could become a therapeutic
target to control inﬂammation in CF and possibly in other chronic
inﬂammatory diseases.
Materials and Methods
Human airway biopsies and ex vivo cultures
Nasal polyp explants from 10 CF patients carrying the common CFTR mu-
tations (	F508/	F508, 	F508/W1282X, 	F508/N1303K, or 	F508/G542X)
and 10 non-CF patients with nonallergic idiopathic polyposis were cultured,
for 4–24 h (9), with or without speciﬁc TG2 inhibitors 1,3-dymethyl-2-[(2-
oxopropyl) thio] imidazolium (R283) (250 M) (12) or halo-dihydroisox-
azole-derivate transglutaminase inhibitor KCC009 (250 M), reactive oxygen
species (ROS) scavenger EUK 134 (50 g/ml; Alexis Biochemical), N-acetyl-
cysteine (NAC, 10 mM; Alexis Biochemical), PPAR antagonist GW9662 (1
M; Alexis Biochemical), or R283 for 24 h, followed by GW9662 (1 M) for
4 h. Informed consent was obtained from all subjects, and the ethical com-
mittee of Regione Campania Health Authority approved the study.
Cell lines and cultures
IB3-1 (human CF bronchial epithelial cell line with the common 	F508/
W1282X CFTR mutation) and C38 (isogenic stably rescued with functional
CFTR) cell lines (LGC Promochem) (2, 7, 10) were stimulated for 6 h with
R283 (250 M) or KCC009 (250 M), ionomycin (1 M; Calbiochem),
BAPTA-AM (5 M, Calbiochem), EUK 134 (50 g/ml), rosiglitazone (10
), NAC (10 mM), proteasome inhibitor MG132 (50 M for 6 h; Calbio-
chem), or R283 for 24 h, followed by 6-h rosiglitazone. Normal human bron-
chial epithelial 16HBE cells were cultured, as previously described (8).
Quantitative RT-PCR
Quantitative RT-PCR was performed using iCycler iQ Multicolour Real-
Time PCR Detector (Bio-Rad) with iQ TM SYBR Green supermix (Bio-
Rad). A relative quantitative method was applied for TG2 mRNA (Qiagen;
catalog QT00081277), normalized by the control GAPDH mRNA.
RNA interference
IB3-1 cells were transfected with 50 nM human TG2, human PPAR, and
scramble small interfering RNAs (siRNAs) duplex using Hiperfect Trans-
fection Reagent (Qiagen) at 37°C for 72 h. The target sequence of TG2
siRNA was 5-CCGCGTCGTGACCAACTACAA-3, and the whole-cell
lysate was then analyzed for Western blot. The PPAR siRNA is a pool of
three sequences, as follows: CCAAGUAACUCUCCUCAAAtt, GAAUG
UGAAGCCCAUUGAAtt, and CUACUGCAGGUGAUCAAGAtt. Trans-
fected cells were then analyzed by confocal microscopy for expression
using anti-PPAR mAb clone E8.
Western blot
First Abs anti-phospho-p42/p44 MAPKs (Cell Signaling Technology),
PPAR (clone E8 sc-7273; Santa Cruz Biotechnology), TG2 (clone
CUB7402; DakoCytomation), N	(-L-glutamyl)-L-lysine isopeptide
(clone 81DIC2; Covalab), and ubiquitin (1:100 clone FL-76, rabbit
polyclonal IgG) were counterstained by a HRP-conjugated anti-IgG Ab
(Amersham, General Healthcare). The amounts of proteins were deter-
mined by a Bio-Rad protein assay to ensure equal protein loading be-
fore Western blot analysis. Fifty micrograms of cell lysate were loaded
in each lane.
Immunoprecipitation
Following cell lysis, 500 g of proteins was incubated at 4°C overnight
with anti-PPAR Ab (clone E8) and then mixed with protein G-Sepha-
rose beads for 2 h. The beads were washed three times with lysis buffer,
and immunoprecipitates were resuspended in SDS loading buffer. Equal
amounts of immunoprecipitate were loaded and analyzed for
Western blot.
ROS detection
Cell lines were pulsed with 10 M 5(and 6)-chloromethyl-27-dichlorodi-
hydroﬂuorescein diacetate acetyl ester (CM-H2DCFDA; Molecular
Probes, Invitrogen), according to manufacturer suggestions, and analyzed
with Wallac 1420 multilabel counter (PerkinElmer). Tissue sections (5
m) of nasal mucosa and cells were incubated with 10 M CM-
H2DCFDA, according to manufacturer suggestions, and an LSM510 Zeiss
confocal laser-scanning unit (Carl Zeiss, Germany) was used for detection.
In situ detection of TG2 activity and protein
TG2 protein and enzyme activity were detected and analyzed by confocal
microscopy. Brieﬂy, for detection of TG2 enzyme activity, live cells were
preincubated with TG2 assay buffer (965 l of 100 mM Tris/HCl (pH 7.4),
25 l of 200 mM CaCl2) for 15 min and then with the same TG2 assay
buffer added with 10 l of 10 mM biotinylated monodansylcadaverine
(bio-MDC; Molecular Probes) for 1 h at room temperature. The reaction
was stopped with 25 mM EDTA for 5 min. The cells were then ﬁxed in 4%
paraformaldehyde for 10 min. The incorporation of labeled substrate
was visualized by incubation with PE-conjugated streptavidin (Dako-
Cytomation; 1:50) for 30 min. Control experiments included the omis-
sion of bio-MDC, as well as replacement of 200 mM CaCl2 with 200
mM EDTA. Blocking experiments were also conducted by incubating
cells with the active site inhibitor R283 (250 M) for 1 h before incu-
bation with the substrates (bio-MDC or biotinylated peptides) and de-
tection of TG2 enzymatic activity. Data were analyzed under ﬂuores-
cence examination by LSM510 Zeiss confocal laser-scanning unit (Carl
Zeiss).
The simultaneous detection of TG2 protein and activity was performed
by incubating live cells with bio-MDC for 1 h at room temperature, ac-
cording to the above described procedure, and then with anti-TG2 CUB
7402 mAb (NeoMarkers; 1:50) for 1 h at room temperature. This was
followed by simultaneous incubation with PE-conjugated streptavidin
(DakoCytomation; 1:50) and FITC-conjugated rabbit anti-mouse Ig F(ab)2
(DakoCytomation; 1:20) for 1 h.
The detection of TG2 activity and protein on tissue sections was per-
formed, as reported in our previous paper (12).
Confocal microscopy
Cell lines were ﬁxed in methanol and permeabilized with 0.5% Triton
X-100 prior incubation with primary Abs. Frozen tissue sections were ﬁxed
in acetone for 10 min. Anti-phospho-p42/p44 (1:500; Cell Signaling Tech-
nology), anti-phosphotyrosine PY99 mAb (1:80, mouse IgG2b), anti-
PPAR (clone E8, sc-7273, 1:100, mouse IgG1; clone H100, sc-7196,
1:100, rabbit polyclonal IgG; Santa Cruz Biotechnology), anti-ubiquitin
(1:100 clone FL-76, rabbit polyclonal IgG), anti-histone deacetylase 6
(HDAC6; 1:100 clone H300, rabbit polyclonal IgG), anti-p65 NF-B
(F-6; 1:100), and anti-ICAM-1 (15.2; 1:200) (Santa Cruz Biotechnol-
ogy) Abs were used for ﬁrst Ab. The Ag expression and distribution
were visualized by indirect immunoﬂuorescence, as previously de-
scribed (12).
ELISA
Human TNF- secretion was measured using the BD OptEIATM TNF-
ELISA kit II (BD Biosciences). Measurements were performed at least in
triplicate. Values were normalized to 106 cells; results were expressed as
mean  SEMs.
Statistical analysis
All experiments were performed at least in triplicate. Data distribution was
analyzed, and statistical differences were evaluated by using ANOVA
Tukey-Kramer test by SPSS 12 software. A p value of 0.05 was consid-
ered signiﬁcant.
Results
PPAR colocalizes in perinuclear aggresomes with ubiquitin
and HDAC6 in CF epithelium
We initially determined whether PPAR, a key inﬂammation reg-
ulator implicated in the prevention of several immunoinﬂamma-
tory disorders (13), had any role in CF. PPAR, produced by sev-
eral cell types, including epithelial cells, regulates inﬂammation
via the speciﬁc inhibition of proinﬂammatory cytokines, such as
TNF-, IL-6, IL-1, and the NF-B pathway, and by modulating
oxidative stress (13–15).
Nasal polyp mucosal biopsies from CF patients and controls
were ex vivo cultured, as previously reported, so that epithelial,
myeloid, and lymphoid components can retain all the interactions
with neighboring cells within their natural environment (9).
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We found that PPAR expression in nasal biopsies from CF
patients and the CFTR-defective IB3-1 cell line was signiﬁcantly
reduced compared with controls and the isogenic C38 cell line
with functional CFTR (Fig. 1, A and B). Remarkably, PPAR was
mainly limited to perinuclear localization in CF tissues and CFTR-
defective IB3-1 cell line (Fig. 1, A and B).
This perinuclear localization was suggestive of aggresomes, a
speciﬁc cellular response against accumulation of ubiquitinated
misfolded and/or aggregated proteins (16), which might also result
from impaired proteasome function (16). Although aggresomes
containing PPAR have not been described before, aggresomes
containing ubiquitinated misfolded 	F508 CFTR molecules have
been previously observed as result of overexpression of the defec-
tive CFTR (16). The aggresomes of CFTR also contain HDAC6, a
microtubule-associated deacetylase that interacts with ubiquitin
and stabilizes polyubiquitin chains (17). We have shown that in the
CFTR-defective IB3-1 cell line, the perinuclear aggregates of
PPAR also colocalize with both HDAC6 and ubiquitin (Fig. 1C),
thus demonstrating the aggresome nature of these aggregates. Be-
cause the presence of aggresomes and HDAC6 is usually the cel-
lular response to eliminate cytoplasmic misfolded proteins (17),
we have then investigated whether PPAR was subjected to pro-
teasome degradation. Treatment with the speciﬁc proteasome in-
hibitor MG132 (18) led to an increase in PPAR protein levels
(Fig. 1, D and E) and PPAR ubiquitination (Fig. 1D) in CFTR-
defective IB3-1 cells. Treatment with MG132 also led to an im-
pressive perinuclear increase of HDAC6- and ubiquitin-PPAR
colocalization (Fig. 1F) in IB3-1 cells, suggesting a role for pro-
teasome degradation.
Similar results were obtained using a polyclonal anti-PPAR Ab
with different epitope speciﬁcity (data not shown). To conﬁrm the
anti-PPAR Ab speciﬁcity, IB3-1 cells were transfected with
FIGURE 1. PPAR expression in airway epithelial
cells. Confocal images of nasal polyp mucosa from CF
patients and controls (A) and IB3-1 and C38 cells (B):
low PPAR expression (green) (as detected by clone E8
Ab) with perinuclear aggregates in nasal CF epithelia
and in IB3-1 cells; CyTRAK Orange (red), nuclear
counterstaining. Yellow color indicates nuclear localiza-
tion of PPAR. C, Confocal images of IB3-1 cells: co-
localization (yellow) of ubiquitin (red, top line) or
HDAC6 (red, bottom line) in perinuclear aggregates of
PPAR (green). D, Left panel, Immunoblot detection of
PPAR in C38 and IB3-1 cells incubated with or with-
out the proteasome inhibitor MG132. Right panel, Im-
munoprecipitated PPAR species from whole-cell
extracts of IB3-1 cells are immunoreactive for the anti-
ubiquitin Ab. Immunoprecipitation (IP): anti-PPAR
Ab; immunoblot (IB): anti-ubiquitin Ab. E, Confocal
images of IB3-1 cells: high PPAR expression (green)
in perinuclear aggregates upon MG132 incubation. F,
IB3-1 cells after incubation with MG132: expression
and colocalization of ubiquitin/PPAR (yellow, left
panel) or HDAC6/PPAR (yellow, right panel) in ag-
gresomes. A–C and E and F, Scale bar, 10 m.
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human PPAR siRNA and then immunostained with anti-PPAR
mAb clone E8. We did not detect any PPAR in the IB3-1 cell
transfected with human PPAR siRNA (data not shown).
TG2 is up-regulated in human CFTR-defective cells
Aggresomes are a prominent cytopathological feature of most neu-
rodegenerative disorders, including Parkinson’s and Huntington’s
diseases (19). In these pathologies, there is also an increase in
TG2, responsible for the aggregation of -synuclein in Parkinson’s
(20–23). TG2 is a pleiotropic enzyme expressed by many cell
types, including epithelial cells, often up-regulated in many
chronic inﬂammatory conditions (22, 23). Therefore, we explored
whether TG2 levels or its enzymatic activity were up-regulated in
CF tissues and CFTR-defective cell lines.
We observed a signiﬁcant increase of TG2 protein and enzymatic
activity in CF tissues as well as the IB3-1 cell line (Fig. 2, A–C). The
increase of TG2 was demonstrated by immunoblot and confocal mi-
croscopy, whereas real-time PCR showed that TG2 transcript was
signiﬁcantly higher in IB3-1 than C38 cell lines (Fig. 2D). These
results clearly indicate that CFTR-defective epithelial cells are char-
acterized by an intrinsic TG2 functional increase.
TG2 induces cross-linking of PPAR and mediates aggresome
formation
We then tested the hypothesis that TG2 might induce posttransla-
tional modiﬁcations (cross-linking) of PPAR in CFTR-defective
cells, because the QG and QXXP motifs in the PPAR sequence
could be recognized as speciﬁc sites for TG2 activity (22).
Double labeling immunoﬂuorescence with anti-PPAR Ab and an
isopeptide cross-link speciﬁcally catalyzed by TG2 (22) demonstrated
colocalization only in IB3-1 perinuclear aggregates (Fig. 3A). Fur-
thermore, using an anti-PPAR Ab, several high molecular mass
bands ranging between 72 and 250 kDa were immunoprecipitated and
detected by the anti-isopeptide Ab in the IB3-1 line (Fig. 3B). Normal
55-kDa PPAR in IB3-1 cells was reduced (Fig. 3C), whereas C38
cell line presented only faint levels of the high molecular mass and a
considerable amount of the normal 55-kDa PPAR (Fig. 3, B and C).
Exposure of the IB3-1 cells to the irreversible TG2-speciﬁc inhibitor
R283 (a gift from M. Grifﬁn, Aston University, Birmingham, U.K.)
(12, 23, 24) tested at increasing concentrations 50–500 M with sim-
ilar results and induced a signiﬁcant reduction of high molecular mass
PPAR (Fig. 3D) and a signiﬁcant increase of the normal 55-kDa
PPAR in the IB3-1 cells (Fig. 3E). This indicated that the cross-
linked PPARwas due to increased TG2 activity. A similar result was
achieved through TG2 gene silencing by siRNA (Fig. 3F). Exposure
of both CF tissues and IB3-1 cells to R283 also resulted in a signif-
icant reduction of PPAR aggregates, restoring a wider intracellular
distribution of PPAR (Fig. 3G).
In IB3-1 cells, PPAR nuclear translocation was promoted only
by R283, whereas rosiglitazone, a PPAR agonist with potent anti-
inﬂammatory activity used in clinic (25), induced only a marginal
nuclear PPAR increase (Fig. 3H). In contrast, rosiglitazone alone
was able to induce an impressive PPAR nuclear translocation in
C38 cells (Fig. 3H).
These results indicate that PPAR aggregates in CFTR-defec-
tive cells are induced by TG2.
TG2 inhibition controls inﬂammation in CF epithelial cells
TG2 activity does not only control the levels and function of PPAR,
but also inﬂuences other markers of inﬂammation. Inhibition of TG2
with either R283 or KCC009 (another TG2-speciﬁc inhibitor, gift
from C. Khosla, Stanford University, Palo Alto, CA; data not shown)
induced a signiﬁcant reduction of the phosphorylated p42/p44
MAPKs (Fig. 4A), ICAM-1, and NF-B activation (data not shown)
both in CF tissues and IB3-1 cells. Inhibition of TG2 by siRNA also
induced a signiﬁcant decrease of the phosphorylated p42/p44 (Fig.
4B) and TNF- release (Fig. 4C) in IB3-1 cells.
The inhibitory activity of R283 on tyrosine phosphorylation, a
well-established marker of epithelial inﬂammation in human CF
airway mucosa (9), was abrogated by 4-h incubation with the
PPAR antagonist GW9662 (Fig. 4D), further indicating that TG2
controls inﬂammation through PPAR.
FIGURE 2. TG2 expression in airway epithelial cells. Confocal im-
ages identiﬁed expression of TG2 (green) and its activity (blue) in ep-
ithelial cells of nasal polyp mucosa from CF patients (A) and IB3-1 CF
cells (B) as compared with controls. Merge indicates overlay of indi-
vidual channels (cyan). Scale bar, 10 m. C, Lysates of C38 and IB3-1
cells were immunoblotted with anti-TG2 Abs. D, Real-time PCR of
TG2 mRNA in C38 and IB3-1 cells. TG2 transcript was signiﬁcantly
higher in IB3-1 than C38 cells (, p  0.05 vs C38 cells). Error bars
represent SEMs.
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Intracellular Ca2 and ROS levels modulate TG2 activity and
inﬂammation in CFTR-defective cells
We then investigated the mechanisms underlying TG2 up-regula-
tion in CFTR-defective cells. Because TG2 activity is strictly Ca2
dependent (22), and high Ca2 mobilization has been shown in CF
nasal or bronchial epithelia (26), we looked at the role of Ca2 in
CFTR-defective cells.
Ca2 decrease, induced by the Ca2 chelator BAPTA-AM
(27), signiﬁcantly reduced TG2 activity (Fig. 4E) as well as
p42/44 phosphorylation (Fig. 4E) in IB3-1 cells. The Ca2
ionophore ionomycin (27), on the contrary, increased TG2 ac-
tivity (Fig. 4E) and phospho-p42/p44 (Fig. 4E) in C38 cells.
These results demonstrated that Ca2 ions drive TG2 activation
and thus inﬂammation in CF epithelium.
FIGURE 3. Effects of TG2 on
PPAR protein expression and local-
ization. A, Confocal images of IB3-1
and C38 cells immunostained with
PPAR (green) and the anti-
isopeptide Ab (red). Merge of individ-
ual channels shows colocalization
(yellow) in perinuclear aggregates. B,
Immunoprecipitated PPAR species
from whole-cell extracts of C38 and
IB3-1 cells are immunoreactive for
the anti-isopeptide cross-link Ab. Im-
munoprecipitation (IP): anti-PPAR
Ab; immunoblot (IB): anti-isopeptide
Ab. C, Immunoblot of PPAR in C38
and IB3-1 cells. D, Effect of R283 on
PPAR immunoreactivity for the anti-
isopeptide Ab in IB3-1 cells. IP: anti-
PPAR Ab; IB: anti-isopeptide Ab. E,
Immunoblot analysis of PPAR in
IB3-1 cells with or without R283. F,
Immunoblot of PPAR in IB3-1 cells:
effect of TG2 siRNA. Scramble
siRNA was used as a negative control.
72 kDa, TG2; 55 kDa, PPAR. Con-
focal images of G, PPAR (green)
immunostaining of CF nasal mucosa
and IB3-1 cells with or without R283,
and H, PPAR (green) in IB3-1 cells
(left panel) and in C38 cells (right
panel) after incubation with PPAR
agonist rosiglitazone (10 M for 6 h)
with or without prior incubation with
R283. CyTRAK Orange (red) nuclear
counterstaining. Yellow color indi-
cates nuclear localization of PPAR.
A, G, and H, Scale bar, 10 m.
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Because TG2 activity is also regulated by ROS (27), we
tested whether ROS inﬂuenced the TG2-induced inﬂammation
in CF.
In agreement with previous reports, high levels of ROS were
only detected in CF tissues and CFTR-defective cells (data not
shown) (28). The ROS scavenger NAC signiﬁcantly reduced TG2
FIGURE 4. Inhibition of TG2 ac-
tivity controls inﬂammation in human
airway CF epithelia and CFTR-defec-
tive cells. A, Confocal images of
phospho-p42/p44 MAPK expression
(green) by CF nasal mucosa and
IB3-1 cells cultured with or without
R283; CyTRAK Orange (red) nuclear
counterstaining. B, Immunoblot of
phospho-p42/p44 MAPKs in IB3-1
cells after TG2 gene silencing or in-
cubation with R283. Scramble siRNA
was used as a negative control. C,
TNF- ELISA in IB3-1 cells after
TG2 silencing or incubation with
R283. The experiment was repeated
three times (, p 0.05 vs IB3-1 cells
cultured in medium alone). Error bars
represent SEMs. Confocal images of
D, phospho-tyr expression (Py99 Ab)
by CF nasal mucosa after incubation
with R283 or R283, followed by
GW9662, and E, TG2 activity (blue)
in IB3-1 cells with Ca2-chelator
BAPTA-AM and in C38 cells with
Ca2-ionophore ionomycin. Phospho-
p42/p44 MAPK expression (green) by
IB3-1 cells cultured with or without
BAPTA-AM and by C38 cells cul-
tured with or without ionomycin.
CyTRAK Orange (red) nuclear coun-
terstaining. F and G, NAC decreases
expression of TG2 activity (blue),
phospho-tyr, phospho-p42/p44 (gr-
een) in CF nasal polyp mucosa (F),
and in IB3-1 cells (G). Expression of
TG2 protein (green) in both CF nasal
polyp mucosa and IB3-1 is not af-
fected by NAC treatment (F and G).
H, TNF- secretion in IB3-1 cell line
cultured for 48 h with or without
NAC. The experiment was repeated
three times (, p 0.05 vs IB3-1 cells
cultured in medium alone). Error bars
represent SEMs. A and D–G, Scale
bar, 10 m.
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activity (Fig. 4, F and G), phosphotyrosine expression (Fig. 4F),
p42/44 phosphorylation (Fig. 4G), and TNF- release (Fig. 4H) in
both CF tissues and IB3-1 cells. Similar results were obtained after
inhibition of ROS by another ROS scavenger, EUK 134 (data not
shown).
CFTR inhibition induces TG2 up-regulation and
inﬂammation in normal bronchial 16HBE cells
To assess that the pathway described to date was a direct conse-
quence of CFTR dysfunction, we blocked the functional CFTR in
the normal bronchial 16HBE cell line with the selective inhibitor
CFTRinh-172 (8). We observed all the modiﬁcations we have
reported above, such as increase of intracellular ROS (Fig. 5A),
increase of TG2 protein and its activity (Fig. 5B), decrease of
PPAR (Fig. 5C), and increase of p42/44 phosphorylation
(Fig. 5C).
Altogether, these results clearly demonstrated how CFTR dis-
ruption directly leads to the development of airway inﬂammation
in CF.
Discussion
The novel ﬁnding of the present study is the demonstration
that CFTR mutations lead to an increase of TG2 levels and
activity that, in turn, down-regulate the anti-inﬂammatory ef-
fects of PPAR. In cftr/ mice, PPAR expression is down-
regulated both at the mRNA and protein levels, and its function
is reduced compared with wild-type littermates (29). Therefore,
PPAR agonists have been exploited in therapeutic approaches
to control inﬂammation in airway diseases in animal models
(30, 31).
We have shown that PPAR is not only reduced in CF epi-
thelium and CFTR-defective cell lines, but also conﬁned to pe-
rinuclear aggresomes, prominent pathological features common
to many neurodegenerative conditions such as Huntington and
Parkinson’s diseases (32). Aggresomes are generated in re-
sponse to alterations of the ubiquitin proteasome system, the
principal cellular mechanism to eliminate misfolded proteins
before they aggregate (33). Aggresomes often develop when a
FIGURE 5. CTR inhibition induces airways inﬂam-
mation. The 16HBE cells were cultured with or without
CFTRinh-172 inhibitor. A, Confocal microscopy of in-
tracellular ROS (CM-H2DCFDA detection, green) or a
Wallac 1420 multilabel counter (each bar represents the
mean plus SEMs of three separate experiments, each
with n  8; , p  0.01 compared with C38 cells). B,
Confocal images of TG2 (green) and its activity (blue).
Merge indicates overlay of individual channels (cyan).
C, Confocal images of PPAR and phospho-p42/44
MAPKs (green); CyTRAK Orange (red) nuclear coun-
terstaining. Immunoblot analysis of PPAR (55 kDa)
and phospho-p42/44 MAPKs (42 and 44 kDa). A–C,
Scale bar, 10 m.
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threshold of misfolded protein is exceeded, and are usually en-
riched of molecular chaperone, proteasome subunits, ubiquitin
conjugates, and the histone deacetylase HDAC6. In CF, the
defective CFTR is often not transported beyond the endoplas-
mic reticulum and accumulates in aggresomes (16, 33). The data
shown in Fig. 1C clearly indicate that also PPAR colocalizes in
aggresomes with ubiquitin and HDAC6. In CFTR-defective cells, the
speciﬁc inhibition of the ubiquitin-proteasome system with MG-132
led to a signiﬁcant increase of PPAR, HDAC6-, and ubiquitin-
PPAR colocalization in aggresomes (Fig. 1, D–F). This suggests that
the formation of these aggresomes in CF is caused by the accumula-
tion of misfolded proteins fated to ﬁnal degradation by the protea-
some-ubiquitination system.
The report that in Parkinson’s disease TG2 cross-links
-synuclein and induces its aggregation in high molecular mass
aggresomes (34) prompted us to investigate whether TG2 also
had a role in the aggresome formation in CF. TG2 is a pleio-
tropic enzyme with a calcium-dependent transamidating activ-
ity that results in cross-linking of proteins via 	(-glutamyl)
lysine bonds (22, 23). Our results clearly demonstrated a sig-
niﬁcant increase of TG2 protein and enzymatic activity in CF
epithelium and CFTR-defective cell lines. TG2 up-regulation
was also responsible for the aggresome formation in CF. Im-
portantly, TG2 induced cross-linking of PPAR and its seques-
tration into aggresomes (Fig. 3, A–D), because the TG2-inhib-
itor R283 produced a signiﬁcant reduction of PPAR protein
aggregates and restored a wider intracellular protein distribu-
tion (Fig. 3, E–G). We have proven the unequivocal role of TG2
in controlling PPAR and inﬂammation by blocking TG2 en-
zymatic activity (R283) as well as its translation (siRNA). Fur-
thermore, the inhibition of the normal CFTR in a normal
16HBE bronchial cell line led to a dramatic up-regulation of
TG2 and inﬂammation, clearly showing the direct link be-
tween CFTR defectiveness and TG2 up-regulation and
inﬂammation.
Collectively, our study provides a molecular explanation of the
reported association between CFTR malfunction and sterile in-
ﬂammation. Highlighting the role of TG2 in CF, we have also
indicated novel ways to modulate inﬂammation, a key component
in CF pathogenesis.
Furthermore, increased amounts of TG2 have been recently
described in other diseases, including cancer, in which up-reg-
ulation of TG2 is associated with an increased metastatic ac-
tivity (35) or drug resistance, as in breast cancer, through the
activation of NF-B (36, 37). Because of its capacity to activate
NF-B, a crucial mediator of inﬂammation-induced tumor
growth and metastatic progression, through depletion of free
IB (38), TG2 provides a mechanistic link between inﬂam-
mation and cancer.
In this view, our study may have a wider impact in the whole
area of inﬂammation and cancer.
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